


Where Canada's experts in
clinical microbiology and
infectious diseases meet

This educational event is an Accredited Learning Activity
(Section 1) as defined by the Maintenance of Certification
program of the Royal College of Physicians and
Surgeons of Canada and approved by AMMI Canada.

* Information available as of time of printing



Point de rencontre des experts
canadiens en microbiologie
médicale et infectiologie

La présente activité est une activité de formation collective
agréée (section 1) au sens que lui donner le Programme
de maintien du certificat du Collège royal des médecins et
chirurgiens du Canada, approuvée par l'AMMI Canada.


* Information disponible à partir du moment de l'impression

2014 Victoria



AMMI CANADA – CACMID ANNUAL CONFERENCE • CONFÉRENCE ANNUELLE

Final Program • Programme final



Victoria, BC
April 3 – 5 avril, 2014

www.ammi.ca



Victoria Conference Centre and The Fairmont Empress

www.cacmid.ca




We are very pleased to welcome you to Victoria for the AMMI Canada – CACMID Annual Conference, THE Canadian meeting in infectious diseases and microbiology. We had a fabulous conference in Québec City last year. This one promises to be even better (and it will certainly be warmer)!

This year's conference will once again bring together students, technologists, and professionals in the areas of diagnostic microbiology, antimicrobial stewardship, infectious diseases, infection prevention and control, and public health. The collaborative efforts of the Central Planning and Scientific Committees have developed an informative and stimulating program drawing upon the knowledge, skills, and expertise of our own Canadian public health, microbiology, and infectious disease experts. This year's program contains a terrific line-up of plenary sessions, symposia, workshops, oral and poster sessions that touch on currently relevant topics, as well as the ever-popular Clinical Vignettes. Plenary sessions will highlight current, critical issues including antimicrobial stewardship programs, emerging infections, and "What's Hot" in adult and paediatric infectious diseases, diagnostic microbiology and infection control. State-of-the-art clinical lectures include MERSCoV, the microbiome, and a debate on the need to screen for AROs. The Special Lecture will enlighten us on the impact climate change has on infectious diseases, both in Canada and globally.

This premier event is made possible through the extraordinary and continued support of our conference sponsors. Be sure to spend some time in the Exhibit Hall; see what it holds for you! Take a glimpse at the products on display throughout our conference and get your questions answered by on-site representatives.

The meeting provides ample opportunity to catch-up with friends, meet colleagues, and lay the groundwork for future collaborations. There will be many formal and informal opportunities to bring everyone together. Please plan to attend the Welcome Reception on Thursday evening. You'll note that the Welcome Reception now includes dinner so there's no need to rush off-site! The Welcome Reception and the Closing Dinner at the Royal BC Museum are ideal networking opportunities in which we hope you will partake.

We are confident that this year's scientific and social program in Victoria will provide you with a memorable and educational experience. On behalf of the Central Planning and Scientific Committees, we thank you for attending. Without you, this meeting would not be as great a success as it is. We look forward to sharing the next few days with you in beautiful Victoria!



A. Mark Joffe
President, AMMI Canada



Heather Adam
President, CACMID



Bienvenue

Nous sommes très heureux de vous accueillir à la Conférence annuelle AMMI Canada – CACMID, LA rencontre canadienne en infectiologie et microbiologie. La conférence de l'an dernier, tenue à Québec, a été fantastique. Celle-ci promet d'être encore mieux (et se tiendra sans contredit à un endroit plus chaud)!

Encore une fois cette année, la Conférence réunira des étudiants, technologues et professionnels des domaines de la microbiologie diagnostique, de la gestion des antimicrobiens, de l'infectiologie, de la prévention et du contrôle des infections et de la santé publique. Grâce aux efforts et à la collaboration des comités de planification générale et scientifique, un programme informatif et stimulant a été élaboré. Il met à profit le savoir, les compétences et les connaissances spécialisées de nos propres experts canadiens en santé publique, microbiologie et infectiologie.

Le programme de cette année comprend une merveilleuse série de séances plénières, de symposiums, d'ateliers, de présentations orales et d'affiches qui traitent de sujets d'actualité pertinents, de même que les très populaires Vignettes cliniques. Les séances plénières porteront sur des enjeux actuels critiques, dont les programmes de gestion des antimicrobiens, les infections émergentes et les sujets du jour aux chapitres de l'infectiologie adulte et pédiatrique, de la microbiologie diagnostique et du contrôle des infections. Des séances cliniques de pointe traiteront notamment du coronavirus MERS CoV, du microbiome et, dans le cadre d'un débat, de la nécessité de dépister les organismes résistants aux antimicrobiens. L'exposé spécial fera, pour sa part, la lumière sur les répercussions des changements climatiques sur les maladies infectieuses, tant au Canada qu'ailleurs dans le monde.

Cet événement de premier ordre est rendu possible grâce à l'extraordinaire soutien continu des commanditaires de notre conférence. Assurez-vous de visiter la Salle des exposants pour voir ce qu'elle vous réserve! Jetez un coup d'œil aux produits exposés tout au long de la conférence et posez vos questions aux représentants sur place.

La Conférence vous permettra de renouer avec vos amis, de rencontrer des collègues et de jeter les bases de futures collaborations. De nombreuses occasions structurées et spontanées permettront de réunir tout le monde. Nous espérons que vous prendrez part à la réception de bienvenue qui aura lieu le jeudi soir. Comme elle comprend maintenant un souper, vous n'aurez pas à quitter les lieux rapidement! La réception de bienvenue et le souper de fermeture, qui auront lieu au Royal BC Museum, sont d'excellentes possibilités de réseautage auxquelles, nous l'espérons, vous prendrez part.

Nous croyons fermement que le programme scientifique et social de la conférence de cette année vous permettra de vivre une expérience éducative des plus mémorables à Victoria. Au nom des comités de planification générale et scientifique, nous vous remercions de votre participation. Sans vous, cette rencontre ne serait pas la réussite qu'elle promet d'être. Nous avons hâte de passer les prochains jours avec vous dans la belle ville de Victoria!



A. Mark Joffe
Le président de l'AMMI Canada



Heather Adam
La présidente de la CACMID



Table of Contents

Welcome to Victoria, Bienvenue à Victoria	5
Central Planning Committee (CPC) Comité de Planification	6
Scientific Planning Committee (SPC) Comité Scientifique	6
Accreditation	6
Are You a Member?	7
AMMI Canada Council	7
CACMID Board	7
Abstract Review Committee	7
Collaborating Societies	8
Education Grants	9
General Information	10
Merit Awards Presentation	12
Poster Awards Presentation	13
The AMMI Canada – CACMID Special Lecture	14
Association, Committee, & Other Group Meetings	15
Integrated Symposia & Workshops	15
Program	16
Program at a Glance	30
Innovation Academy	33
Poster Presentations	34
Author Index	44
Conflict of Interest	46
Speaker Biographies	48
Exhibitor Overview	51
Exhibitor Directory	52
Floor Plans	58
Sponsors	60

Objectives

The AMMI Canada - CACMID Annual Conference provides an interactive venue where experts in the fields of microbiology, infectious diseases, infection prevention and control, and public health meet. The Conference attracts attendees from across Canada and internationally.

As in previous years, the 2014 Conference will provide updates on a variety of topics to a diverse audience of clinicians, microbiologists, laboratory technologists, public health professionals, infection prevention and control practitioners, students and residents.

In addition to the pre-meeting workshops, the program will offer plenary sessions, State of the Art Clinical Lectures, a Special Lecture, integrated symposia, short oral presentations, poster presentations, workshops and interactive clinical vignettes. The Innovation Academy will be on hiatus in 2014 but will return to the 2015 meeting. The 2014 meeting will be a chance for attendees to showcase their research as well as get up to speed with the latest in the areas of microbiology, adult and paediatric infectious diseases and related subjects. Dynamic expert speakers will be invited from across Canada and internationally to ensure another exciting meeting.

In addition to the scientific component, the meeting will provide ample opportunity for attendees to network, exchange ideas, and reconnect with colleagues.

The 2014 meeting will address topics including:

- Antimicrobial stewardship
- Emerging infections
- Latest hot topics in adult and paediatric infectious diseases, diagnostic microbiology and infection prevention and control
- Up to date information on “MERS-CoV”
- A debate on the value of screening for AROs
- Microbiome: Pathogen discovery and novel therapies

And a whole lot more!



Welcome to Victoria, British Columbia – full of life! Bienvenue à Victoria, Colombie-Britannique – une ville pleine de vie!



On behalf of the Greater Victoria Visitors & Convention Bureau (Tourism Victoria), I'd like to welcome you to our beautiful city!

Victoria is abundant with the youthful energy of the West Coast and blends well with the time-honored British, European and Asian traditions. As British Columbia's capital city, Victoria is full of life.

Greater Victoria not only boasts exceptional landscapes and mild year-round climate, we also have an abundance of activities and adventures around every corner. Explore our city, its fabulous culture and heritage as represented in everything from Canada's oldest Chinatown to our remarkable First Nations offerings. We guarantee your must-do list will be overflowing – from whale watching, kayaking and hiking to tea sipping, culinary experiences and garden strolling.

I encourage you to stop by our Visitor Centre in the Inner Harbour for activity suggestions and city information. Our friendly and courteous staff are more than happy to help. I hope you enjoy your stay and are able to take in some of our wonderful surroundings during your time here.

Sincerely,

Paul Nursey
President & CEO

Au nom du Greater Victoria Visitors & Convention Bureau (Tourisme Victoria), je vous souhaite la bienvenue dans notre magnifique ville!

Victoria est une ville dynamique de la Côte Ouest qui réunit les traditions britanniques, européennes et asiatiques. Capitale de la Colombie-Britannique, Victoria est une ville pleine de vie.

En plus d'offrir d'exceptionnels paysages et un temps doux à longueur d'année, le Grand Victoria offre une vaste gamme d'activités et d'aventures. Explorez notre ville et découvrez sa merveilleuse culture et son héritage présents partout, que l'on pense au plus vieux quartier chinois au Canada et aux remarquables joyaux des Premières Nations. Votre liste de choses à faire sera longue – observer les baleines, faire du kayak et de la randonnée pédestre, prendre le thé, vivre des expériences gastronomiques et visiter les jardins.

Je vous encourage à passer au Centre d'information touristique au port intérieur pour obtenir des suggestions d'activités et des renseignements sur la ville. Notre personnel amical et courtois sera heureux de vous aider. J'espère que vous apprécierez votre séjour chez nous et que vous profiterez de nos spectaculaires paysages tout au long de votre visite.

Sincères salutations.

Paul Nursey
Président-directeur général

TOURISM
VICTORIA

Event Mobi App



Want all this and more at your fingertips? Download the Event Mobi app at eventmobi.com/victoria2014 for quick and easy access to the entire final program! Remember to add the app as an icon on your smartphone's homepage so you never lose it.

Central Planning Committee (CPC) Comité de Planification

AMMI CANADA

A. Mark Joffe
President, CPC Co-Chair

Daniel Gregson
President Elect

B. Lynn Johnston
Past President

Isabelle Chiu
Scientific Planning Committee Co-Chair

Shariq Haider
Sponsorship Committee Co-Chair

Mel Krajden
Co-Treasurer

CACMID

Heather Adam
President

Gregory Tyrrell
Past President

Jeff Fuller
Vice President
Scientific Planning Committee Co-Chair
Sponsorship Committee Co-Chair

Matthew Gilmour
Co-Treasurer

Paul Levett
Meeting Secretary, Abstract Chair

Scientific Planning Committee (SPC) Comité Scientifique

AMMI CANADA

Isabelle Chiu
Co-Chair

Gerald Evans

Sarah Forgie

Todd Hatchette

Matthew Oughton

David Patrick

Michael Payne

Susan Poutanen

Cécile Tremblay

Duncan Webster

CACMID

Jeff Fuller
Co-Chair

Meghan Dey

Michael Drebot

Matthew Gilmour

Paul Levett

Jessica Minion

Samir Patel

Accreditation

A. For specialists certified with the Royal College of Physicians and Surgeons of Canada (RCPSC): This educational event is approved as an Accredited Learning Activity, (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

MAINPORT - Transfer of Hours

The Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning activities to be transferred directly into participants' MAINPORT Transfer of Hours.

Please indicate your RCPSC ID Number when registering.

B. For specialists certified with the American Medical Association (AMA): Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Please indicate your AMA ID Number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiologists and Diplomates of the American Board of Medical Microbiology: The Canada College of Microbiologists (CCM) accredits the AMMI Canada – CACMID Annual Conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A one hour educational activity is equivalent to one CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, at the conference registration desk or by email to the FCCM co-chair (hadam@dsmanitoba.ca) following the conference.



AMMI Canada Council

A. Mark Joffe (Edmonton, AB)
President

Daniel Gregson (Calgary, AB)
President Elect

B. Lynn Johnston (Halifax, NS)
Past President

Mel Krajden (Vancouver, BC)
Treasurer

Deborah Yamamura (Hamilton, ON)
Secretary

Tony Mazzulli (Toronto, ON)
Medical Microbiology Section Head

Michael Libman (Montréal, QC)
Infectious Disease Section Head

Members of Council

Steven Drews (Calgary, AB)

Andrew Morris (Toronto, ON)

Caroline Quach (Montréal, QC)

Romina Reyes (Burnaby, BC)

Michel Roger (Montréal, QC)

Mark Tyndall (Ottawa, ON)

Ex-Officio Members

Isabelle Chiu (Edmonton, AB)
Program Planning Committee Chair

Michael Payne (Vancouver, BC)
Associate Committee Chair

Donald Sheppard (Montréal, QC)
Grants and Awards Committee Chair

CACMID Board

Heather Adam (Winnipeg, MB)
President, CPC Co-Chair

Gregory Tyrrell (Edmonton, AB)
Past President

Jeff Fuller (Edmonton, AB)
Vice President

Matthew Gilmour (Winnipeg, MB)
Secretary Treasurer

Paul Levett (Regina, SK)
Meeting Secretary/ Councillor

Councillors

Meghan Dey (Ottawa, ON)

Michael Drebot (Winnipeg, MB)

Jessica Minion (Regina, SK)

Samir Patel (Toronto, ON)

Abstract Review Committee

Paul Levett (Regina, SK)
Chair

Heather Adam (Winnipeg, MB)

Sylvie Champagne (Vancouver, BC)

Meghan Dey (Ottawa, ON)

Steven Drews (Calgary, AB)

Jeff Fuller (Edmonton, AB)

Matthew Gilmour (Winnipeg, MB)

Daniel Gregson (Calgary, AB)

Linda Hoang (Vancouver, BC)

A. Mark Joffe (Edmonton, AB)

B. Lynn Johnston (Halifax, NS)

Tony Mazzulli (Toronto, ON)

Jessica Minion (Regina, SK)

Andrew Morris (Toronto, ON)

Heather Onyett (Kingston, ON)

Samir Patel (Toronto, ON)

Romina Reyes (Burnaby, BC)

Mark Tyndall (Ottawa, ON)

Anupma Wadhwa (Toronto, ON)

Deborah Yamamura (Hamilton, ON)

Are You a Member?

To join AMMI Canada please contact:

Deborah Yamamura, Secretary, AMMI Canada
c/o AMMI Canada Secretariat
192 Bank Street, Ottawa, ON K2P 1W8
Phone: 1-866-467-1215 (toll free)
613-260-3233 ext. 103

Fax: 613-260-3235

info@ammi.ca

For more information on AMMI Canada visit: www.ammi.ca

To join CACMID please contact:

Matthew W. Gilmour, Secretary Treasurer, CACMID
Clinical Microbiologist, Diagnostic Services Manitoba
MS673C – Health Sciences Centre
820 Sherbrook Street, Winnipeg, MB R3A 1R9
Phone: 204-787-4597

Fax: 204-787-4699

matthew.gilmour@cacmid.ca

For more information on CACMID visit: www.cacmid.ca



Collaborating Societies

Alberta Society for
Infectious Diseases



Société des maladies
infectieuses de l'Alberta



ASSOCIATION DES
MICROBIOLOGISTES DU
QUÉBEC



Canadian Association
of HIV Research (CAHR)

Canadian Collège of
Microbiologists



Collège Canadien des
Microbiologistes



Canadian Foundation
for Infectious Diseases
Fondation canadienne
des maladies infectieuses



Canadian Society of Hospital Pharmacists
Société canadienne des pharmaciens d'hôpitaux



Canadian Society for Medical Laboratory Science
Société canadienne de science de laboratoire médical



Canadian Society of
Microbiologists (CSM)



Pan American Society for
Clinical Virology (Clearwater)



Education Grants

AMMI Canada

For Associate Members ONLY

Eligibility

The applicant must be an AMMI Canada Associate Member in good standing. To be eligible the applicant must register for the AMMI Canada – CACMID Annual Conference 2014 and pay the full student conference registration fee. One-day registrants are not eligible.

Application

An education grant application form will be available at the registration desk during the conference or can be downloaded from the AMMI Canada website – Annual Conference section (www.ammi.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and sent to info@ammi.ca or faxed to 613-260-3235.

\$250 Cdn for Associate Members from British Columbia* and Washington State

\$500 Cdn for Associate Members from Alberta and Saskatchewan

\$750 Cdn for Associate Members from Manitoba, Ontario, Québec, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, New Brunswick, North West Territories, Yukon, Nunavut and the United States, other than Washington state

***N.B.:** Associate members attending from Victoria and Vancouver Island are ineligible for grants.

CACMID

For Technical Staff and Clinical Microbiology Fellows

Eligibility

Applicants must be microbiology laboratory technologists or technicians, or clinical microbiology fellows registered in a Canadian training program (e.g. Canadian College of Microbiologists), and all must be active members of CACMID. Each applicant is eligible for only one grant. To be eligible, the applicant must be the presenting author in an oral or poster session at the AMMI Canada – CACMID Annual Conference 2014 in Victoria.

Application

An education grant application form will be available at the registration desk during the conference or can be downloaded from the CACMID website (www.cacmid.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and mailed to the CACMID Secretary Treasurer (www.cacmid.ca/contact-us).

\$ 250 for technical staff attending from British Columbia* and Washington State

\$ 500 for technical staff attending from Alberta and Saskatchewan

\$ 750 for technical staff attending from Manitoba, Ontario and Québec

\$ 1,000 for technical staff attending from Nova Scotia, Prince Edward Island, Newfoundland & Labrador, North West Territories, Yukon, Nunavut, and International

***N.B.:** Technical staff attending from Victoria are ineligible for grants.

N.B.: Clinical microbiology fellows (all must be Canadian residents) may submit itemized expenses with receipts to a maximum of \$1,000.

Exhibit Hours

Room: Carson Hall (VCC)

Thursday April 3

1100 – 1300

1835 – 2030

Welcome reception and dinner

Friday April 4

1100 – 1300

The AMMI Canada – CACMID Annual Conference has received tremendous support from our exhibiting companies. We encourage you to visit the exhibit hall to discover the leading edge of business and research in the fields of medical microbiology, infectious diseases, medicine, pharmaceuticals and diagnostics.

Morning breaks and lunches will be served in the exhibit hall on Thursday and Friday.

Don't miss the opportunity to network with colleagues and friends during the Thursday evening welcome reception and dinner!

Event Mobi App



Want all this and more at your fingertips? Download the Event Mobi app at eventmobi.com/victoria2014 for quick and easy access to the entire final program! Remember to add the app as an icon on your smartphone's homepage so you never lose it.

General Information

Conference Evaluations

The conference has moved to an online evaluation system.

Conference Attendees:

Please scan the QR code below with your mobile device to download and complete the **2014 PROGRAM EVALUATION**



Or follow this link:

www.surveymonkey.com/s/Victoria2014ProgramEvaluation

If you don't have a QR code scanner installed on your phone, may we suggest one of the following:

iPhone

Download an application called Quick Scan from the App Store

Android

Download an application called Bar Code Scanner from the market place

Windows Phone

Download a program called Microsoft Tag

Blackberry, Palm, and other phones

Download an application called NeoReader.

Note: Blackberry 10 users have a QR scanner built in to the native app, Smart Tags.

All of these applications are free!

Once you have the application, open it on your phone. It will access your phone's camera and automatically start searching for a readable QR code. Hold your phone over the QR code above and it will automatically take you to the evaluation.

Abstracts

There will be NO printed version of the abstracts. All abstracts can be found online in the conference sections of the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites. They are also available as a supplement to the Canadian Journal of Infectious Diseases & Medical Microbiology (www.pulsus.com).

Disclaimer

The Central Planning and Scientific Planning Committees will make every effort to present the program as published and printed. However, the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the annual conference, for any cause beyond their reasonable control. The above-mentioned are not liable for any loss or inconvenience caused as a result of such alteration. In the event of cancellation of the annual conference, all pre-paid fees will be refunded, however the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents are not liable for any loss or inconvenience caused as a result of such cancellation, and delegates are therefore advised to take out their own travel insurance and extend their policy for personal possessions as the annual conference does not cover individuals against cancellations of bookings or theft or damage of belongings.

Handouts

Handouts will NOT be available at the conference. Following conference, presentations approved by speakers for posting will be uploaded to both the AMMI Canada (www.ammi.ca) and CACMID (www.cacmid.ca) websites.



Hotel Information



The Fairmont Empress hotel in Victoria, BC sits majestically at the cornerstone of Victoria's sparkling Inner Harbour and vibrant city centre. This Vancouver Island luxury hotel is located in

British Columbia's capital city and features turn of the century architecture, classic beauty and an unrivaled location. Since 1908, it is Vancouver Island's most celebrated resort, spa and meeting destination. The Victoria hotel features the highly acclaimed Willow Stream Spa regarded as one of the best spas in Canada; - a must on each visit to Victoria. Epitomizing style and service, our Fairmont Gold product underwent a multi-million dollar renovation offering unparalleled luxury, ranked among the best Fairmont Gold experiences in Canada.

The Fairmont Empress

721 Government Street
Victoria, British Columbia, Canada
V8W 1W5

Phone: 250-384-8111
Fax: 240-381-4334

Check in: 1600

Check out: 1100

If flights arrive early, the hotel will do their best to accommodate an earlier check-in

Parking

Valet and self-park - \$30/ day

Note: valet includes in-and-out privileges

Willow Stream Spa

Experience the Fairmont Empress Victoria's in-house spa and salon. All AMMI Canada - CACMID Annual Conference attendees receive a 20% discount.

To make a reservation, contact:

Phone: 250-995-4650 ext. 4650

Toll Free: 1-866-854-7444

Email: emp.spareservations@fairmont.com

Lost and Found

Please go to the Registration Desk for lost or found items.

Messages and Conference Updates

A message board will be available by the Registration Desk for posting messages for other delegates.

Last-minute program changes will be announced through the Event Mobi app at eventmobi.com/victoria2014.

Registration Desk

Room: Pre-Function 1A (VCC)

Wednesday April 2: 1200 – 1800

Thursday April 3: 0700 – 1730

Friday April 4: 0700 – 1700

Saturday April 5: 0700 – 1700

Speaker Ready Room

Room: Sooke (VCC)

Wednesday April 2: 1300 – 1800

Thursday April 3: 0700 – 1730

Friday April 4: 0700 – 1700

Saturday April 5: 0700 – 1600

Victoria, BC

Victoria is a unique blend of old world charm and new world experiences. Heritage architecture, colourful gardens and traditions such as afternoon tea mixed with soft adventure such as kayaking, fishing, hiking, cycling and golf; culinary experiences such as gourmet farm and wine tours, microbreweries and world class dining; and arts and culture. As an island destination, Victoria offers visitors an escape from the hurried world and beams with ambience. Victoria also boasts the mildest climate in Canada and is green year-round.



Internet Café

**Thursday April 3 to
Saturday April 5**

Room: Registration Foyer

Hours:

Thursday April 3:

0700-1730

Friday April 4:

0700-1730

Saturday April 5:

0700-1730



Merit Awards Presentation

Thursday April 3
1715 – 1735
Room: Lecture Theatre (VCC)

Masters of Ceremony:

Jeff Fuller (Edmonton, AB)

Daniel Gregson (Calgary, AB)

2014 AMMI Canada - Astellas Post Residency Fellowship

Dr. Ilan Schwartz is the recipient of this year's fellowship. Dr. Schwartz is awarded a one year fellowship for his research proposal entitled: "Emmonsiosis: Optimizing diagnostics, and an investigation into risk factors and burden of disease."

Presenting the award: Catherine Leckie, Senior Hospital Product Specialist, Astellas Pharma Canada, Inc.

2014 AMMI Canada – Pfizer Post Residency Fellowship

Dr. Tom Havey is the recipient of this year's fellowship. Dr. Havey is awarded a one year fellowship for his research proposal entitled: "Relative clinical impacts of VITEK MS Matrix – Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF) and Antimicrobial Stewardship Program (ASP) on management of Bloodstream Infections (BSIs) : A controlled interrupted time-series study".

2013 Distinguished Service Award

Dr. Anita Rachlis is presented this award in recognition of her many years of service to AMMI Canada as Chair and member of the Education/ Continuing Professional Development Committee and for her contributions to HIV care and research in Canada since the beginning of the HIV/AIDS epidemic. Dr. Rachlis is a Professor of Medicine at the University of Toronto, the Medical Director of the Sunnybrook HIV Ambulatory Clinic, and for many years was Infectious Diseases Division Chief at Sunnybrook Health Sciences Centre in Toronto. Dr. Rachlis' pursuits in medical education have demonstrated dedication to developing knowledge and clinical skills in new physicians, supporting the continuing education of her colleagues, and advancing the role of AMMI Canada as an association that promotes quality education for infectious diseases physicians and medical microbiologists.

Presenting the award: Mark Joffe, President AMMI Canada

2013 AMMI Canada Lifetime Achievement Award

Dr. Low is presented this award posthumously in recognition of his outstanding and distinguished career as a medical microbiologist who was nationally and internationally acknowledged as an exemplary researcher, teacher, mentor, and leader. Dr. Low served as Microbiologist-in-Chief at Mount Sinai Hospital in Toronto from 1985 until 2013, a role that later expanded to include the University Health Network. During those years, his research interests focused on antimicrobial resistant bacteria and invasive group A streptococcal infections and led to the publication of more than 380 papers in peer-reviewed journals. He was one of the public faces of medicine during the SARS epidemic. The leadership he demonstrated during that difficult time was recognized by his receiving several awards and being named Medical Director of the Ontario Public Health Laboratory, which he helped transform into the Ontario Agency for Health Protection and

Promotion. Over the course of his career, Dr. Low trained, supervised, and mentored countless students, residents, and fellows in infectious diseases and clinical and medical microbiology.

Presenting the award: Mark Joffe, President AMMI Canada

John G. FitzGerald – CACMID Outstanding Microbiologist Award

Dr. Mark Wainberg is the recipient of the 2014 John G. FitzGerald - CACMID Award. Dr. Wainberg is Director of the McGill AIDS Centre and also Director of Research at the Lady Davis Institute for Medical Research in Montréal. His contributions to microbiology have been exemplary, including breakthrough research on HIV that lead to the use of 3TC in the treatment of AIDS. As such, Dr. Wainberg's advice and consul is sought worldwide in the field of retrovirology, and he is regarded as an excellent teacher and mentor to his many students and colleagues. Dr. Wainberg is also an extremely prolific researcher and author, with over 500 manuscripts and 260 book chapters editorials and commentaries over the space of his career. A focus of the John G. FitzGerald-CACMID Award is to an individual who excels at clinical service, teaching, research or a combination of these areas. Dr. Wainberg is such an individual who is outstanding in all aspects. His contributions to Microbiology in Canada are large and place him in a similar category to that of the individual the award is named after, Dr. John FitzGerald.

Presenting the award: Heather Adam, President CACMID

Canadian College of Microbiologists (CCM) Distinguished Service Award

The Canadian College of Microbiologists (CCM) Distinguished Service Award is given to members of the Canadian College of Microbiologists in recognition of outstanding professional contributions to the field of microbiology in Canada in the areas of research, teaching and involvement in the Canadian College of Microbiologists. The recipient of the award this year is Dr Syed Sattar from the University of Ottawa.

Presenting the award: Marc Desjardins, President CCM

Canadian Foundation for Infectious Diseases (CFID) Dr. Juan A. Embil Award for Excellence in Infectious Diseases Research

Dr. Jerome Leis, is the recipient of this award. This award celebrates the commitment of a member of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada to inspiring interest and excitement in the field of infectious diseases. The award recognizes clinical specialists in infectious diseases who have performed extraordinary service as role models and mentors to junior clinicians, faculty, fellows, and students involved in the field of infectious diseases.

Presenting the award: Susan Richardson, President CFID



Canadian Foundation for Infectious Diseases (CFID)

Dr. John M. Embil Mentorship Award in Infectious Diseases

Dr. Curtis L. Cooper, is the recipient of this award. This award celebrates the commitment of a member of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada to inspiring interest and excitement in the field of infectious diseases. The award recognizes clinical specialists in infectious diseases who have performed extraordinary service as role models and mentors to junior clinicians, faculty, fellows, and students involved in the field of infectious diseases.

Presenting the award: Susan Richardson, *President CFID*

Dr. Lindsay E. Nicolle Editorial Award

This award is given annually in honour of Dr. Lindsay E. Nicolle, the Founding Editor-in-Chief of The Canadian Journal of Infectious Diseases & Medical Microbiology. This award is given to an individual who has made a significant contribution to infectious diseases and medical microbiology as demonstrated by the impact of their original research published in The Canadian Journal of Infectious Diseases & Medical Microbiology.

Presenting the award: Robert Kalina, *President Pulsus Group*

Canadian Foundation for Infectious Diseases (CFID) Safe Drinking Water Grant

Dr. Younggy Kim (McMaster University) is the recipient of this award for his proposal entitled "Electrochemical disinfection using copper and/or silver". The CFID Safe Drinking Water Pilot Project Grant was established as seed funding for the promotion of studies investigating one of Canada's most valuable resources, water.

Presenting the award: Natalie Prystajecy *Chair, CFID Awards Committee*

Canadian Foundation for Infectious Diseases (CFID)

Summer Student Research Awards

There are three recipients of this award:

- 1) Alex Rewegan, *McMaster University*
- 2) Sophie Felletier, *Ontario Public Health Laboratory*
- 3) Lauren Smith, *Hospital for Sick Children*

The CFID Summer Student Research Awards were established to attract bright young minds with outstanding academic records to the field of infectious diseases, microbiology, and infection control; and to fulfill the CFID mission of supporting research in infectious diseases.

Presenting the award: Natalie Prystajecy *Chair, CFID Awards Committee*

Poster Award Presentations

Saturday April 5

1515 – 1530

Masters of Ceremony:

Jeff Fuller (*Edmonton, AB*)

Daniel Gregson (*Calgary, AB*)

Awards will be presented to the six best poster presentations by students/trainees.

Each of the following awards consists of \$800 and an engraved plaque:

Association of Medical Microbiology and Infectious Disease

(AMMI) Canada Poster Award

Presenting the award: Mark Joffe, *President AMMI Canada*

Canadian Association for Clinical Microbiology and Infectious Diseases

(CACMID) Poster Award

Presenting the award: Heather Adam, *President CACMID*

Canadian Association for Clinical Microbiology and Infectious Diseases

(CACMID) Technologist Poster Award

Presenting the award: Heather Adam, *President CACMID*

Canadian College of Microbiologists (CCM) Poster Award

Presenting the award: Marc Desjardins, *CCM President*

Canadian College of Microbiologists (CCM)

Dr. Kenneth Rozee Memorial Poster Award

Presenting the award: Marc Desjardins, *CCM President*

The following award consists of \$500 and an engraved plaque:

Dr. Susan King Paediatric Abstract Award

This award is given annually to the best abstract by a trainee on a paediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and the Hospital for Sick Children (Division of Infectious Diseases).

Presenting the award: Joan Robinson, *Chair PICNIC*



The AMMI Canada – CACMID Special Lecture



The Impact of Climate and Environmental Changes on Infectious Diseases

Thursday April 3

Immediately following the Awards Presentations

Room: Lecture Theatre (VCC)

Moderators: Heather Adam (Winnipeg, MB)
Mark Joffe (Edmonton, AB)

Speaker: David Fisman (Toronto, ON)

Dr. Fisman is an infectious disease physician and epidemiologist at the University of Toronto's Dalla Lana School of Public Health, where he is Professor of Epidemiology. He is also a practicing infectious diseases physician at the Toronto Western Hospital. He trained in infectious diseases at Beth Israel Deaconess Medical Centre in Boston and from 1999 to 2001 was an Agency for Healthcare Research and Quality (AHRQ) Fellow in Health Policy at Harvard Centre for Risk Analysis. His interests are in analytical and mathematical epidemiology of infectious diseases, and in health economic evaluation of communicable disease control programs.

The global environment is changing at an unprecedented rate, and in a manner attributable to climate change mediated by anthropogenic "greenhouse gases", including carbon dioxide and methane. Direct links between the physical environment and infection have been recognized since the time of Hippocrates (ca. 400 B.C.E.) and are still readily observable in low-income countries with limited health-enhancing infrastructure (e.g., water treatment and sewage management capabilities). The impact of the physical environment on infection risk is less clear – and less well studied – in high-income countries. Nonetheless, there are numerous known mechanisms whereby climate and weather may impact the epidemiology of infectious disease syndromes in high-income countries like Canada, though these mechanisms differ across infectious disease

groupings (e.g., may be distinct for waterborne, vectorborne, and enteric diseases). Climate change (a term that embraces changing temperatures, precipitation patterns, and the frequency of extreme weather events) could impact all three components of the host-pathogen-environment epidemiological triad but understanding of the impacts of climate on infectious disease risk is in its infancy (as are tools necessary to generate such understanding). Better insights into the impact of climate change on infectious disease epidemiology is important for clinical care provision, design and refinement of disease surveillance systems, optimal protection of vulnerable populations, and implementation of cost-effective prevention strategies. In this lecture, I shall review existing evidence of unprecedented anthropogenic climatic change, discuss the implications of such change for several infectious diseases of public health importance, and review currently available methodological tools and disease surveillance systems, that might allow better preparation for the impact of global environmental change on infectious disease risk in Canada.

Objectives:

- Summarize the implications of changing weather patterns and changing frequency of extreme weather events for infectious disease epidemiology, globally and in Canada
- List the challenges of the study of climate change and infectious disease in Canada, including limitations of data sources, challenges in aggregating disease counts and exposure measures in time and space, and the multi-dimensional nature of climate change impacts on the environment
- Outline evidence suggesting that vector-borne disease incidence, including incidence of Lyme disease and West Nile virus infection, is influenced by weather and climatic factors
- Show the links between extreme weather and climatic change to enteric disease in the Canadian context will also be reviewed



Association, Committee, & Other Group Meetings

Wednesday April 2

- 0800 – 1630 AMMI Canada Council Meeting
Room: Balmoral (Fairmont Empress)
Chair: Mark Joffe
- 1400 – 1600 CCM Board Meeting
Room: Library (Fairmont Empress)
Chair: Marc Desjardins
- 1800 – 2100 CFID Board Meeting
Room: Library (Fairmont Empress)
Chair: Susan Richardson
- 1830 – 2000 CACMID Board Meeting
Room: Balmoral (Fairmont Empress)
Chair: Heather Adam

Thursday April 3

- 0700 – 0845 AMMI Canada AGM and Sections Meetings
Room: Ivy Ballroom (Fairmont Empress)
Chair: Mark Joffe
- 1130 – 1400 Royal College MM Specialty Committee Meeting
Room: Library (Fairmont Empress)
Chair: David Haldane
- 1130 – 1400 Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Annual Meeting
Room: Kensington (Fairmont Empress)
Chair: Joan Robinson

Friday April 4

- 0730 – 0845 CACMID AGM
Room: Ivy Ballroom (Fairmont Empress)
Chair: Heather Adam
- 1130 – 1400 Royal College ID Specialty Committee Meeting
Room: Library (Fairmont Empress)
Chair: Andrew Morris
- 1300 – 1400 Exhibitor Debrief
Room: Victoria (VCC)
Chairs: Jeff Fuller and Shariq Haider
- 1730 – 1930 Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Editorial Board Meeting
Room: Library (Fairmont Empress)
Chair: John Conly
- 1730 – 2000 Canadian Hospital Epidemiology Committee (CHEC) Meeting
Room: Ivy Ballroom (Fairmont Empress)
Chair: Virginia Roth

Saturday April 5

- 0745 – 0845 CCM AGM
Room: Ivy Ballroom (Fairmont Empress)
Chair: Marc Desjardins
- 1230 – 1400 MALDI-TOF Users Group Meeting
Room: Ivy Ballroom (Fairmont Empress)
Chairs: Kathryn Bernard and Philippe Legacé-Wiens

Integrated Symposia

Co-developed by AMMI Canada

Room: Crystal Ballroom
(Fairmont Empress)

Thursday April 3

1230 – 1430

Hosted by Cubist
Pharmaceuticals Canada
*Management of Drug Resistant
Gram+ and Gram- Infections:
Current and Future Approaches*

Friday April 4

1230 – 1430

Hosted by Pfizer Canada
*The Complexities of CAP Caused
by S. pneumoniae: Taking a
Closer Look at Community-
Acquired Pneumonia in Adults*

Workshops

Co-developed by AMMI Canada

Room: Crystal Ballroom
(Fairmont Empress)

Thursday April 3

0800 – 0900

Hosted by Astellas Pharma
Canada
*Debate on Role of Combination
Therapy for Invasive Aspergillosis*

Friday April 4

0800 – 0900

Hosted by Sunovion
Pharmaceuticals Canada

*Outpatient Parenteral Antibiotic
Therapy (OPAT): An East –
West Divide of Feasibility*

Saturday April 5

0800 – 0900

Hosted by bioMérieux
*The Need for MIC and
Resistance Testing*



Wednesday April 2

0800 – 1630 AMMI Canada Council Meeting
Room: Balmoral (Fairmont Empress)

0800 – 1200 CCM Workshop Canadian College of Microbiologists  Collège Canadien des Microbiologistes

Laboratory Automation - Not Just a Pipe Dream

Room: Oak Bay 2 (VCC)

*Automation in Microbiology –
 a Paradigm Shift with Widespread Clinical Impact*

Speaker: Susan Poutanen (Toronto, ON)

Objectives:

- Review options for automation in diagnostic microbiology laboratories
- Discuss the clinical impact of automation on laboratory function, clinical care, antimicrobial stewardship, and infection control
- Outline practical steps in implementing automation in order to maximize its clinical impact

Implementation of MALDI-TOF in a Large, Urban Canadian Hospital

Speaker: Marc Romney (Vancouver, BC)

Objectives:

- Describe issues relating to MALDI-TOF procurement and validation
- Review the direct identification of organisms from positive blood cultures using MALDI-TOF
- Understand the clinical impact of MALDI-TOF technology on patient care in 2014

Microbiology Laboratory Automation, a True Story!

Speaker: Jean-François Gagnon (Québec, QC)

Objectives:

- Make the right choice for your microbiology lab automation
- Understand the workbench organization around microbiology lab automation
- Describe the human factor challenges in implementation of microbiology lab automation

1230 – 1700 Trainees' Day

Room: Saanich 1 & 2 (VCC)

1230 – 1300 Lunch & Registration

1300 – 1345 *Curriculum Vitae (CV) Development*

Speaker: Alicia Sarabia (Toronto, ON)

Objectives:

- Describe the general format and the categories that should be included in a CV
- Tailor a CV to suit the different potential types of employment opportunities for an Infectious Diseases/Microbiology trainee
- Identify the "do's and don'ts" in CV writing, with an emphasis on what trainee activities to include or exclude
- Apply the concept of and the general considerations in writing a cover letter

1345 – 1445 *International Opportunities*

Speakers: Jan Hajek (Vancouver, BC)

Tim O'Shea (Hamilton, ON)

Objectives:

- Gain insights regarding international work through shared personal experiences
- Identify ways that physicians can get involved in international health, both in Canada and abroad
- Identify international opportunities in research, education, clinical and laboratory work
- Address the ethical dimensions of international work

1445 – 1500 BREAK

1500 – 1600 *Career Opportunities in Infectious Diseases and Microbiology - Panel Discussion*

Speakers: Christopher Lowe (Toronto, ON)

Julianne Kus (Toronto, ON)

Soren Gantt (Vancouver, BC)

Karsten Hammond (Victoria, BC)

Objectives:

- Identify current and future job opportunities in Infectious Diseases and Microbiology
- Describe methods that would prepare a trainee in obtaining a position in their field
- Contrast the advantages and disadvantages of various career paths in Infectious Diseases and Microbiology



1600 – 1700 *Physician - Industry Interactions during Training and Beyond*

Speakers: Gerald Evans (Kingston, ON)
John Galbraith (Victoria, BC)

Objectives:

- Review the CMA guidelines for physician-industry interactions
- Describe the CMA guidelines for physician-industry interactions
- Contrast examples of good and poor partnership with industry
- Illustrate how industry can influence physician behaviour
- List the requirements for reporting conflicts of interest

**1300 – 1700 Quality Management (QM) Seminar
Quality and Safety and Risk in the
Medical Laboratory**

Room: Oak Bay 1 (VCC)

Improving Elder Care and Patient Safety Through Improved Urine Collection

Speaker: Victor Leung (Montréal, QC)

Objectives:

- Describe the process of implementing an evidence-based tool kit in residential care to reduce inappropriate collection of urine cultures
- Improve diagnosis of asymptomatic bacteriuria

Enhancing Patient Safety Through Improved Blood Culturing

Speaker: John Galbraith (Victoria, BC)

Objective:

- Illustrate improved blood culture processing techniques to optimize patient outcomes at local and remote sites

Mounting a National Proficiency Test (PT) for 16S rRNA Gene Sequencing and/or MALDI-TOF Analysis

Speaker: Kathy Bernard (Winnipeg, MB)

Objective:

- Recognize that modern laboratory systems do not perform equally when presented with difficult challenges

A Trending View of Proficiency Testing Of Throat Swabs

Speaker: Veronica Restelli (Vancouver, BC)

Objective:

- Be aware that laboratory performance can fluctuate even with routine test requests

Extended Costs of Poor Quality

Speaker: Michael Noble (Vancouver, BC)

Objective:

- Conclude that laboratory performance errors have impact far beyond budget

1300 – 1800 Speaker Ready Room
Room: Sooke (VCC)

1400 – 1600 CCM Board Meeting
Room: Library (Fairmont Empress)

1700 – 1800 Trainees' Day Reception
Room: Saanich 1 & 2 (VCC)

1800 – 2100 CFID Board Meeting
Room: Library (Fairmont Empress)

1830 – 2000 CACMID Board Meeting
Room: Balmoral (Fairmont Empress)

Welcome Reception and Dinner in Exhibit Hall

Thursday April 3

1835 – 2030

Room: Carson Hall (VCC)

You are invited to attend the 2014 Annual Conference Welcome Reception and Dinner.

Whether you'd like to share your experiences of the conference so far, discuss the day's biggest debates or simply enjoy a drink and dinner, the Welcome Reception and Dinner is the perfect place to make new acquaintances and catch up with old friends.

Join the conference planning committees, conference speakers, sponsors, exhibitors and fellow delegates in a relaxed and informal atmosphere, while enjoying culinary delights in a stand up style dinner.



Thursday April 3

0700 – 0845 AMMI Canada AGM and Sections Meetings

Room: Ivy Ballroom (Fairmont Empress)

0700 – 1730 Speaker Ready Room

Room: Sooke (VCC)

0800 – 0900 Workshop

**co-developed by AMMI Canada and
Astellas Pharma Canada**

Room: Crystal Ballroom (Fairmont Empress)

A Debate on the Role of Combination Therapy for Invasive Aspergillosis

Speakers: Michel Laverdière (Montréal, QC)
Shariq Haider (Hamilton, ON)
Stephen Sanche (Saskatoon, SK)

Objectives

By the end of this session the participant will be able to:

- Summarize the epidemiology of Invasive Aspergillosis (identifying high risk groups) in Canada
- Recognize the morbidity and mortality of Invasive Aspergillosis
- Employ the available evidence both supporting and refuting the role combination therapy for Invasive Aspergillosis
- Outline changing paradigms in the management of Invasive Aspergillosis

0830 – 0900 Break

Room: Registration Area (VCC)

0900 – 1100 Plenary: Antimicrobial Stewardship Program

Room: Lecture Theatre (VCC)

Moderators: Susan Poutanen (Toronto, ON)
Alexander Wong (Regina, SK)

0900 – 1000 *Setting up an Antimicrobial Stewardship Program:
Practical Approach, Step by Step Guide and the
Best Outcome Measures for a Program*

Speaker: Andrew Morris (Toronto, ON)

Objectives:

- List the basic steps required to initiate a successful hospital stewardship program
- Choose methods to collect data to inform indicators of program success
- Propose the most successful approach to resourcing programs

1000 – 1100 *The Veterinary / Agriculture Angle for
Antimicrobial Stewardship*

Speaker: Scott Weese (Guelph, ON)

Objectives:

- Describe how antimicrobials are used in animals
- Highlight differences in antimicrobial use between different animal types (food animals vs. companion animals)
- Illustrate the complexity of antimicrobial use and resistance in animal species
- Assess the relative use of antimicrobials in humans and different animal species, and the potential impact on antimicrobial resistance

1100 – 1130 Break

Room: Carson Hall (VCC)

1100 – 1300 Exhibit Hall Open

Room: Carson Hall (VCC)

1100 – 1230 Student Poster Judging (presenters at posters)

Room: Carson Hall (VCC)

1100 – 1300 Poster Viewing

Room: Carson Hall (VCC)

1130 – 1400 Royal College MM Specialty Committee Meeting

Room: Library (Fairmont Empress)

1130 – 1400 Paediatric Investigators Collaborative Network on

Infections in Canada (PICNIC) Annual Meeting

Room: Kensington (Fairmont Empress)

1230 – 1300 Exhibit Hall Lunch

Room: Carson Hall (VCC)

**1230 – 1430 Integrated Symposium
co-developed by AMMI Canada and
Cubist Pharmaceuticals Canada**

Room: Crystal Ballroom (Fairmont Empress)
Lunch provided

*Management of Drug Resistant Gram+ and Gram- Infections:
Current and Future Approaches*

Speakers: Andrew Simor (Toronto, ON)
Theodore (Ted) Steiner (Vancouver, BC)

Objectives:

By the end of this session the participant will be able to:

- Describe the impact of Gram-positive bacterial resistance, with a focus on methicillin resistant *Staphylococcus aureus* (MRSA) and acute bacterial skin and skin structure infections (ABSSSI) in Canada
- Recognize the impact of Gram-negative bacterial resistance, with a focus on multi-drug resistant (MDR) pathogens (eg. *Pseudomonas aeruginosa*), and complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) in Canada



1430 – 1445 Break
Room: Registration Area (VCC)

1445 – 1545 State of the Art Clinical Lecture
Room: Lecture Theatre (VCC)

MERS-CoV Close-up

Moderator: Susan Poutanen (Toronto, ON)

Speaker: Allison McGeer (Toronto, ON)

Objectives:

- Discuss the epidemiology, clinical presentation, diagnosis, and management of MERS
- Explore hospital outbreaks of MERS
- Describe infection prevention and control issues around emerging infections

1545 – 1600 Break
Room: Registration Area (VCC)

1600 – 1700 Oral Presentations: Session A

Room: Esquimalt (VCC)

A01 1600 – 1615

Clostridium difficile: a Study in the Search for Features Associated with the Ability to Cause Outbreaks

A. WEN^{1,2}, G. BROUKHANSKI^{1,2}

¹Public Health Ontario Laboratories, Toronto, ON, ²LMP, University of Toronto, Toronto, ON

A02 1615 – 1630

Molecular Epidemiology of Clostridium difficile in a British Columbia Community: Shift in Pulsed-field Gel Electrophoresis Profiles between 2008 and 2013

A.N. JASSEM¹, N. PRYSTAJECKY¹, F. MARRA¹, P. KIBSEY², K. TAN², P. UMLANDT¹, L. JANZ¹, S. CHAMPAGNE³, BCAMM MEMBERS⁴, B. GAMAGE⁵, B. HENRY¹, L. HOANG¹

¹BC Centre for Disease Control Public Health and Reference Laboratory, Vancouver, BC, ²Island Health, Victoria, BC, ³St. Paul's Hospital, Vancouver, BC, ⁴British Columbia Association of Medical Microbiologists, BC, ⁵Provincial Infection Control Network of British Columbia, Vancouver, BC

A03 1630 – 1645

Evaluation of a Colorex C. difficile from CHROMagar for isolation of Clostridium difficile from stool specimens for characterisation and strain typing by molecular methods

G. BROUKHANSKI^{1,2}, C. LEE³

¹Public Health Ontario Laboratories, Toronto, ON, ²LMP, University of Toronto, Toronto, ON, ³St. Joseph's Healthcare, Hamilton, ON

A04 1645 – 1700

Identification and Characterization of a Clostridium difficile Isolate with Reduced Susceptibility to Vancomycin

A. WONG¹, D.A. BOYD², G. GOLDING², M. GRAHAM², C. FRENETTE³, L. HOLMES⁴, K. KATZ⁵, P. KIBSEY⁶, A. MCGEER⁷, M. MILLER³, D. MOORE⁸, A.E. SIMOR⁹, K. SUH¹⁰, G. TAYLOR¹¹, G.G. ZHANEL¹², D. GRAVEL¹³, M.R. MULVEY², CANADIAN NOSOCOMIAL INFECTION SURVEILLANCE PROGRAM (CNISP)

¹Royal University Hospital, Saskatoon, SK, ²National Microbiology Laboratory, Winnipeg, MB, ³McGill University Health Centre, Montréal, QC, ⁴Children's and Women's Health Center, Vancouver, BC, ⁵North York General Hospital, Toronto, ON, ⁶Royal Jubilee Hospital, Victoria, BC, ⁷Mount Sinai Hospital, Toronto, ON, ⁸Montréal Children's Hospital, Montréal, QC, ⁹Sunnybrook Health Sciences Centre, Toronto, ON, ¹⁰The Ottawa Hospital, Ottawa, ON, ¹¹University of Alberta Hospital, Edmonton, AB, ¹²Health Sciences Centre, Winnipeg, MB

1600 – 1700 Oral Presentations: Session B

Room: Oak Bay 1 (VCC)

B01 1600 – 1615

Is the Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE), Extended-Spectrum -lactamase-producing Enterobacteriaceae (ESBL), Carbapenem-Resistant Enterobacteriaceae (CRE) and Clostridium difficile Infection (CDI) Changing in Canadian Hospitals? A Comparison of Survey Results in 2010 and 2012

A.E. SIMOR¹, V. WILLIAMS¹, A. MCGEER², G. HAN³, Z. HIRJI⁴, O. LARIOS⁵, K. WEISS⁶, A. KISS⁷

¹Sunnybrook Health Sciences Centre, Toronto, ON, ²Mount Sinai Hospital, Toronto, ON, ³Provincial Infection Control Network of British Columbia, Vancouver, BC, ⁴Bridgepoint Health, Toronto, ON, ⁵University of Calgary, Calgary, AB, ⁶Hopital Maisonneuve-Rosemont, Montréal, QC, ⁷Institute of Clinical Evaluative Sciences, Toronto, ON

B02 1615 – 1630

Changing Trends in Vancomycin-Resistant Enterococci (VRE) Bacteremia: the Power and Pitfalls of Using Publicly Reported Infection Rates

G. GARBER^{1,2}, K. ADOMAKO¹, C. PREMATUNGE¹, F. LAM¹, G. DIDIODATO^{1,3}, J. ROBERTSON¹, C. EGAN¹

¹Public Health Ontario, Toronto, ON, ²Ottawa Hospital Research Institute, Ottawa, ON, ³Royal Victoria Regional Health Centre, Barrie, ON

B03 1630 – 1645

A Survey of Infection Prevention and Control Policies for the Management of Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE), and Clostridium difficile Infection (CDI) in Canadian Hospitals

V. WILLIAMS¹, A.E. SIMOR¹, A. MCGEER², G. HAN³, Z. HIRJI⁴, A. KISS⁵, O. LARIOS⁶, K. WEISS⁷

¹Sunnybrook Health Sciences Centre, Toronto, ON, ²Mount Sinai Hospital, Toronto, ON, ³Provincial Infection Control Network of British Columbia, Vancouver, BC, ⁴Bridgepoint Health, Toronto, ON, ⁵Institute for Clinical Evaluative Sciences, Toronto, ON, ⁶University of Calgary, Calgary, AB, ⁷Hopital Maisonneuve-Rosemont, Montréal, QC



B04

1645 – 1700

Developing a Culture of Evaluative Research for Infection Prevention and Control Practice

G. GARBER^{1,2}, K. ADOMAKO¹, F. LAM¹, J. ROBERTSON¹,
C. PREMATUNGE¹, C. EGAN¹

¹Public Health Ontario, Toronto, ON, ²Ottawa Hospital Research Institute, Ottawa, ON

1600 – 1700 Oral Presentations: Session C

Room: Oak Bay 2 (VCC)

C01

1600 – 1615

RIDA®GENE Parasitic Stool Panel and xTAG® Gastrointestinal Pathogen Panel for the Detection of Common Intestinal Parasites

T. LLOYD¹, J. CARSON^{1,2}, W. CHAN^{1,2}, D. PILLAI^{1,2}

¹Calgary Laboratory Services, Calgary, AB, ²University of Calgary, Calgary, AB

C02

1615 – 1630

The Prevalence of Common Intestinal Parasitic Pathogens from Community Patients in Ontario 2008-2012

D. LUNGRIN, D. JAMES, D. LETO, H. ALMOHRI

LifeLabs Medical Laboratory Services, Toronto, ON

C03

1630 – 1645

Antifungal Susceptibility of Invasive Candida Isolates from Canadian Hospitals: Results of the CANWARD 2013 Study

J. FULLER¹, S. SHOKOPLES¹, L-A. TURNBULL¹, R. RENNIE¹, H.J. ADAM^{2,3},
M. BAXTER^{2,3}, D.J. HOBAN^{2,3}, G.G. ZHANEL^{2,3}

¹Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB,
²Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB,
³Diagnostic Services of Manitoba, Winnipeg, MB

C04

1645 – 1700

Antifungal Susceptibility of Respiratory Aspergillus Isolates from Canadian Hospitals: Results of the CANWARD 2013 Study

J. FULLER¹, S. SHOKOPLES¹, L-A. TURNBULL¹, R. RENNIE¹, H.J. ADAM^{2,3},
M. BAXTER^{2,3}, D.J. HOBAN^{2,3}, G.G. ZHANEL^{2,3}

¹Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB,
²Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, AB,
³Diagnostic Services of Manitoba, Winnipeg, AB

1600 – 1700 Oral Presentations: Session D

Room: Saanich 1 & 2 (VCC)

D01

1600 – 1615

Measles, Mumps and Rubella Virus Genotypes Identified in Canada in 2012 and 2013

L. MENDOZA¹, J. HIEBERT¹, A. PETERSON¹, J. BEIRNES¹,
L. PODHORODECKI¹, H. SCHULZ², A. SEVERINI^{1,2}

¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB,
²Department of Medical Microbiology, University of Manitoba, Winnipeg, MB

D02

1615 – 1630

Update on the Molecular Characteristics of West Nile Virus in British Columbia

M.K. LEE¹, S. MAN¹, K. FERNANDO¹, T. LO¹, Q. WONG¹, B. HENRY²,
M. MORSHED¹

¹BC Public Health Microbiology and Reference Laboratory, Vancouver, BC,
²BC Centre for Disease Control, Vancouver, BC

D03

1630 – 1645

Evaluation of the COBAS® AmpliPrep/TaqMan® CMV Test for CMV Quantitative Viral Load Testing

C. LOWE^{1,2}, L. MERRICK¹, G. RITCHIE¹, C. SHERLOCK^{1,2}

¹Providence Health Care, Vancouver, BC, ²University of British Columbia, Vancouver, BC

D04

1645 – 1700

Rapid Genotyping of Human Rotavirus Using a SYBR Green Real-Time RT-PCR with Melting Curve Analysis

Y.T. TONG¹, B. LEE¹, X.L. PANG^{1,2}

¹University of Alberta, Edmonton, AB, ²Provincial Laboratory for Public Health (ProvLab), Edmonton, AB

1700 – 1710

Break

Room: Registration Area (VCC)

1710 – 1735

Awards Presentations

Room: Lecture Theatre (VCC)

Masters of Ceremony:

Jeff Fuller (Edmonton, AB)
Daniel Gregson (Calgary, AB)



1735 – 1835 AMMI Canada – CACMID Special Lecture

Room: Lecture Theatre (VCC)

The Impact of Climate and Environmental Changes on Infectious Diseases

Moderators: Heather Adam (Winnipeg, MB)
Mark Joffe (Edmonton, AB)

Speaker: David Fisman (Toronto, ON)

Objectives:

- Summarize the implications of changing weather patterns and changing frequency of extreme weather events for infectious disease epidemiology, globally and in Canada
- List the challenges to the study of climate change and infectious disease in Canada, including limitations of data sources, challenges in aggregating disease counts and exposure measures in time and space, and the multi-dimensional nature of climate change impacts on the environment
- Outline the evidence suggesting that vector-borne disease incidence, including incidence of Lyme disease and West Nile virus infection, is influenced by weather and climatic factors
- Show the links between extreme weather and climatic change to enteric disease in the Canadian context will also be reviewed

1835 – 2030 Welcome Reception and Dinner in Exhibit Hall

Room: Carson Hall (VCC)

Friday April 4

0700 – 1700 Speaker Ready Room

Room: Sooke (VCC)

0730 – 0845 CACMID AGM

Room: Ivy Ballroom (Fairmont Empress)

0800 – 0900 Workshop

co-developed by AMMI Canada

and Sunovion Pharmaceuticals

Room: Crystal Ballroom (Fairmont Empress)

Outpatient Parenteral Antibiotic Therapy (OPAT):

An East – West Divide of Feasibility

Speakers Coleman Rotstein (Toronto, ON)
Gregory Rose (Ottawa, ON)
Andrew Pattullo (Calgary, AB)

Objectives

By the end of this session the participant will be able to:

- Review the epidemiology of skin and soft tissue infections in Canada
- Recognize the evidence for OPAT
- Describe the East and West perspective of success and challenges in OPAT implementation.

0830 – 0900 Break sponsored by Siemens

Room: Registration Area (VCC)

0900 – 1100 Plenary: Emerging Infections

Room: Lecture Theatre (VCC)

Moderators: Todd Hatchette (Halifax, NS)
Jason LeBlanc (Halifax, NS)

0900 – 0940 *Novel Emerging Respiratory Virus Surveillance (NERVS)
– H7N9 and Other Update*

Speaker: Danuta Skowronski (Vancouver, BC)

Objectives:

- Describe current clinical, epidemiologic and virologic trends in H7N9 and other emerging respiratory pathogens
- Summarize current risk assessment and anticipate possible future scenarios
- Outline public health response activities, with a focus on early detection and containment

0940 – 1020 *Emerging Tick-Borne Diseases in Canada:
Lyme Disease and Beyond*

Speaker: Robbin Lindsay (Winnipeg, MB)

Objectives:

- Describe the biology and ecology of the tick vectors that transmit the agents of Lyme disease and other emerging pathogens in Canada
- Identify the changing dynamic of risk of human exposure to these tick-associated pathogens including the mechanisms that are likely driving disease emergence
- Recognize the challenges that public health authorities face with respect to pathogen detection and implementation of effective disease prevention strategies

1020 – 1100 *The Importance of National and International
Laboratory Networking in Responding to Emerging
Infectious Diseases*

Speakers: Michael Drebot (Winnipeg, MB)

Objectives:

- Describe the history, successes, and objectives of the Canadian Public Health Laboratory Network (CPHLN) and recognize how it has evolved over the years
- Recognize current International Lab Networking activities involving Canadian Infectious Disease Experts and how they link to the CPHLN
- Discuss the role of lab networks in reagent and strain sharing when preparing for emerging infectious diseases
- Recall examples of how International Laboratory Networks have responded to a Public Health Emergency of International Concern involving emerging infectious diseases

1100 – 1130 Break

Room: Carson Hall (VCC)



- 1100 – 1300 Exhibit Hall Open
Room: Carson Hall (VCC)
- 1100 – 1230 Poster Viewing (presenters at posters)
Room: Carson Hall (VCC)
- 1100 – 1300 Poster Viewing
Room: Carson Hall (VCC)
- 1130 – 1400 Royal College ID Specialty Committee Meeting
Room: Library (Fairmont Empress)
- 1230 – 1300 Exhibit Hall Lunch
Room: Carson Hall (VCC)

1230 – 1430 Integrated Symposium
Co-developed by AMMI Canada and Pfizer Canada

Room: Crystal Ballroom (Fairmont Empress)
Lunch provided

The Complexities of CAP Caused by S. pneumoniae: Taking a Closer Look at Community-Acquired Pneumonia in Adults

Speakers: Shelly McNeil (Halifax, NS)
George Zhanel (Winnipeg, MB)

Objectives:

By the end of this session the participant will be able to:

- Discuss the burden of illness of community-acquired pneumonia (CAP) amongst adults in Canada
- Review a novel urinary antigen test to help detect *S. pneumoniae* CAP
- Identify the impact of *S. pneumoniae*, particularly multi-drug resistant *S. pneumoniae*, at all points of care
- Explain the preliminary results from the Community Acquired Pneumonia Immunization Trial in Adults (CAPITA) trial

- 1300 – 1400 Exhibitor Debrief
Room: Victoria (VCC)

1445 – 1545 State of the Art Clinical Lecture
Room: Lecture Theatre (VCC)

To Screen or not to Screen: the Role of Hospital-Based Infection Control Programs in Controlling Antibiotic-Resistant Organisms

Moderator: Matthew Oughton (Montréal, QC)

Debaters: **For:** Allison McGeer (Toronto, ON)
Against: Elizabeth Bryce (Vancouver, BC)

Resolution: *Be it resolved that screening and transmission control for antibiotic-resistant organisms should be mandatory components of hospital-based infection control programs*

Objective:

- Argue for and against mandatory screening and transmission control for antibiotic resistant organisms

- 1545 – 1600 Break
Room: Registration Area (VCC)

1600 – 1745 Oral Presentations: Session E

Room: Esquimalt (VCC)

E01 1600 – 1615

Epidemiology of Bordetella pertussis Genotypes in Alberta: January 2012 – August 2012

K. SIMMONDS¹, S. FATHIMA^{2,3}, L. CHUI^{2,4}, M. LOVGREN², P. SHOOK², M. SHUEL⁵, G. TYRRELL^{2,4}, R. TSANG⁵, S. DREWS^{2,6}

¹Alberta Health, ²ProvLab, Alberta Health Services, AB, ³London School of Hygiene and Tropical Medicine, London, UK, ⁴University of Alberta, Edmonton, AB, ⁵National Microbiology Laboratory, Winnipeg, MB, ⁶University of Calgary, Calgary, AB

E02 1615 – 1630

A Highly Unusual Late Autumn Legionella pneumophila Serogroup1 Knoxville Sequence Type 222 Outbreak in an Inner City Neighborhood in Calgary, Canada

S. HOSEINI¹, S. DREWS^{2,3}, J. CONLY^{4,5}, N. PUNJA⁶, H. KIMBERLY⁶, K. SIMMONDS⁷, K. BERNARD^{8,9}, J. CARSON^{4,10}, J. MACDONALD^{1,6}, B. FRIESEN^{1,11}

¹Department of Community Health Sciences, University of Calgary, ²ProvLab Alberta, Alberta Health Services, ³Department of Microbiology, Immunology, and Infectious Diseases, ⁴Department of Pathology and Laboratory Medicine, University of Calgary, ⁵Infection Prevention and Control, Alberta Health Services, ⁶Alberta Health Services, Calgary, ⁷Alberta Health, Edmonton, AB, ⁸National Microbiology Laboratory – Public Health Agency of Canada, ⁹University of Manitoba, Department of Medical Microbiology, Winnipeg, MB, ¹⁰Section of Microbiology, Calgary Laboratory Services, ¹¹Medical Officer of Health, Safe & Healthy Environments & Tobacco Reduction, Population, Public & Aboriginal Health, Alberta Health Services, Calgary, AB

E03 1630 – 1645

Molecular Profiling of Human and Cattle Shiga Toxin-Producing Escherichia coli Strains in Alberta, Canada

L. CHUI^{1,2}, V. LI¹, P. FACH³, S. DELANNOY³, K. MALEJCZYK², A. POON¹, R. KING⁴, M-C. LEE⁵

¹Provincial Laboratory for Public Health, Edmonton, AB, ²University of Alberta, Edmonton, AB, ³Anses (French Agency for Food, Environmental and Occupational Health and Safety), Food Safety Laboratory, Maisons-Alfort, France, ⁴Alberta Agriculture and Rural Development, Edmonton, AB, ⁵DynaLIFE, Edmonton, AB

E04 1645 – 1700

Molecular Characterization of Drug Resistant Mycobacterium tuberculosis in the Province of Québec

H. SOUALHINE¹, J. SPINATO¹, E. BÉLANGER-TRUELLE¹, L. CÔTÉ¹, C. TREMBLAY^{1,2}

¹Institut national de santé publique du Québec, Montréal, QC, ²Université de Montréal, Montréal, QC



E05 1700 – 1715

The Re-Emergence of Multidrug-Resistant Salmonella enterica serotype Newport in Canada: Is there an Animal-Food Link?

M.R. MULVEY¹, S. WEGER¹, R. FINLEY², S. LANGNER¹, V. ALLEN³, G. GERMAN⁴, S. BEKAL⁵, S. EL BAILEY⁶, D. HALDANE⁷, L. HOANG⁸, G.B. HORSMAN⁹, M. LOUIE¹⁰, L. ROBERTS¹¹, J. WYLIE¹², J. PARMLEY², D. LÉGER², B. AVERY², R. IRWIN²

¹National Microbiology Laboratory, Winnipeg, MB, ²Public Health Agency of Canada, Guelph, ON, ³Public Health Ontario, Toronto, ON, ⁴Queen Elizabeth Hospital, Charlottetown, PEI, ⁵Institut national de santé publique du Québec, Montréal, QC, ⁶Saint John Regional Hospital, Saint John, NB, ⁷Provincial Public Health Laboratory Network of Nova Scotia, Halifax, NS, ⁸BC Centre for Disease Control, Vancouver, BC, ⁹Saskatchewan Disease Control Laboratory, Regina, SK, ¹⁰Alberta Provincial Laboratory for Public Health, Calgary, AB, ¹¹Newfoundland Public Health Laboratory, St. John's, NL

F02 1615 – 1630

Risk Factors For Treatment of Asymptomatic Bacteriuria: Does an Educational Intervention Reduce Unnecessary Treatment?

A. BROOKS^{1,2}, N. IRFAN¹, S. MITHOOWANI², D. LEE², A. CARDUCCI³, S. CELETTI³, A. CHENG³, D. MERTZ^{1,2}

¹Hamilton Health Sciences, Hamilton, ON, ²McMaster University, Hamilton, ON, ³University of Waterloo, Waterloo, ON

F03 1630 – 1645

Cost of Fosfomycin Compares Favourably to Reimbursed Agents as Empirical Treatment of Uncomplicated Urinary Tract Infections

L. PERRAULT¹, G.G. ZHANEL², C. LAROCHE³, J. LELORIER⁴, D. MITCHELL¹, S. DAHAN⁵

¹International Market Access Consulting, Repentigny, QC, ²University of Manitoba, Winnipeg, MB, ³Clinique Médicale Cadillac, Montréal, QC, ⁴Université de Montréal, QC, ⁵Triton Pharma Inc., Montréal, QC

F04 1645 – 1700

Reversal of Gonorrhea Antibiotic Resistance Trends in British Columbia: Can We Save the Oral Option?

R. LESTER^{1,3}, T. HOTTES^{1,3}, Y. CHANG², L. HOANG^{2,3}

¹BC Centre for Disease Control, Vancouver, BC, ²Provincial Health Services Authority Laboratories, Vancouver, BC, ³University of British Columbia, Vancouver, BC

F05 1700 – 1715

Surveillance of Antimicrobial Resistance (AMR) and Antimicrobial Utilization (AU) in Canada: Final Results of a Comprehensive Review and Ten Recommendations to Achieve Optimal Canadian Surveillance Programs

L. SAXINGER¹, J. GRANT², P. KEEN², D. PATRICK²

¹University of Alberta, Edmonton, AB, ²University of British Columbia, Vancouver, BC

F06 1715 – 1730

Shifts in Epidemiology of Blood Stream Infection (BSI) on an Inpatient Hematology Ward: Piperacillin Tazobactam Resistance, and Implications for Empiric Febrile Neutropenic Treatment

L. SAXINGER, S. SMITH, G. TAYLOR

University of Alberta, Edmonton, AB

E06 1715 – 1730

Emergence of Multidrug-Resistant Salmonella Dublin from Human and Animal Sources in Québec

S. BEKAL¹, G. CÔTÉ², M. NADEAU², B. LEFEBVRE¹, A. BHARAT³, R. MANDES³, R. FINLEY⁴, C. TREMBLAY¹, M. R. MULVEY³

¹Laboratoire de santé publique du Québec, Sainte-Anne-De-Bellevue, QC, ²Ministère de l'Agriculture, des Pêcheries et de l'Alimentation du Québec, Québec, QC, ³Public Health Agency of Canada, Winnipeg, MB, ⁴Public Health Agency of Canada, Guelph, ON

E07 1730 – 1745

Molecular Serotyping for Salmonella

L. CHUI^{1,2}, C. FERRATO³, M. LOUIE³

¹Provincial Laboratory for Public Health, Edmonton, AB, ²University of Alberta, Edmonton, AB, ³Provincial Laboratory for Public Health, Calgary, AB

1600 – 1745 Oral Presentations: Session F

Room: Oak Bay 1 (VCC)

F01 1600 – 1615

A Point Prevalence Study to Measure Appropriateness of Antimicrobial Prescribing on General Internal Medicine Patients as Part of an Antimicrobial Stewardship Program

K. DUPLISEA¹, S. NELSON², S. OLEGARIO¹, A. MORRIS^{2,3}, P. BUNCE¹

¹University Health Network, Toronto, ON, ²Mount Sinai Hospital, Toronto, ON, ³University of Toronto, Toronto, ON



F07

1730 – 1745

Buyer Beware: Investigation of an Automated Washer Unit for Cleaning and Sanitizing Commodes on an Acute Care Blood and Marrow Transplant-Hematology-Oncology Ward and Implications for Microbial Transmission

L. WARD¹, R. MCCOMBIE¹, L. HARRISON¹, J. LEAVITT¹, J. CONLY^{1,2},
T. LOUIE^{1,2}

¹Alberta Health Services - Calgary and Area, Calgary, AB, ²Departments of Medicine and Microbiology, Immunology & Infectious Diseases, Synder Institute for Chronic Diseases, University of Calgary, Calgary, AB

1600 – 1745 Oral Presentations: Session G

Room: Oak Bay 2 (VCC)

G01

1600 – 1615

Use of Electrical Treatment for the Recovery of Microbial Ribosomal RNA Followed by RT-PCR for the Detection and Identification of Bacteria and Fungi in Blood Samples

T. MAZZULLI^{1,2}, A.A. KHINE³, C. STONE³, B. SHAH³, S. TALEBPOUR³,
R. MAASKANT³, T. ALAVIE³

¹Mount Sinai Hospital/University Health Network Department of Microbiology, Toronto, ON, ²University of Toronto, Toronto, ON, ³Qvella Corporation, Richmond Hill, ON

G02

1615 – 1630

Adoption of Massively Parallel Real-time PCR Assays for Detection of Viral and Bacterial Pathogens on a Nanofluidic Biochip

N.A. ANTONISHYN, D. BIRCH, C. AGOPSOWICZ, K. SCHMALENBERG,
R.R. MCDONALD, P.N. LEVETT, G.B. HORSMAN

Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, SK

G03

1630 – 1645

Evaluation of Molecular Assays for the Detection of Influenza Viruses and RSV in Respiratory Specimens

T. MAZZULLI^{1,2}, G. MOUSSA¹, K. ROTTENGATTER³, M. HESS³

¹Mount Sinai Hospital/University Health Network Department of Microbiology, Toronto, ON, ²University of Toronto, Toronto, ON, ³Altona Diagnostics GmbH, Hamburg, Germany

G04

1645 – 1700

Detection of Circulating Norovirus Genotypes: Hitting a Moving Target

B-L. ROONEY¹, K. BINKHAMIS^{1,2}, J. PETTIPAS², E. GRUDESKI³,
X.L. PANG^{4,5}, T. BOOTH³, T.F. HATCHETTE^{1,2}, J. LEBLANC^{1,2}

¹Dalhousie University, Halifax, NS, ²Capital District Health Authority, Halifax, NS, ³National Microbiology Laboratory, Winnipeg, MB, ⁴Provincial Laboratory for Public Health, Edmonton, AB, ⁵University of Alberta, Edmonton, AB

G05

1700 – 1715

Pooled Nucleic Acid Testing Increases the Diagnostic Yield of Acute HIV Infection Compared to 3rd and 4th Generation HIV EIA

K. CHU¹, D. COOK², A. MAK¹, N. CHAHIL¹, M. STEINBERG³,
M. GILBERT^{2,4}, M. KRAJDEN^{1,2,3}

¹Public Health Microbiology & Reference Laboratory, Vancouver, BC, ²BC Centre for Disease Control, Vancouver, BC, ³Simon Fraser University, Burnaby, BC, ⁴University of British Columbia, Vancouver, BC

G06

1715 – 1730

Dual Enzyme Immunoassay (EIA) Screening for Confirmation of HCV Infection

N. CHAHIL¹, K. CHU¹, A. MAK¹, D. COOK², A. MCNABB¹, M. KRAJDEN^{1,2,3}

¹Public Health Microbiology & Reference Laboratory, Vancouver, BC, ²BC Centre for Disease Control, Vancouver, BC, ³University of British Columbia, Vancouver, BC

G07

1730 – 1745

Seroprotection against Emerging and Re-Emerging Influenza Viruses: Results of an Age-Based Serosurvey, British Columbia, 2013

C. CHAMBERS¹, D.M. SKOWRONSKI¹, S. SABAIUDUC², D. PURYCH³,
N.Z. JANJUA¹, G. DE SERRES⁴, M. PETRIC², M. KRAJDEN², D. KOBASA⁵, Y. LI⁵

¹BC Centre for Disease Control, Vancouver, BC, ²Public Health Microbiology Reference Laboratory, Vancouver, BC, ³BC Biomedical Laboratories, Surrey, BC, ⁴Institut National de Santé Publique de Québec, Québec City, QC, ⁵National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

1600 – 1745 Oral Presentations: Session H

Room: Saanich 1 & 2 (VCC)

H01

1600 – 1615

Urine Collection Systems that are Designed to Preserve Urinary Pathogens During Transport: Effect of System and Transport Time on Bacterial Survival

K. GAUCHIER-PITTS¹, R. RENNIE¹, L-A. TURNBULL¹, C. OOSTERHOFF²

¹University of Alberta Hospital, Edmonton, AB, ²Red Deer Regional Hospital, Red Deer, AB

H02

1615 – 1630

Comparison of BD MAX MRSA Assay Using a Combined Nasal/Perianal Eswab to Nasal and Perianal Swabs Cultured on Chrom Agar and Broth Enrichment Media

C. ELLIS, W. CICCOTELLI

Grand River Hospital, Kitchener, ON



Saturday April 5

0700 – 1600 Speaker Ready Room
Room: Sooke (VCC)

0745 – 0845 CCM AGM
Room: Ivy Ballroom (Fairmont Empress)

0800 – 0900 Workshop
co-developed by AMMI Canada and bioMérieux
Room: Crystall Ballroom (Fairmont Empress)

The Need for MIC and Resistance Testing

Speakers: Matthew Oughton (Montreal, QC)
Pamela C. Kibsey (Victoria, BC)

Objectives

By the end of this session the participant will be able to:

- Demonstrate the updates and advances in Carbapenem resistance detection
- Identify the current needs for antimicrobial susceptibility testing, focusing MIC or S-I-R

0830 – 0900 Break
Room: Registration Area (VCC)

0900 – 1100 Plenary: What's Hot in Adult and Paediatric Infectious Diseases, Infection Control and Diagnostic Microbiology

Room: Lecture Theatre (VCC)

Moderators: Cécile Tremblay (Montréal, QC)
Duncan Webster (Saint John, NB)

0900 – 1000 *Adult and Paediatric Clinical Quick-Fire Discussion*
Speakers: Neil Rau (Oakville, ON)
Joan Robinson (Edmonton, AB)

Objectives:

- Highlight new developments in the literature on topics related to adult and paediatric infectious diseases
- Explore some of the controversies in the literature on topics related to adult and paediatric infectious diseases
- A brief review of therapeutic advances in adult and paediatric infectious diseases

1000 – 1030 *What's Hot in Infection Control*

Speaker: Titus Wong (Vancouver, BC)

Objectives:

- Review headline outbreaks
- Highlight new developments in Infection Control literature
- Review new technologies in Infection Control

1030 – 1100 *What's Hot in Diagnostic Microbiology*

Speaker: Edith Blondel-Hill (Kelowna, BC)

Objectives:

- Discuss new recommendations for susceptibility testing especially as it pertains to antibiotic resistant organisms
- Review new pathogens and their clinical significance
- Review the new technologies that will improve time to result for microbiology laboratory

H03 1630 – 1645

Detecting Mycobacterium avium Complex in Respiratory Specimens by a Duplex qPCR Using the ABI 7900 Fast Real-Time PCR System

N. LOWTHER¹, D. EISLER¹, A. MCNABB¹, P. TANG^{1,2}

¹B.C. Centre for Disease Control, PHSA, Vancouver, BC, ²University of British Columbia, Vancouver, BC

H04 1645 – 1700

Development of a Real-time PCR Assay for the Differentiation of Streptococcus pneumoniae and Streptococcus pseudopneumoniae

T. LEE¹, K. ADIE¹, A. MCNABB¹, L. HOANG^{1,2}, P. TANG^{1,2}

¹BC Centre for Disease Control, Vancouver, BC, ²University of British Columbia, Vancouver, BC

H05 1700 – 1715

Comparison of Viral Transport Medium and Amies Transport Medium with Charcoal for the Detection of Bordetella pertussis by PCR

L. ZHOU, L. HOANG, M. PETRIC

BC Centre for Disease Control, Vancouver, BC

H06 1715 – 1730

Evaluation of the TBcID Assay for the Detection of Mycobacterium tuberculosis Complex Organisms Directly from Liquid Culture

M. SHARMA^{1,2}, S. CHRISTIANSON¹, J.A. KARLOWSKY^{2,3}, D. KEIN¹, N. SMART¹, J. WOLFE¹

¹National Microbiology laboratory, PHAC, Winnipeg, MB, ²Med Micro, University of Manitoba, Winnipeg, MB, ³Clinical Micro, Health Sciences Centre, Winnipeg, MB

H07 1730 – 1745

Antimicrobial Susceptibility Testing (AST) by Broth Microdilution (BMD) using CLSI Guidelines for Corynebacterium Isolates Referred to the National Microbiology Laboratory

K. BERNARD^{1,2}, A.L. PACHECO¹, T. BURDZ¹, D. WIEBE¹

¹National Microbiology Laboratory, Winnipeg MB, ²U of Manitoba Department Medical Microbiology, Winnipeg MB

1730 – 1930 Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Editorial Board Meeting
Room: Library (Fairmont Empress)

1730 – 2000 Canadian Hospital Epidemiology Committee (CHEC) Meeting
Room: Ivy Ballroom (Fairmont Empress)



1100 – 1110 Break
Room: Registration Area (VCC)

1110 – 1225 Oral Presentations: Session I

Room: Esquimalt (VCC)

I01 1110 – 1125

Application of Multiple Molecular Methods for Subtyping Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae Isolates from Multiple Hospitals

Y. CHANG¹, C. NG¹, E. BRODKIN², B. MAC^{3,2}, D. PURYCH^{4,2}, D.A. BOYD⁵, K. FAKHARUDDIN⁵, M.R. MULVEY⁵, L. HOANG¹

¹BC Public Health Microbiology & Reference Laboratory, Vancouver, BC, ²Fraser Health Authority, Surrey, BC, ³Surrey Memorial Hospital, Surrey, BC, ⁴Royal Columbian Hospital, New Westminster, BC, ⁵National Microbiology Laboratory, Winnipeg, MB

I02 1125 – 1140

Evaluation of the β -LACTATM Test for the Rapid Detection of Extended Spectrum Beta Lactamases in Enterobacteriaceae from Perianal Swabs

P. SHETH^{1,4}, M. TADROS², W. SMALL³, Z. HUSSAIN³

¹Department of Microbiology, Kingston General Hospital, Kingston, ON, ²Department of Microbiology, Surrey Memorial Hospital, Surrey, BC, ³Department of Microbiology, St. Michaels Hospital, Toronto, ON, ⁴Department of Pathology and Molecular Medicine, Queens University, Kingston, ON

I03 1140 – 1155

Evaluation of Three Chromogenic Media for the Detection of Vancomycin Resistant Enterococci (VRE)

H. ALMOHRI, S. SMITH, L. VAN ZUILEN

LifeLabs Medical Laboratory Services, Toronto, ON

I04 1155 – 1210

Use of Wellcolex Colour Shigella (WCS) Latex Agglutination to Detect Shigella among Non-Lactose Fermentors (NLF) Identified (ID) by MALDI-TOF as Escherichia coli

B.M. WILLEY^{1,2}, C. VERMEIREN³, G. RICCI⁴, C. WATT⁵, P. LO^{1,2}, A.E. SIMOR^{5,6}, S.M. POUTANEN^{1,2,6}

¹Mount Sinai Hospital, Toronto, ON, ²University Health Network, Toronto, ON, ³Shared Hospital Laboratory, Toronto, ON, ⁴William Osler Health Sciences Centre, Markham, ON, ⁵Sunnybrook Health Sciences Centre, Toronto, ON, ⁶University of Toronto, Toronto, ON

I05 1210 – 1225

Evaluation of a Novel Enterococcosel Enrichment Broth in Combination with a Chromogenic VRE Plate within a Region of High VRE Prevalence

P. KORNHERR, K. GUINDON, L. NGUYEN, S. VALUPADAS

Gamma-Dynacare Medical Laboratories, Ottawa, ON

1110 – 1225 Oral Presentations: Session J

Room: Oak Bay 1 (VCC)

J01 1110 – 1125

Comparison of Continuous Random Access Testing for C. trachomatis on a Panther® Instrument to Batch Testing on a cobas® 4800 System

M. CHERNESKY¹, D. JANG¹, J.F. FLANDIN², J. GILCHRIST¹, M. SMIEJA¹, S. RATNAM³

¹St. Joseph's Healthcare/McMaster University, Hamilton, ON, ²Public Health Laboratory, St. John's, NL, ³Memorial University, Division of Community Health and Humanities, St. John's, NL

J02 1125 – 1140

Genotyping of Lymphogranuloma venereum Chlamydia Serovars at the National Microbiology Laboratory

A. SEVERINI^{1,2}, V. ZUBACH¹, F. ROY¹

¹Public Health Agency of Canada, Winnipeg, MB, ²University of Manitoba, Winnipeg, MB

J03 1140 – 1155

A Preliminary Molecular-Based Assay for the Detection of Antimicrobial Resistant Neisseria gonorrhoeae

S. PETERSON¹, I. MARTIN¹, W. DEMCZUK¹, L. HOANG², J. WYLIE³, V. ALLEN⁴, B. LEFEBVRE⁵, M. LOVGREN⁶, G.B. HORSMAN⁷, D. HALDANE⁸, T. WONG⁹, C. ARCHIBALD⁹, M.R. MULVEY¹

¹Bacteriology and Enteric Diseases Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, MB, ²British Columbia Centres for Disease Control Public Health Microbiology & Reference Laboratory, Vancouver, British Columbia, BC, ³Cadham Provincial Laboratory, Winnipeg, MB, ⁴Public Health Ontario Laboratories, Toronto, ON, ⁵Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, QC, ⁶Provincial Laboratory for Public Health, Edmonton, AB, ⁷Saskatchewan Disease Control Laboratory, Regina, SK, ⁸Queen Elizabeth II Health Sciences Centre, Halifax, NS, ⁹Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON



J04

1155 – 1210

*A New Rise in an Old Disease: LGV in British Columbia 2004-2013*L. HOANG^{1,2,3}, J. KELLY^{2,4}, A. SEVERINI⁵, R. LESTER³¹British Columbia Public Health Microbiology and Reference Laboratory, Vancouver, BC,²Department of Pathology and Laboratory Medicine, The University of British Columbia,Vancouver, BC, ³BC Centre for Disease Control, Vancouver, BC, ⁴Department ofPathology, Royal Jubilee Hospital, Victoria, BC, ⁵Public Health Agency of Canada,

Winnipeg, MB

J05

1210 – 1225

*Whole-Genome Sequencing of Neisseria gonorrhoeae Isolates with Reduced Cephalosporin Susceptibilities Collected in Canada Between 2001 and 2012*W. DEMCZUK¹, T. LYNCH², I. MARTIN¹, V. ALLEN³, L. HOANG⁴,
B. LEFEBVRE⁵, M. LOVGREN⁶, G.B. HORSMAN⁷, T. WONG⁸,
C. ARCHIBALD⁸, G. VAN DOMSELAAR⁹, M. GRAHAM⁹, M.R. MULVEY¹¹Bacteriology and Enteric Diseases Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, ²Alberta Health Services, Calgary, AB, ³Public Health Ontario Laboratories, Toronto, ON, ⁴British Columbia Centres for Disease Control, Public Health Microbiology & Reference Laboratory, Vancouver, BC, ⁵Laboratoire de Santé Publique du Québec, Ste-Anne-de-Bellevue, QC, ⁶Provincial Laboratory for Public Health, Edmonton, AB, ⁷Saskatchewan Disease Control Laboratory, Regina, SK, ⁸Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON, ⁹Science Technology Cores and Service Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB**1110 – 1225 Oral Presentations: Session K****Room:** Oak Bay 2 (VCC)**K01**

1110 – 1125

*The National Notifiable Diseases Database (NDDDB): A New Resource for Public Health*S. BALAKUMAR^{1,2}¹National Collaborating Centre for Infectious Diseases, Winnipeg, MB,²University of Manitoba, Winnipeg, MB**K02**

1125 – 1140

*Impact of Conjugant Pneumococcal Vaccine Programs on Rates of Invasive Pneumococcal Disease (IPD), 2001-2013*A. MCGEER^{1,2}, K. GREEN¹, W. RUDNICK^{1,2}, A. SHIGAYEVA¹,
S. PONG-PORTER¹, A. PLEVNESHI¹, TORONTO INVASIVE BACTERIAL
DISEASES NETWORK¹¹Mount Sinai Hospital, Toronto, ON, ²University of Toronto, Toronto, ON**K03**

1140 – 1155

*Babesia and Hepatitis E Seroprevalence in Canadian Blood Donors*M. FEARON¹, V. SCALIA², S. O'BRIEN², M. BIGHAM³, A. ANDONOV⁴,
S. WEGER⁴, F. BERNIER⁵, S. DUBUC⁵, G. DELAGE⁵, M. GERMAIN⁵¹Canadian Blood Services, Toronto, ON, ²Canadian Blood Services, Ottawa, ON,³Canadian Blood Services, Vancouver, BC, ⁴National Microbiology Laboratory, Winnipeg, MB,⁵Héma Québec, Montréal, QC**K04**

1155 – 1210

*A Prospective Comparison of Rotavirus and Norovirus Severe Gastroenteritis Following the Implementation of a Publicly Funded Rotavirus Vaccine Program in Québec*M.K. DOLL¹, M. GONZALES², H. CHAREST³, A. GAGNEUR⁴,
D.L. BUCKERIDGE¹, C. QUACH^{1,2}¹McGill University, Montréal, QC, ²The Montreal Children's Hospital, Montréal, QC,³Quebec Public Health Laboratory (LSPQ), Montréal, QC, ⁴Sherbrooke University Hospital, Sherbrooke, QC**K05**

1210 – 1225

*Hospitalization due to Respiratory Syncytial Virus (RSV) Infection in Immunosuppressed Adults: A Retrospective Cohort Study*K. HASSAN¹, C. VOLLING^{1,2}, T. MAZZULLI^{1,2}, A. MCGEER^{1,2}¹Mount Sinai Hospital, Toronto, ON, ²University of Toronto, Toronto, ON**1110 – 1225 Oral Presentations: Session L****Room:** Saanich 1 & 2 (VCC)**L01**

1110 – 1125

*Detection of non-O157 Escherichia coli in Saskatchewan Using Chromogenic Culture Medium and PCR Screening*D. DAKU¹, R. DEPAULO^{1,2}, D. THIRY¹, R.R. MCDONALD¹,
G.B. HORSMAN¹, P.N. LEVETT¹¹Saskatchewan Disease Control Laboratory, Regina, SK, ²National Microbiology Laboratory, PHAC, Winnipeg, MB**L02**

1125 – 1140

*Pooled Nucleic Acid Amplification Test for Screening of Stool Specimens for Shiga Toxin-Producing Escherichia coli*F. CHOU¹, M.A. CROXEN¹, A.N. JASSEM¹, K. PINTAR², F. POLLARI²,
A. PACCAGNELLA¹, J. ISAAC-RENTON¹, L. HOANG¹, N. PRYSTAJECKY¹¹BC Centre for Disease Control Public Health and Reference Laboratory, Vancouver, BC,²FoodNet Canada, Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Ottawa/Guelph, ON

L03

1140 – 1155

Heat-Resistant Shiga Toxin-Producing Escherichia coli (STEC) - a New Emerging Pathogen?

L. CHUI^{1,2}, R. KASSAM¹, A. POON¹

¹Provincial Laboratory for Public Health, Edmonton, AB, ²University of Alberta, Edmonton, AB

L04

1155 – 1210

Two-Step Identification of Shiga-Toxigenic Escherichia coli (STEC) with Chromogenic Media (CGM) and Enzyme Immunoassay (EIA) from Human Stool Specimens

K. TAN¹, B. WALKER¹, L. HOANG², P. KIBSEY¹

¹Island Health, Victoria, BC, ²BC Centre for Disease Control Public Health and Reference Laboratory, Vancouver, BC

L05

1210 – 1225

Shiga-Toxin Producing Escherichia coli (STEC) Infections in the Province of Québec: Results of 13 Years of Surveillance Program

S. BEKAL¹, F. DOUALLA-BELL¹, C. GAULIN², G. GRAVEL³, C. TREMBLAY¹

¹Laboratoire de santé publique du Québec, Sainte-Anne-De-Bellevue, QC, ²Ministère de la santé et des services sociaux, Québec, QC, ³Ministère de la santé et des services sociaux, Montréal, QC

1230 – 1400 MALDI-TOF Users Group Meeting
Room: Ivy Ballroom (Fairmont Empress)

1230 – 1400 Lunch
Room: Crystal Ballroom (Fairmont Empress)

1400 – 1500 State of the Art Clinical Lecture
Sponsored by the Canadian Foundation for Infectious Diseases (CFID)

Room: Lecture Theatre (VCC)

Microbe-managing: Manipulating the Human Gut Microbial Ecosystem to Enhance Health

Moderator: Matthew Gilmour (Winnipeg, MB)

Speaker: Emma Allen-Vercoe (Guelph, ON)

Objectives:

- Describe the complexity and elegance of the healthy human gut microbial ecosystem
- Illustrate the potential consequences of collateral damage to this microbial ecosystem through the use of antimicrobials in medicine and the environment
- Consider the potential use of 'microbial ecosystem therapeutics' as paradigm-shifting elements of future, personalized medicine approaches to healthcare

1500 – 1515 Break
Room: Registration Area (VCC)

1515 – 1530 Poster Awards Presentations
Room: Lecture Theatre (VCC)

Masters of Ceremony: Jeff Fuller (Edmonton, AB)
Daniel Gregson (Calgary, AB)

1530 – 1800 Clinical Vignettes
Room: Lecture Theatre (VCC)

Chair: Caroline Quach (Montréal, QC)

Discussants: Gerald Evans (Kingston, ON)
Mark Miller (Montréal, QC)

The audience, using an audience response system, along with the discussants, will work through the cases to try and solve them.

1900 – 2200 Closing Dinner
Room: First People's Gallery and Modern History Gallery (Royal BC Museum)



Closing Dinner

Saturday April 5
1900 – 2200

Location: First People's Gallery and Modern History Gallery
Royal BC Museum

Cost: \$65 plus 5% GST

Satisfy your hunger with a delectable closing dinner and challenge your understanding of the First Nations peoples of British Columbia.

In the Modern History Gallery, explore turn-of-the-century streets, a replica of North America's second-oldest Chinatown, and a Northern BC pioneer farm. Mingle with fur traders and explorers and investigate the rich history of British Columbia.

Learn about the rich art and culture of the First Nations peoples in the breathtaking First Peoples Galleries. Dine among silent totems, a testament to the peoples' strength and creativity and then learn the legends of Captain Cook.

- Please note that red wine will not be served at the Closing Dinner as a precaution to preserve the pieces in the Royal BC Museum's collection. Thank you for your understanding
- We recommend wearing flat shoes as the floor is uneven
- You are welcome to bring your cameras to this event



Event Mobi App



Want all this and more at your fingertips? Download the Event Mobi app at eventmobi.com/victoria2014 for quick and easy access to the entire final program! Remember to add the app as an icon on your smartphone's homepage so you never lose it.

Program at a Glance

Wednesday
April 2

Thursday
April 3

Friday
April 4

Saturday
April 5

0700	0800	0900	1000	1100	1200
					1200 – 1800
	0800 – 1630 AMMI Canada Council Meeting Room: Balmoral				
	0800 – 1200 CCM Workshop Room: Oak Bay 2				
0700 – 1730 Registration Open					
0700 – 1730 Speaker Ready Room Room: Sooke					
0700 – 0845 AMMI Canada AGM and Sections Meetings Room: Ivy Ballroom		0900 – 1100 Plenary: Antimicrobial Stewardship Program Room: Lecture Theatre		1100 – 1300 Exhibit Hall Open Room: Carson Hall	
	0800 – 0900 Workshop: Astellas Pharma Canada Room: Crystal Ballroom A Debate on the Role of Combination Therapy for Invasive Aspergillosis Speakers: Michel Laverdière, Shariq Haider, and to be confirmed	0900 – 1000 Setting up an Antimicrobial Stewardship Program: Practical Approach, Step by Step Guide and the Best Outcome Measures for a Program Speaker: Andrew Morris		1100 – 1300 Poster Viewing Room: Carson Hall	
		1000 – 1100 The Veterinary / Agriculture Angle for Antimicrobial Stewardship Speaker: Scott Weese		1100 – 1300 BREAK Room: Registration Area	1130 – 1400 Royal College MM Specialty Committee Meeting Room: Library
	BREAK				1130 – 1400 Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Annual Meeting
					LUNCH
0700 – 1700 Registration Open					
0700 – 1700 Speaker Ready Room Room: Sooke					
	0730 – 0845 CACMID AGM Room: Ivy Ballroom	0900 – 1100 Plenary: Emerging Infections Room: Lecture Theatre		1100 – 1300 Exhibit Hall Open Room: Carson Hall	
	0800 – 0900 Workshop: Sunovion Pharmaceuticals Room: Crystal Ballroom Outpatient Parenteral Antibiotic Therapy (OPAT): An East – West Divide of Feasibility Speakers: Coleman Rotstein, Gregory Rose, and Andrew Pattullo	0900 – 0940 Novel Emerging Respiratory Virus Surveillance (NERVS) – H7N9 and Other Update Speaker: Danuta Skowronski		1100 – 1300 Poster Viewing Room: Carson Hall	
		0940 – 1020 Emerging Tick-Borne Diseases in Canada: Lyme Disease and Beyond Speaker: Robbin Lindsay		1100 – 1300 BREAK Room: Registration Area	1130 – 1400 Royal College ID Specialty Meeting Room: Library
		1020 – 1100 The Importance of National and International Laboratory Networking in Responding to Emerging Infectious Diseases Speaker: Michael Drebot			
	BREAK				LUNCH
0700 – 1700 Registration Open					
0700 – 1630 Speaker Ready Room Room: Sooke					
	0745 – 0845 CCM AGM Room: Ivy Ballroom	0900 – 1100 Plenary: What's Hot in Adult and Paediatric Infectious Diseases, Infection Control and Diagnostic Microbiology Room: Lecture Theatre		1110 – 1225 Oral Presentations: Session I Room: Esquimalt	
	0800 – 0900 Workshop: bioMérieux Room: Crystal Ballroom The Need for MIC and Resistance Testing Speakers: Matthew Oughton and Pamela C. Kibsey	0900 – 1000 Adult and Paediatric Clinical Quick-fire Discussion Speakers: Joan Robinson and Neil Rau		1110 – 1225 Oral Presentations: Session J Room: Oak Bay 1	
		1000 – 1030 What's Hot in Infection Control Speaker: Titus Wong		1110 – 1225 Oral Presentations: Session K Room: Oak Bay 2	
		1030 – 1100 What's Hot in Diagnostic Microbiology Speaker: Edith Blondel-Hill		1110 – 1225 Oral Presentations: Session L Room: Saanich 1 & 2	
	BREAK			1100 – 1110 BREAK Room: Registration Area	

31



SAVE THE DATE

Dates: April 16 – 18 avril

Location: Delta Prince Edward and Prince
Edward Island Convention Centre



Innovation Academy

Reminder: The next Innovation Academy will take place at the 2015 Conference in lovely Charlottetown, PEI.

This competition encourages the promotion of novel and creative strategies that have the potential to stimulate significant change in Clinical Medicine, Laboratory Medicine, Infection Prevention and Control, Antimicrobial Stewardship, Public Health or education devoted to any of these disciplines.

Here is your opportunity to present your pioneering approach to clinical or educational program delivery, transformative quality improvement initiatives, or the invention of new diagnostic platforms or medical devices.

Successful submissions will be chosen for a 3 minute oral “pitch” followed by a 3 minute Q&A. Presentations will be adjudicated based on originality, creativity, applicability, ease of duplication, sustainability

and overall significance. The winner will be awarded a \$1,500 cash prize, second place will receive an iPad and third place will be given complimentary registration to the AMMI Canada - CACMID Annual Conference 2016.

Start preparing now!

Only a select few will be chosen for presentation.



Poster Presentations

**Thursday April 3
and Friday April 4**

Room:
Carson Hall (VCC)

Poster Viewing:

Thursday April 3,
at 1100 – 1300

Friday April 4,
at 1100 – 1300

Presenters at Posters:

Thursday April 3,
at 1100 – 1230

Friday April 4,
at 1100 – 1230

Student Poster Presentations (SP01 – SP46)

Poster Presentations (P01 – P59)

Exhibit Booths
Food & Beverages
Main Entrance



P21	P42	P43	SP07	SP28	SP08	SP29	SP45	SP44	SP43	SP42	SP40	SP39	
P01	P22	P44	SP06	SP27	SP09	SP32	SP32	SP33	SP34	SP35	SP37	SP38	
P20	P41	P45	SP04	SP26	SP10	SP33	SP34	SP35	SP36	SP37	SP38	SP39	
P19	P40	P46	SP02	SP24	SP11	SP34	SP35	SP36	SP37	SP38	SP39	SP40	
P18	P39	P47	SP01	SP23	SP12	SP35	SP36	SP37	SP38	SP39	SP40	SP41	
P05	P26	P48	P59	SP22	SP13	SP36	SP37	SP38	SP39	SP40	SP41	SP42	
P06	P27	P49	P58	SP21	SP14	SP37	SP38	SP39	SP40	SP41	SP42	SP43	
P07	P28	P50	P57	SP20	SP15	SP38	SP39	SP40	SP41	SP42	SP43	SP44	
P15	P34	P51	P56	SP19	SP16	SP39	SP40	SP41	SP42	SP43	SP44	SP45	
P08	P29	P52	P55	SP18	SP17	SP40	SP41	SP42	SP43	SP44	SP45	SP46	
P09	P30	P53	P54	SP17	SP18	SP41	SP42	SP43	SP44	SP45	SP46	SP47	
P13	P33	P54	P53	SP16	SP17	SP42	SP43	SP44	SP45	SP46	SP47	SP48	
P14	P34	P55	P54	SP15	SP18	SP43	SP44	SP45	SP46	SP47	SP48	SP49	
P11	P32	P53	P54	SP14	SP17	SP44	SP45	SP46	SP47	SP48	SP49	SP50	
P10	P31	P52	P53	SP13	SP16	SP45	SP46	SP47	SP48	SP49	SP50	SP51	
				SP12	SP15	SP46	SP47	SP48	SP49	SP50	SP51	SP52	
				SP11	SP14	SP47	SP48	SP49	SP50	SP51	SP52	SP53	
				SP10	SP13	SP48	SP49	SP50	SP51	SP52	SP53	SP54	
				SP09	SP12	SP49	SP50	SP51	SP52	SP53	SP54	SP55	
				SP08	SP11	SP50	SP51	SP52	SP53	SP54	SP55	SP56	
				SP07	SP10	SP51	SP52	SP53	SP54	SP55	SP56	SP57	
				SP06	SP09	SP52	SP53	SP54	SP55	SP56	SP57	SP58	
				SP05	SP08	SP53	SP54	SP55	SP56	SP57	SP58	SP59	
				SP04	SP07	SP54	SP55	SP56	SP57	SP58	SP59	SP60	
				SP03	SP06	SP55	SP56	SP57	SP58	SP59	SP60	SP61	
				SP02	SP05	SP56	SP57	SP58	SP59	SP60	SP61	SP62	
				SP01	SP04	SP57	SP58	SP59	SP60	SP61	SP62	SP63	
				SP00	SP03	SP58	SP59	SP60	SP61	SP62	SP63	SP64	
				SP00	SP03	SP59	SP60	SP61	SP62	SP63	SP64	SP65	
				SP00	SP03	SP60	SP61	SP62	SP63	SP64	SP65	SP66	
				SP00	SP03	SP61	SP62	SP63	SP64	SP65	SP66	SP67	
				SP00	SP03	SP62	SP63	SP64	SP65	SP66	SP67	SP68	
				SP00	SP03	SP63	SP64	SP65	SP66	SP67	SP68	SP69	
				SP00	SP03	SP64	SP65	SP66	SP67	SP68	SP69	SP70	
				SP00	SP03	SP65	SP66	SP67	SP68	SP69	SP70	SP71	
				SP00	SP03	SP66	SP67	SP68	SP69	SP70	SP71	SP72	
				SP00	SP03	SP67	SP68	SP69	SP70	SP71	SP72	SP73	
				SP00	SP03	SP68	SP69	SP70	SP71	SP72	SP73	SP74	
				SP00	SP03	SP69	SP70	SP71	SP72	SP73	SP74	SP75	
				SP00	SP03	SP70	SP71	SP72	SP73	SP74	SP75	SP76	
				SP00	SP03	SP71	SP72	SP73	SP74	SP75	SP76	SP77	
				SP00	SP03	SP72	SP73	SP74	SP75	SP76	SP77	SP78	
				SP00	SP03	SP73	SP74	SP75	SP76	SP77	SP78	SP79	
				SP00	SP03	SP74	SP75	SP76	SP77	SP78	SP79	SP80	
				SP00	SP03	SP75	SP76	SP77	SP78	SP79	SP80	SP81	
				SP00	SP03	SP76	SP77	SP78	SP79	SP80	SP81	SP82	
				SP00	SP03	SP77	SP78	SP79	SP80	SP81	SP82	SP83	
				SP00	SP03	SP78	SP79	SP80	SP81	SP82	SP83	SP84	
				SP00	SP03	SP79	SP80	SP81	SP82	SP83	SP84	SP85	
				SP00	SP03	SP80	SP81	SP82	SP83	SP84	SP85	SP86	
				SP00	SP03	SP81	SP82	SP83	SP84	SP85	SP86	SP87	
				SP00	SP03	SP82	SP83	SP84	SP85	SP86	SP87	SP88	
				SP00	SP03	SP83	SP84	SP85	SP86	SP87	SP88	SP89	
				SP00	SP03	SP84	SP85	SP86	SP87	SP88	SP89	SP90	
				SP00	SP03	SP85	SP86	SP87	SP88	SP89	SP90	SP91	
				SP00	SP03	SP86	SP87	SP88	SP89	SP90	SP91	SP92	
				SP00	SP03	SP87	SP88	SP89	SP90	SP91	SP92	SP93	
				SP00	SP03	SP88	SP89	SP90	SP91	SP92	SP93	SP94	
				SP00	SP03	SP89	SP90	SP91	SP92	SP93	SP94	SP95	
				SP00	SP03	SP90	SP91	SP92	SP93	SP94	SP95	SP96	
				SP00	SP03	SP91	SP92	SP93	SP94	SP95	SP96	SP97	
				SP00	SP03	SP92	SP93	SP94	SP95	SP96	SP97	SP98	
				SP00	SP03	SP93	SP94	SP95	SP96	SP97	SP98	SP99	
				SP00	SP03	SP94	SP95	SP96	SP97	SP98	SP99	SP100	

Poster Presentations

P01

Comparison Between Intrathecal Antibody Production against Neurotropic Viruses in Pediatric and Adult Onset Multiple Sclerosis

K. HARATIAN, P. FALLAH

Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Alborz, Iran

P02

Combination Use of Antiviral and Anti-Inflammatory Agents against Lethal Infection of Avian Influenza Virus H5N1 in Animal Model

B.J. ZHENG, K.W. CHAN, S.K.P. LAU, P.C.Y. WOO, K.H. CHAN, D.Y. JIN, K.Y. YUEN

The University of Hong Kong, Hong Kong, Hong Kong

P03

Genetic Diversity of Epstein - Barr Virus in the Setting of Transplant Relative to Non-Transplant Settings: Proof-of-Principle

U. ALLEN^{1,3,5}, P. HU^{1,2}, S. PEREIRA^{1,2}, T. PATON^{1,2}, J. BEYENE^{1,4}, N. KHODAI-BOORAN^{1,3}, A. DIPCHAND^{1,5}, D. HÉBERT^{1,4}, V. NG^{1,5}, T. NALPATHAMKALAM^{1,2}, S. READ^{1,3}

¹Hospital for Sick Children, University of Toronto, Toronto, ON, ²The Centre for Applied Genomics, Toronto, ON, ³Research Institute, Hospital for Sick Children, Toronto, ON, ⁴McMaster University, Hamilton, ON ⁵Transplant Centre, Hospital for Sick Children, Toronto, ON

P04

Determination of the Biological Form of Human Cytomegalovirus DNA in the Plasma of Solid Organ Transplant Recipients

Y.T. TONG¹, X.L. PANG^{2,1}, J.K. PREIKSAITIS¹

¹University of Alberta, Edmonton, AB, ²Provincial Laboratory for Public Health (ProvLab), Edmonton, AB

P05

HCV Clearance is Associated with Improved Immune Phenotype

L. BARRETT^{1,2}, L. DAIGH², C. WANG², J. JOHL², S. KOTTILIL²

¹Dalhousie University, Halifax, NS, ²National Institute of Allergy and Infectious Disease, NIH, Bethesda, USA



P06

Performance of Two Avidity Assays, Bio-Rad Avidity and Sedia Lag Avidity, to Estimate Recent HIV Infection in Québec

B. SERHIR¹, D. HAMEL², J.P. ROUTH³, S-N. BEAULAC¹, M. LEGAULT⁴, M. FAUVEL¹, F. DOUALLA-BELL¹, C. TREMBLAY^{1,5}

¹Institut national de santé publique du Québec/ Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, ²Institut national de santé publique du Québec/ DRBST, Québec, QC, ³Institut thoracique de Montréal, McGill University, Montréal, QC, ⁴CHUM St-Luc, Montréal, QC, ⁵CHUM Hôtel-Dieu, Montréal, QC

P07

Lyme Disease in Nova Scotia: Many Humans Have Been Infected?

T.F. HATCHETTE^{1,2}, L. JOHNSTON³, E. SCHLEIHAUF⁴, A. MASK⁴, A. LALANY⁴, D. HALDANE^{1,2}, M. DREBOT⁵, M. BAIKIE⁶, T. COLE⁷, R. GOULD⁸, R. LINDSAY⁶

¹Capital District Health Authority, Halifax, NS, ²Department of Pathology, Dalhousie University, Halifax, NS, ³Department of Medicine, Dalhousie University, Halifax, NS, ⁴Public Health Agency of Canada, Ottawa, ON, ⁵National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, ⁶Department Health and Social Services, Government of Nunavut, Iqaluit, NU, ⁷Nova Scotia Department of Health and Wellness, Halifax, NS, ⁸York Region Public Health, York, ON

P08

Evaluation of PAB Lyme EIA for the Diagnosis of Borrelia burgdorferi infection

K. KADKHODA^{1,2}, G. SMART¹

¹Cadham Provincial Laboratory, Winnipeg, MB, ²University of Manitoba, Winnipeg, MB

P09

Novel Real-Time PCR Assay Panel for the Detection of Common Respiratory Pathogens in a Convenient, Strip-Tube Array Format

M. HASAN^{1,2}, V. YOUNG¹, G. AL-RAWAHI^{1,2}, E. THOMAS^{1,2}, R. TAN^{1,2}, P. TILLEY^{1,2}

¹Children's and Women's Health Centre of BC, Vancouver, BC, ²University of British Columbia, Vancouver, BC

P10

Validation of a Plaque Reduction Neutralization Test for Rubella: Performance Comparison with Virus-Specific IgG EIAs

B. SERHIR¹, C. DAGENAIS¹, A. OGEE-NWANKWO², R. LAMIRANDE¹, T.F. HATCHETTE³, N. CROWCROFT⁴, F. DOUALLA-BELL¹, C. TREMBLAY^{1,5}

¹Institut national de santé publique du Québec/ Laboratoire national de santé publique, Sainte-Anne-de-Bellevue, QC, ²Centers for Disease Control and Prevention-Measles, Mumps, Rubella & Herpes Lab. Branch, Atlanta, GA, USA, ³Department of Pathology, Dalhousie University, Halifax, NS, ⁴Public Health Ontario, Toronto, ON, ⁵CHUM Hôtel-Dieu, Montréal, QC

P11

Immune Biomarkers Predictive of Respiratory Viral Infection in Elderly Nursing Home Residents

J. JOHNSTONE¹, R. PARSONS¹, F. BOTELHO¹, J. MILLAR¹, S. MCNEIL², T. FULOP³, J. MCELHANEY⁴, M. ANDREW², S. WALTER¹, P.J. DEVEREAUX¹, R. BRINKMAN^{5,6}, M. MALEKESMAEILI⁵, J. MAHONY¹, J. BRAMSON¹, M. LOEB¹

¹McMaster University, Hamilton, ON, ²Dalhousie University, Halifax, NS, ³Université de Sherbrooke, Sherbrooke, QC, ⁴Northern Ontario Medical School, Sudbury, ON, ⁵University of British Columbia, Vancouver, BC, ⁶British Columbia Cancer Agency, Vancouver, BC

P12**Withdrawn****P13**

Validation of Hologic Gen-Probe APTIMA Combo 2 Assay for Chlamydia trachomatis in Eye Specimens

B. HON, R. AZANA, L. HOANG

BC Centre for Disease Control, Vancouver, BC

P14

Detection of Circulating Respiratory Viruses in Riyadh Using a Multiplex Real-Time PCR

A. ALHETHEEL^{1,2}, A. SOMILY^{1,2}, F. ALZAMIL^{1,2}, A. ALBARRAG^{1,2}, S.M. IQBAL^{1,2}, M.M. ALSAADI^{1,2}

¹College of Medicine/King Saud University, Riyadh, Saudi Arabia, ²King Khalid University Hospital, Riyadh, Saudi Arabia

P15

Molecular Detection of Pneumocystis jirovecii by Real-Time PCR

P. JAYARATNE^{1,3}, L. DALLE VEDOVE², D. YAMAMURA^{2,3}

¹St. Joseph's Healthcare, Hamilton Regional Laboratory Medicine Program, Hamilton, ON, ²Hamilton Health Sciences, Hamilton Regional Laboratory Medicine Program, Hamilton, ON, ³McMaster University, Department of Pathology and Molecular Medicine, Hamilton, ON

P16

Multiplex Real-Time PCR Detection of Herpes Simplex Viruses 1 and 2, Varicella Zoster Virus and Human Beta-Globin

D. EISLER¹, A. MCNABB¹, P. TANG^{1,2}

¹B.C. Public Health Microbiology & Reference Laboratory, Vancouver, BC, ²University of British Columbia, Vancouver, BC



P17

Does the BD Viper HSV-Qx Assay Require a Grey Zone?

A. LANG¹, T. AL-SIYABI^{1,2}, C. ROBERTS², T. MAZZULLI^{3,4},
T.F. HATCHETTE^{1,2}, J. LEBLANC^{1,2}

¹Dalhousie University, Halifax, NS, ²Capital District Health Authority, Halifax, NS,
³Mount Sinai Hospital, Toronto, ON, ⁴University Health Network and University of Toronto,
Toronto, ON

P18

Rapid Detection of Rotavirus in Fecal Specimens by PCR during Acute Gastroenteritis among Children Younger than Six Years of Age

K. HARATIAN¹, A.M. MEYBODI²

¹Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Alborz, Iran,
²Department of genetics at reproductive biomedicine research center, Royan Institute for
reproductive biomedicine, ACEOR, Tehran, Iran

P19

Type Distribution of Human Papillomaviruses in Non-familial Breast Cancer Patients in Iran

K. HARATIAN¹, P. FALLAH¹, A.M. MEYBODI²

¹Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Alborz, Iran,
²Department of Genetics at Reproductive Biomedicine Research Center,
Royan Institute of Reproductive Biomedicine, ACEOR, Tehran, Iran

P20

Comparison of Nucleic Acid Extraction from Stool Samples Among Four Autoextractors and their Performance for Detection of Gastroenteritis Viruses using Real-Time RT-PCR

Y. QIU¹, D. ADACHI², X.L. PANG^{1,2}

¹Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB,
²Alberta Provincial Laboratory for Public Health, Edmonton, AB

P21

Comparison of Two Molecular Typing Methods for Streptococcus pneumoniae

A. LANG^{1,3,4}, M. EL-SHERIF^{3,4}, T.F. HATCHETTE^{3,4}, S. MCNEIL^{1,2,3,4},
J. LEBLANC^{1,2,3,4}

¹Dalhousie University, Halifax, NS, ²Capital District Health Authority, Halifax, NS,
³Canadian Center for Vaccinology, Halifax, NS, ⁴The PCIRN Serious Outcomes
Surveillance Network Investigators, Halifax, NS

P22

Antimicrobial Susceptibilities and Multi-Antigen Sequence Types (Ng-Mast) of Neisseria gonorrhoeae Isolated in Canada, 2008-2012

W. DEMCZUK¹, I. MARTIN¹, P. SAWATZKY¹, G. LIU¹, V. ALLEN², L. HOANG³,
B. LEFEBVRE⁴, M. LOVGREN⁵, D. HALDANE⁶, P. VAN CAESELEE⁷,
G.B. HORSMAN⁸, S. RATNAM⁹, R. GARCEAU¹⁰, T. WONG¹¹,
C. ARCHIBALD¹¹, M.R. MULVEY¹

¹Bacteriology and Enteric Diseases Program, National Microbiology Laboratory, Public
Health Agency of Canada, Winnipeg, MB, ²Public Health Ontario Laboratories, Toronto, ON,
³British Columbia Centres for Disease Control Public Health Microbiology & Reference
Laboratory, Vancouver, BC, ⁴Laboratoire de santé publique du Québec, Ste-Anne-de-
Bellevue, QC, ⁵Provincial Laboratory for Public Health, Edmonton, AB, ⁶Queen Elizabeth II
Health Sciences Centre, Halifax, NS, ⁷Cadham Provincial Laboratory, Winnipeg, MB,
⁸Saskatchewan Disease Control Laboratory, Regina, SK, ⁹Newfoundland & Labrador
Public Health Laboratory, St. John's, NL, ¹⁰Hôpital Dr G.L. Dumont, Moncton, NB,
¹¹Centre for Communicable Diseases and Infection Control, Public Health Agency of
Canada, Ottawa, ON

P23

Carbapenemase Detection in Clinically Relevant Enterobacteriaceae and Pseudomonas aeruginosa by MALDI-TOF MS

P. CHONG¹, M. UNGER², D.A. BOYD¹, G. WESTMACOTT¹, M.R. MULVEY^{1,2}

¹Public Health Agency of Canada, Winnipeg, MB, ²University of Manitoba, Winnipeg, MB

P24

Use of Chromogen Specificity in Urine Agars to Reduce MALDI-TOF Workload Associated with Identification (ID) of Escherichia coli

B.M. WILLEY^{1,2}, O. OLEUNG^{1,2}, A. TSANG^{1,2}, S. KIM^{1,2}, I. MANJI^{1,2},
E. RAMOUTAR^{1,2}, S. THARMARADINAM^{1,2}, P. LO^{1,2}, S.M. POUTANEN^{1,2,3}

¹Mount Sinai Hospital, Toronto, ON, ²University Health Network, Toronto, ON,
³University of Toronto, Toronto, ON

P25

VITEK MS PLUS (VMS) Identification (ID) Performance when Challenged with Mixed Bacteria (MB) or Mixed Yeast (MY) Cultures

B.M. WILLEY^{1,2}, E. RAMOUTAR^{1,2}, P. LO^{1,2}, S.M. POUTANEN^{1,2,3}

¹Mount Sinai Hospital, Toronto, ON, ²University Health Network, Toronto, ON,
³University of Toronto, Toronto, ON



P26

Colorimetric Detection of 3rd Generation Cephalosporin Resistance (3GCR) in Enterobacteriaceae (ENT): A Retrospective Evaluation of the Rapid Bio-Rad BLACTA Test (BLT)

B.M. WILLEY^{1,2}, S. TRIMI^{1,2}, D.A. BOYD⁴, A. TSANG^{1,2}, I. MANJI^{1,2},
O. OLEUNG^{1,2}, S. KIM^{1,2}, P. LO^{1,2}, M.R. MULVEY⁴, S.M. POUTANEN^{1,2,3}

¹Mount Sinai Hospital, Toronto, ON, ²University Health Network, Toronto, ON, ³University of Toronto, Toronto, ON, ⁴National Microbiology Laboratory, Winnipeg, MB

P27

Pilot Prospective Evaluation of the BLACTA Test (BLT) for Predicting 3rd Generation Cephalosporin Resistance (3GCR) in Short-Incubation Blood Culture Isolates (SIBCI) of Escherichia coli (EC), Klebsiella pneumoniae (KP), Klebsiella oxytoca (KO) and Proteus mirabilis (PM)

B.M. WILLEY^{1,2}, X. TRIMI^{1,2}, P. LO^{1,2}, S.M. POUTANEN^{1,2,3}

¹Mount Sinai Hospital, Toronto, ON, ²University Health Network, Toronto, ON,
³University of Toronto, Toronto, ON

P28

Evaluation of the Value of Testing Ciprofloxacin Susceptibility in Salmonella sp by Concurrent Nalidixic Acid Disk Diffusion and Ciprofloxacin Disk Diffusion Using the New Revised CLSI Disk Diffusion Breakpoints

H. ALMOHRI, S. SMITH, D. JAMES, C. MORRIS

LifeLabs Medical Laboratory Services, Toronto, ON

P29

Validation of BD BACTEC™ PLUS Plastic Aerobic/F Resin Medium Using Recommended Reference ATCC Strains Seeded Blood Culture and BD BACTEC™ FX, 9240 and 9120 Instruments

J. XIONG, T. KONG, D. HANCOCK, W. CHAPMAN

St Joseph's Health Center, Toronto, ON

P30

In vitro Beta-Lactam Susceptibility Testing of Streptococcus pneumoniae Using Liofilchem Gradient Diffusion Compared to CLSI Broth Microdilution

M. CHARLES, B. BERENGER, L.A. TURNBULL, R. RENNIE, J. FULLER

Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB

P31

Evaluation of Selective Media for the Detection of Ciprofloxacin-Resistant Enterobacteriaceae (CR-E) from Rectal Specimens

A. CAMPIGOTTO¹, D. SOARES², S. MUBAREKA^{1,2}, M. VEARNCOMBE^{1,2},
A.E. SIMOR^{1,2}

¹University of Toronto, Toronto, ON, ²Sunnybrook Health Sciences Centre, Toronto, ON

P32

Study of BIOMIC V3 Automated Versus Manual Reading of MicroScan ESBL Plus Panel Results

P.N. LEVETT¹, T. ASH¹, D. GIBBS², A. WANG², N. THIERJUNG²

¹Saskatchewan Disease Control Laboratory, Regina, SK, ²Giles Scientific Inc., Santa Barbara, CA, USA

P33

Comparative Performance of ESwab and M40 in Extreme Transport Conditions

P. DALEY^{1,2}, C. PENNEY¹, F. JANES², W. MIDODZI¹

¹Memorial University, St. John's, NL, ²Eastern Health, St. John's, NL

P34

A Simple Spectrophotometric Method to Measure Flocked Swab Absorption as an Alternative to Complex Research Methods

B. GANDHI¹, T. MAZZULLI^{1,2}

¹Department of Microbiology, Mt. Sinai Hospital and University Health Network, Toronto, ON,
²University of Toronto, Toronto, ON

P35

Clinical Utility of Reflexive Throat Culture on Negative Rapid Antigen Tests for the Diagnosis of Group A Streptococcal Pharyngitis in Adults

T.C. DINGLE, A.N. ABBOTT, F.C. FANG

University of Washington, Seattle, WA, USA

P36

Effect of Minimizing Salivary Contamination by Selective Processing of Sputum Plugs on Sputum Microbiology

A. EFTHIMIADIS³, D. YAMAMURA^{1,2}, L. DARLINGTON³, P. NAIR^{1,3}

¹McMaster University, Hamilton, ON, ²Hamilton Regional Laboratory Medicine Program, Hamilton, ON, ³St. Joseph's Healthcare, Hamilton, ON

P37**Withdrawn**

P38

CANWARD 2013: Antimicrobial Resistance in Pathogens Isolated from Canadian Hospital Clinics, Emergency Rooms, Medical/Surgical Wards and Intensive Care Units

M. BAXTER¹, H.J. ADAM^{1,2}, M. MCCracken³, A.J. DENISUIK¹, G. GOLDING^{1,3}, J.A. KARLOWSKY^{1,2}, D.J. HOBAN^{1,2}, G.G. ZHANEL¹

¹University of Manitoba, Winnipeg, MB, ²Diagnostic Services Manitoba, Winnipeg, MB, ³National Microbiology Laboratory, Winnipeg, MB

P39

Reduction of Clostridium difficile Infection (CDI) Rates Through Stewardship: Difficulty Engaging Prescribers, With Implications for Stewardship Project Design

P. JONES¹, M. GUIRGUIS², A. SOBEY¹, L. SAXINGER¹

¹University of Alberta, Edmonton, AB, ²Alberta Health Services, Edmonton, AB

P40

Prevalence of Extended-Spectrum β -Lactamase, Ampc Cephalosporinase, and Carbapenemase Producing Enterobacteriaceae Over a Four-Year Period in Stool Samples Submitted to Laboratories in the Okanagan Region of British Columbia, Canada

C. HILL¹, A. JOHNSON¹, E. BLONDEL-HILL^{2,3}, V. HADWELL³

¹University of British Columbia- Okanagan, Kelowna, BC, ²University of British Columbia, Vancouver, BC, ³Kelowna General Hospital, Kelowna, BC

P41

Increase in Prevalence of Extended-Spectrum-Beta-Lactamase (ESBL) Producing Gram-Negative Bacilli (Gnb) Isolated From Patients With Intra-Abdominal Infections In Canada From 2008-2012

S.M. POUTANEN^{1,2,3}, R. RENNIE⁴, D. ROSCOE⁵, B. TOYE⁶, C. LEE⁷, V. LOO⁸, D. HOBAN⁹, D. GRIMARD¹⁰, P. JUTRAS¹¹, J. BLONDEAU¹², J. PITOUT¹³, S.E. GILCHRIST¹⁴, J-F. POULIOT¹⁴

¹ University Health Network, Toronto, ON, ²Mount Sinai Hospital, Toronto, ON, ³University of Toronto, ON, ⁴Alberta Health Services, Edmonton, AB, ⁵Vancouver General Hospital, Vancouver, BC, ⁶The Ottawa Hospital, Ottawa, ON, ⁷St. Joseph's Healthcare, Hamilton, ON, ⁸McGill University Health Centre, Montreal, QC, ⁹Health Sciences Centre, Winnipeg, MB, ¹⁰Centre de Sante et de Services Sociaux de Chicoutimi, Chicoutimi, QC, ¹¹Centre Hospitalier Regional de Rimouski, Rimouski, QC, ¹²Royal University Hospital, Saskatoon, SK, ¹³University of Calgary, Calgary, AB, ¹⁴Merck Canada Inc., Kirkland, QC

P42

Use of Spot Audits to Measure Appropriateness of Antimicrobial Therapy on General Internal Medicine as Part of an Antimicrobial Stewardship Program

K. DUPLISEA¹, S. NELSON^{1,3}, A. MORRIS^{1,2,3}, P. BUNCE¹

¹University Health Network, Toronto, ON, ²Mount Sinai Hospital, Toronto, ON, ³University of Toronto, Toronto, ON

P43

Carriage of Ciprofloxacin-Resistant Enteric Organisms in Patients Undergoing Transrectal Ultrasound-guided Biopsies of the Prostate (TRUSBP): What We Found and How We Found It

C. FRASER¹, J. FRANCIS-EVERD¹, P. NICOLE¹, A. JACKSON-LEE^{1,3}, A. SARABIA^{1,2}

¹Trillium Health Partners, Mississauga, ON, ²University of Toronto, Mississauga, ON, ³McMaster University, Hamilton, ON

P44

Withdrawn

P45

Impact of a Borderline Zone on the Concordance of Tuberculin Skin Test and Interferon Gamma Release Assay Results among a Low-Risk Cohort in Maritime Canada

S. MATERNIAK¹, C. STEVES², D. KUNIMOTO³, H. MACKENZIE³, D. WEBSTER^{1,2,4}

¹Infectious Diseases Research Unit, Saint John, NB, ²Dalhousie University, Halifax, NS, ³University of Alberta, Edmonton, AB, ⁴Horizon Health Network, Saint John, NB

P46

Comparison of Chicago Sky Blue (CB) and Calcofluor White (CW) Staining Methods for the Diagnosis of Dermatomycosis (DE) and Onychomycosis (ON)

L. CONGLY

Saskatchewan Disease Control Laboratory, Ministry of Health, Regina, SK

P47

Comparison of Sabouraud Dextrose Agar with Cyclohexamide, Chloramphenicol and Gentamicin Media Prepared by Three Different Suppliers

J. MUSA, D. BRAMBERGER, S. NIGH, H. ALMOHRI

LifeLabs Medical Laboratory Services, Toronto, ON

P48

Emmonsiosis in South Africa - Clinical and Laboratory Features of 27 Cases

I.S. SCHWARTZ¹, S. DLAMINI^{2,3}, N. GOVENDER⁴, C. CORCORAN⁵, H.W. PROZESKY^{6,7}, M. MENDELSON^{2,3}, J. TALJAARD^{6,7}, R. COLEBUNDERS^{8,9}, C. KENYON⁹

¹University of Manitoba, Winnipeg, MB, ²University of Cape Town, ³Groote Schuur Hospital, Cape Town, Western Cape, ⁴National Institute of Communicable Diseases, Johannesburg, ⁵Ampath National Laboratory Services, Centurion, Gauteng, ⁶Stellenbosch University, Stellenbosch, ⁷Tygerberg Hospital, Cape Town, Western Cape, South Africa, ⁸University of Antwerp, ⁹Institute of Tropical Medicine, Antwerp, Belgium



P49**Evaluation of Yeast MIC Strips (Liofilchem, Italy) for Antifungal Susceptibility Testing****C. HILL¹, B. WANG², A. JOHNSON¹**¹University of British Columbia-Okanagan, Kelowna, BC, ²Kelowna General Hospital, Kelowna, BC**P50****Inter-laboratory Comparability Study of Voriconazole Therapeutic Drug Monitoring****J. FULLER¹, S. SHOKOPLES¹, Y. THEORET², R. ROBITIALLE³, J. ZEIDLER⁴, D. COLANTONIO⁵, V. KULASINGAM⁶, D. HOLMES⁷, M. ROMNEY⁷, R. PELLETIER⁸**¹Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB, ²CHU St. Justine Hospital, Montréal, QC, ³Maisonneuve-Rosemont Hospital, Department of Biochemistry, University of Montréal, Montréal, QC, ⁴Hamilton General Hospital, Hamilton, ON, ⁵Hospital for Sick Children, Department of Pediatric Laboratory Medicine, University of Toronto, Toronto, ON, ⁶University Health Network, University of Toronto, Toronto, ON, ⁷Department of Pathology and Laboratory Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, ⁸CHU de Québec, l'Hôtel-Dieu, Québec City, QC**P51****An Unusual Case of Gram-negative Meningitis****N. RAJAPAKSE^{1,2}, J. CARSON^{2,3}, D. PILLAI^{2,3}, R. READ^{2,4}**¹Alberta Children's Hospital, ²University of Calgary, ³Calgary Laboratory Services, ⁴Peter Lougheed Hospital, Calgary, AB**P52****Seeing Red: A Curious Skin Manifestation****A. SHROFF, S. HAIDER**

McMaster University, Hamilton, ON

P53**A Case of *Leclercia adecarboxylata* Bacteremia in a Neutropenic Patient****D. LETO¹, L. JIAO²**¹Department of Medicine, Division of Infectious Diseases, McMaster University, Hamilton, ON, ²Medical Microbiology Postgraduate Training Program, Department of Laboratory Medicine and Molecular Pathology, McMaster University, Hamilton, ON**P54****Foodborne Botulism: Urgent Collaboration and Consultation Required****J. WONG¹, B. AUK¹, B. WONG¹, N. PRYSTAJECKY¹, D. MOREAU², D. HOYANO², P. KIBSEY², J. ISAAC-RENTON¹**¹BC Public Health Microbiology & Reference Laboratory, Vancouver, BC, ²Vancouver Island Health Authority, Victoria, BC**P55****A Five-Year Assessment of Private Well Owner Submission Behaviours in Southeastern Ontario****A. MAIER¹, J. KROLIK^{1,2}, P. BELANGER^{3,4}, G. EVANS^{1,5}, A. MAJURY^{1,2,3,5}**¹Public Health Ontario, ²Department of Pathology and Molecular Medicine, ³Department of Public Health Sciences, Queen's University, ⁴Kingston, Frontenac and Lennox & Addington Public Health, ⁵Department of Biomedical and Molecular Sciences; Kingston, ON**P56****Withdrawn****P57****The Brainspan Learning Game: What's in it for instructors?****J. GNARPE**

University of Alberta, Edmonton, AB

P58**A Clinical Overview of Tigecycline Use at a Tertiary Care Teaching Organization over 5 Years****A. CARDUCCI¹, A. BROOKS², M. SUNG², S. HAIDER^{2,3,4}, D. MERTZ^{2,3,4}, N. IRFAN²**¹University of Waterloo School of Pharmacy, Waterloo, ON, ²Hamilton Health Sciences, Hamilton, ON, ³Department of Medicine McMaster University, Hamilton, ON, ⁴Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON**P59****MICA*008 allele: A Genetic Predisposing Factor for Resistance against *Chlamydia Trachomatis* Infection****M. TOTONCHI¹, M. MOAZENCHI¹, R.S. YAZDI², H. HOSEINIFAR², U. ASADPOR¹, M.A.S. GILANI², H. GOURABI¹, A.M. MEYBODI¹**¹Department of Genetics at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR., Tehran, Iran, ²Department of Andrology at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR., Tehran, Iran

Student Poster Presentations

SP01

Straight From the Cow's Mouth (Clinical Vignette Poster)

D. DIXIT¹, J. TANG¹, A. GROLLA², G. TAYLOR¹

¹University of Alberta, Edmonton, AB, ²National Microbiology Laboratory, Winnipeg, MB

SP02

Predictors of Asymptomatic Clostridium difficile Colonization on Hospital Admission

L. KONG¹, N. DENDUKURI¹, I. SCHILLER¹, A-M. BOURGAULT¹,
P. BRASSARD^{1,2}, L. POIRIER³, F. LAMOTHE⁴, C. BÉLIVEAU³, S. MICHAUD⁵,
N. TURGEON⁶, B. TOYE⁷, E. FROST⁵, R. GILCA^{8,9}, A. DASCAL², V. LOO¹

¹McGill University Health Centre, Montréal, QC, ²Jewish General Hospital, Montréal, QC,
³Hôpital Maisonneuve-Rosemont, Montréal, QC, ⁴Centre hospitalier universitaire de
Montréal, Montréal, QC, ⁵Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC,
⁶Centre hospitalier universitaire de Québec-Hôtel-Dieu de Québec, Québec, QC,
⁷The Ottawa Hospital, Ottawa, ON, ⁸Université Laval, Québec, QC, ⁹Institut national de
santé publique du Québec, Québec, QC

SP03

Withdrawn

SP04

Characterization of Penicillin-Resistant (PRSP) and Multi-Drug Resistant (MDR) Streptococcus pneumoniae (SPN) in Canadian Hospitals, 2007-2012

A.R. GOLDEN¹, B. FULTZ¹, M. ROSENTHAL¹, K.A. NICHOL², H.J. ADAM^{1,2},
M. BAXTER¹, D.J. HOBAN^{1,2}, G.G. ZHANEL¹

¹University of Manitoba, Winnipeg, MB, ²Diagnostic Services Manitoba, Winnipeg, MB

SP05

Withdrawn

SP06

Practices Surrounding Outpatient Antibiotic Therapy for Intravenous Drug Users: A Survey

D. WHELLAMS, C. MAIN, D. MERTZ, N. SINGHAL

McMaster University, Hamilton, ON

SP07

Molecular Epidemiology and Virulence Characteristics of Extended-Spectrum β -Lactamase-Producing Escherichia coli (EC) Isolated in Canadian Hospitals from 2007 to 2012

A.J. DENISUIK¹, P. LAGACÉ-WIENS^{1,2}, P.J. SIMNER^{1,2}, M.R. MULVEY^{1,3},
M. BAXTER¹, H.J. ADAM^{1,2}, D.J. HOBAN^{1,2}, G.G. ZHANEL¹

¹University of Manitoba, Winnipeg, MB, ²Diagnostic Services Manitoba, Winnipeg, MB,
³National Microbiology Laboratory, Winnipeg, MB

SP08

Prevalence and Characteristics of Escherichia coli and Salmonella spp. in the Feces of Wild Urban Norway and Black Rats (Rattus norvegicus and Rattus rattus): Implications for Public Health

C. HIMSWORTH^{1,2}, E. ZABEK², A. DESRUISSEAU³, J. PARMLEY^{3,4},
R. REID-SMITH^{3,4}, C. JARDINE⁴, P. TANG¹, D. PATRICK¹

¹University of British Columbia, Vancouver, BC, ²British Columbia Ministry of Agriculture,
Abbotsford, BC, ³Public Health Agency of Canada, Guelph, ON, ⁴University of Guelph,
Guelph, ON

SP09

Chronic Otitis Media due to Nontuberculous Mycobacteria: A Case of Successful Treatment with Topical Boric Acid (Clinical Vignette Poster)

M-A. LEFEBVRE, S.J. DANIEL, C. QUACH

Montreal Children's Hospital, McGill University Health Centre, Montréal, QC

SP10

The Case of the Non-Responding Osteomyelitis (Clinical Vignette Poster)

S. KHAN, I. KITAI

The Hospital for Sick Children, Toronto, ON

SP11

Changing Trends in β -Hemolytic Streptococcal Bacteremia in Manitoba, Canada: 2007-2012

I.S. SCHWARTZ¹, Y. KEYNAN¹, M.W. GILMOUR^{1,2}, B. DUFAULT¹,
P. LAGACÉ-WIENS^{1,2}

¹University of Manitoba, Winnipeg, MB, ²Diagnostic Services Manitoba, Winnipeg, MB

SP12

Blinded Comparative Performance and Efficiency of Urine Chromogenic Agars

Y. GAO¹, F. JANES², K. KIDNEY², J. RYAN², P. DALEY^{1,2}

¹Memorial University, St. John's, NL, ²Eastern Health, St. John's, NL



SP13***Staphylococcus aureus and Streptococcus pneumoniae Nasal Colonization Rates Among Patients with Laboratory Confirmed Influenza Virus Infection*****A. CAMPIGOTTO¹, H. WONG², A.E. SIMOR^{1,2,3}, A. MCGEER^{1,3,4}, J. GUBBAY^{1,3}, K. GREEN^{4,5}, K. HASSAN^{4,5}, T. MAZZULLI^{1,4}, S. MUBAREKA^{1,2}**¹University of Toronto, ²Sunnybrook Health Sciences Centre, ³Public Health Ontario Laboratory, ⁴Mount Sinai Hospital, ⁵Toronto Invasive Bacterial Diseases Network, Toronto, ON**SP14*****C the DIFFerence: Strategies for Improving Early Appropriate Isolation in Suspected C. difficile Cases*****M. WAN¹, C. LUONG¹, P. SO¹, E. WONG¹, W. WONG¹, S. GABRIEL², M. CRUMP³, P. DOYLE⁴**¹Department of Medicine, University of British Columbia, Vancouver, BC, ²Infection Control, Vancouver Coastal Health, Vancouver, BC, ³Infection Control, Vancouver General Hospital, Vancouver, BC, ⁴Division of Medical Microbiology and Infection Control, Vancouver General Hospital, Vancouver, BC**SP15*****To sCRen or not to sCRen for Carbapenem-resistant Enterobacteriaceae in Recipients of Out-of-Country Medical Care: A Cost Analysis*****N. RAJAPAKSE^{1,2}, J. VAYALUMKAL^{2,3}, C. PEARCE³, G. REES³, L. KAMHUKA³, G. PEIRANO⁴, C. PIDHORNEY³, D. LEDGERWOOD³, N. ALFIERI³, K. HOPE³, D. GREGSON^{2,4}, J. PITOUT^{2,4}, T. LOUIE^{2,3}, J. CONLY^{2,3}**¹Alberta Children's Hospital, ²University of Calgary, ³Infection Prevention and Control – Alberta Health Services, ⁴Calgary Laboratory Services, Calgary, AB**SP16*****Management and Outcomes in Patients with Staphylococcus Aureus Bacteremia after Implementation of an Automated Infectious Diseases Consult: a Before/After Study*****L. MARTIN¹, M. TOVA-HARRIS¹, S. TAYEB¹, A. BROOKS^{1,2}, C. MAIN^{1,2}, D. MERTZ^{1,2}**¹McMaster University, Hamilton, ON, ²Hamilton Health Sciences, Hamilton, ON**SP17*****Nosocomial Gram-Negative Bacteremia in a General Systems Intensive Care Unit: Epidemiology, Antimicrobial Susceptibility Patterns, Treatment and Outcomes*****T. DRAGAN, W. SLIGL, S. SMITH**¹University of Alberta, Edmonton, AB**SP18*****Validation of Susceptibility Testing Results from Organisms Isolated Directly from Colorex Orientation® Agar*****C. HILL¹, E. BLONDEL-HILL^{2,3}, V. HADWELL³, H. JEWSBURY³, B. WANG³**¹University of British Columbia- Okanagan, Kelowna, BC, ²University of British Columbia, Vancouver, BC, ³Kelowna General Hospital, Kelowna, BC**SP19*****Effectiveness of Rotavirus Vaccination against Severe Rotavirus Infection among Children Aged <3 Years in Québec*****M.K. DOLL¹, A. GAGNEUR², H. CHAREST³, M. GONZALES⁴, D.L. BUCKERIDGE¹, C. QUACH^{1,4}**¹McGill University, Montréal, QC, ²Sherbrooke University Hospital, Sherbrooke, QC, ³Quebec Public Health Laboratory (LSPQ), Montréal, QC, ⁴The Montreal Children's Hospital, Montréal, QC**SP20*****Post-Splenectomy Immunization at Tertiary Care Facilities in Hamilton, Ontario*****A. SHROFF, J. MURDOCH, A. BROOKS, N. IRFAN, T. O' SHEA**

McMaster University, Hamilton, ON

SP21***Value of an Active Surveillance Policy to Document Clearance of Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus Amongst In-patients with Prolonged Admissions*****A. GHOSH¹, L. JIAO¹, F. AL-MUTAWA¹, C. O'NEILL², D. MERTZ^{1,2}**¹McMaster University, Hamilton, ON, ²Hamilton Health Sciences, Hamilton, ON**SP22*****Emergency Department and Inpatient Management of Febrile Infants Under Six-Weeks of Age: Perceived Utility of Respiratory Virus Testing*****B. BURSTEIN, S. DUBROVSKY, C. QUACH**

The Montreal Children's Hospital, Montréal, QC

SP23***Descriptive Analysis of HBV and HCV Positive Patients Referred from a Refugee Clinic*****S. BRAR¹, K. DOUCETTE²**¹University of Alberta, Department of Medicine, Edmonton, AB, ²University of Alberta, Division of Infectious Diseases, Edmonton, AB

SP24

Replacing the Staphylococcal Protein A (spa) Gene Alters its Biological Characteristics, Behavior and Virulence in a High-Virulence Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Strain USA300

A. KHATEB¹, J. CONLY^{1,2,3,4}, K. WU¹, J. MCCLURE¹, G.D. ARMSTRONG³, K. ZHANG^{1,2,3,4}

¹Centre for Antimicrobial Resistance, Synder Institute for Chronic Diseases, Calgary, AB, ²Departments of Pathology and Laboratory Medicine, Calgary, AB, ³Microbiology, Immunology & Infectious Diseases and Medicine, Calgary, AB, ⁴Alberta Health Services-Calgary and Area, Calgary, AB

SP25 **Withdrawn**

SP26

Infections Caused by Actinomyces neuii: a Case Series and Literature Review of an Unusual Bacterium

N. ZELYAS¹, S. GEE¹, R. RENNIE¹, B. NILSSON², T. BENNETT³

¹Provincial Laboratory for Public Health, Edmonton, AB, ²Queen Elizabeth II Hospital, Grande Prairie, AB, ³Red Deer Regional Hospital, Red Deer, AB

SP27

Urinary Tract Infection Caused by an Unusual Pathogen Identified Using Cystine-Lactose-Electrolyte Deficient Media and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (Clinical Vignette Poster)

B. BERENGER^{1,2}, L. CHUI^{1,2}, A. BORKENT¹, M-C. LEE^{1,3}

¹University of Alberta, Edmonton, AB, ²Alberta Provincial Laboratory for Public Health, Edmonton, AB, ³DynaLIFEDxLaboratory Services, Edmonton, AB

SP28

Carbapenemase Producing Organisms in BC, 2008 - 2013

I. SEKIROV¹, C. NG², R. AZANA², B. MACK^{1,3}, P. KIBSEY^{1,4}, A. STEFANOVIC^{1,5}, S. CHAMPAGNE^{1,6}, E. BLONDEL-HILL^{1,7}, L. HOANG^{1,2}

¹University of British Columbia, Vancouver, BC, ²BC Center for Disease Control, Vancouver, BC, ³Fraser Health Authority, Surrey, BC, ⁴Vancouver Island Health Authority, Victoria, BC, ⁵Vancouver Coastal Health Authority, Vancouver, BC, ⁶Providence Health Care, Vancouver, BC, ⁷Interior Health Authority, Kelowna, BC

SP29

Chronic Necrotizing Aspergillosis in a Diabetic Patient Using Marijuana

L. REMINGTON¹, J. FULLER^{2,3}, W. MAURICIO^{2,3}, I. CHIU¹

¹Division of Infectious Diseases University of Alberta, Edmonton, AB, ²Provincial Laboratory Alberta Health Services, Edmonton, AB, ³Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

SP30 **Withdrawn**

SP31 **Withdrawn**

SP32

In vitro Beta-Lactam Susceptibility Testing of Streptococcus pneumoniae by Commercial Methods Compared to CLSI Broth Microdilution

M. CHARLES¹, B. BERENGER¹, L-A. TURNBULL^{2,3}, R. RENNIE^{2,3}, J. FULLER^{2,3}

¹University of Alberta, Edmonton, AB, ²Provincial Laboratory for Public Health, Edmonton, AB, ³Alberta Health Services, Edmonton, AB

SP33

Pseudo-Outbreak of Mycobacterium fortuitum due to Contaminated Ice Machines

N. SANT^{2,3,1}, M. DESJARDINS^{2,3,1}, V. CHIRIP¹, R. ETINGER¹, I. GORN¹, V. ROTH^{2,3}

¹Eastern Ontario Regional Laboratories, Ottawa, ON, ²The Ottawa Hospital, Ottawa, ON, ³The University of Ottawa, Ottawa, ON

SP34

Clinical Significance and Correlation between EBV Qualitative PCR on Plasma and Whole Blood EBV Viral Load in Haematopoietic Stem Cell Transplant (HSCT) Pediatric Patients

H. AL HASHAMI, U. ALLEN, T. SCHECHTER, Y. YAU

Hospital for Sick Children, Toronto, ON

SP35

Antibacterial Activity of Stearylamine-containing Liposomes against Helicobacter pylori

M.A. MAHMOUD, L. DA SILVEIRA CAVALCANTE, J.L. HOLOVATI, M.M. KEELAN

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB



SP36 Withdrawn

SP37

Phylogenetic Analysis of Distinct Hepatitis C Virus Genomic Regions for Identification of Transmission Clusters in British Columbia

I. LUO^{1,2}, V. MONTOYA^{1,2}, A. OLMSTEAD^{1,2}, F. LAMOURY³, T. APPELEGATE³, J. GREBELY³, M. KRAJDEN^{1,2}

¹BC Centre for Disease Control, Vancouver, BC, ²University of British Columbia, Vancouver, BC, ³Kirby Institute, University of New South Wales, Sydney, NSW, Australia

SP38

Utilization of Bordetella pertussis and B. parapertussis PCR Testing in a Regional Children's Hospital

C. ELLIS¹, T. KARNAUCHOW²

¹University of Ottawa, Ottawa, ON, ²Regional Virology Laboratory, Children's Hospital of Eastern Ontario, Ottawa, ON

SP39

Evaluation of Antimicrobial Prescribing in Hospitalized Solid Organ Transplant Recipients Through Serial Real-Time Point Prevalence Audits

Y. YANG¹, M. SO^{1,2}, S. HUSSAIN^{2,3,4}, C. BELL^{3,4}, A. MORRIS^{2,3,4}

¹Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, ²University Health Network, Toronto, ON, ³Mount Sinai Hospital, Toronto, ON, ⁴Department of Medicine, University of Toronto, Toronto, ON

SP40

Sickness Presenteeism among General Paediatrics Resident Physicians in Canada

K. MITCHELL, J. VAYALUMKAL

University of Calgary, Department of Paediatrics, Calgary, AB

SP41 Withdrawn

SP42

Elevated S100A12 Gene Expression at the Time of Initial Presentation is Associated with Increased Severity of Illness during Sepsis

N. LYLE¹, C. FJELL¹, D. HANCOCK², J. BOYD¹, R. HANCOCK¹

¹University of British Columbia, Vancouver, BC, ²Centenary Institute of Cancer Medicine and Cell Biology, New South Wales, Australia

SP43

Organism Identification on Early Subculture Colonies by VitekMS Matrix-Assisted Laser Desorption Ionization-Time of Flight (VITEKMS) and its Impact on Antibiotic Stewardship

Y. YU¹, W. MCCAFFREY², M. MCCONNELL², N. IRFAN³, D. YAMAMURA^{1,2}

¹McMaster University, Hamilton, ON, ²Hamilton Regional Laboratory Medicine Program, Hamilton, ON, ³Hamilton Health Sciences, Hamilton, ON

SP44

'GRAINS' Of Wrath (Clinical Vignette Poster)

R. SOMAYAJI, L. BERTHIAUME, K. FONSECA, J. CONLY

University of Calgary, Calgary, AB

SP45

Using Photography-based Social Media in Infectious Diseases Education: #Apictureiswortha1000microbes #Instagrampositiveinmedicaleducation

M. WOOD, S. FORGIE

University of Alberta, Edmonton, AB

Event Mobi App

Get the Conference on the Go!

Access the Event Mobi app for the AMMI Canada – CACMID Annual Conference 2014 at eventmobi.com/victoria2014.

It's easy to use: just access it on your browser on your mobile device or desktop. Save it to your bookmarks or save it to your homepage so you can easily find it again. Want to learn more?



Check out the Event Mobi how-to video!



Author Index

Adachi D	P20	Bigham M	K03	Cole T	P07	Ellis C	H02,SP38	Gould R	P07	Hoyano D	P54
Adam HJ	C03, C04, P38, SP04, SP07	Binkhamis K	G04	Colebunders R	P48	El-Sherif M	P21	Gourabi H	P59	Hu P	P03
Adie K	H04	Birch D	G02	Congly L	P46	Ettinger R	SP33	Govender N	P48	Hussain S	SP39
Adomako K	B02,B04	Blondeau J	P41	Conly J	E02,F07,SP15, SP24,SP44	Fach P	E03	Graham M	A04,J05	Hussain Z	I02
Agopsowicz C	G02	Blondel-Hill	EP40,SP18,SP28	Cook D	G05,G06	Fakharuddin K	I01	Grant J	F05	Iqbal SM	P14
Al Hashami H	SP34	Booth T	G04	Corcoran C	P48	Fallah P	P01,P19	Gravel D	A04	Irfan N	F02,P58,SP20,SP43
Alavie T	G01	Borkent A	SP27	Côté G	E06	Fang FC	P35	Gravel G	L05	Irwin R	E05
Albarrag A	P14	Botelho F	P11	Côté L	E04	Fathima S	E01	Grebely J	SP37	Isaac-Renton J	L02,P54
Alfieri N	SP15	Bourgault A-M	SP02	Crowcroft N	P10	Fauvel M	P06	Green K	K02,SP13	Jackson-Lee A	P43
Alhetheel A	P14	Boyd DA	A04,I01,P23,P26	Croxen MA	L02	Fearon M	K03	Gregson D	SP15	James D	C02,P28
Allen U	P03,SP34	Boyd J	SP42	Crump M	SP14	Fernando K	D02	Grimard D	P41	Janes F	P33,SP12
Allen V	E05,J03,J05,P22	Bramberger D	P47	Da Silva Cavalcante L	SP35	Ferrato C	E07	Grolla A	SP01	Jang D	J01
Almohri H	C02,I03,P28,P47	Bramson J	P11	Dagenais C	P10	Finley R	E05,E06	Grudeski E	G04	Janjua NZ	G07
Al-Mutawa F	SP21	Brar S	SP23	Dahan S	F03	Fjell C	SP42	Gubbay J	SP13	Janz L	A02
Al-Rawahi G	P09	Brassard P	SP02	Daigh L	P05	Flandin JF	J01	Guindon K	I05	Jardine C	SP08
Alsaadi MM	P14	Brinkman R	P11	Daku D	L01	Fonseca K	SP44	Guirguis M	P39	Jassem AN	A02,L02
Al-Siyabi T	P17	Brodin E	I01	Daley P	P33,SP12	Forge S	SP45	Hadwell V	P40,SP18	Jayarathne P	P15
Alzamil F	P14	Brooks AF	F02,P58,SP20	Daniel SJ	SP09	Francis-Evered J	P43	Haider S	P52,P58	Jewsbury H	SP18
Andonov A	K03	Broukhanski G	A01,A03	Darlington L	P36	Fraser C	P43	Haldane D	E05,J03,P07,P22	Jiao L	P53,SP21
Andrew M	P11	Buckeridge DL	K04,SP19	Dascal A	SP02	Frenette C	A04	Hamel D	P06	Jin DY	P02
Antonishyn NA	G02	Bunce P	F01,P42	De Serres G	G07	Friesen B	E02	Han G	B01,B03	Johl J	P05
Applegate T	SP37	Burdz T	H07	De Gange G	K03	Frost E	SP02	Hancock D	P29,SP42	Johnson A	P40,P49
Armstrong G	SP24	Burstein B	SP22	Delannoy S	E03	Fuller J	C03,C04,P30,P50, SP29,SP32	Hancock R	SP42	Johnston L	P07
Archibald C	J03,J05,P22	Campigotto A	P31,SP13	Demczuk W	J03,J05,P22	Fulop T	P11	Haratian K	P01,P18,P19	Johnstone J	P11
Asadpor U	P59	Canadian Nosocomial Infection Surveillance Program (CNISP)	A04	Dendukuri N	SP02	Fultz B	SP04	Harrison L	F07	Jones P	P39
Ash T	P32	Carducci A	F02,F05,P58	Denisuk AJ	P38, SP07	Gabriel S	SP14	Hasan M	P09	Jutras P	P41
Auk B	P54	Carson J	C01,E02,P51	DePaulo R	L01	Gagneur A	K04,SP19	Hassan K	K05,SP13	Kadkhoda K	P08
Avery B	E05	Celetti S	F02	Desjardins M	SP33	Gamage B	A02	Hatchette TF	G04,P07,P10, P17,P21	Kamhuka L	SP15
Azana R	P13,SP28	Chahil N	G05,G06	Desruisseau A	SP08	Gandhi B	P34	Hébert D	P03	Karlowsky JA	H06, P38
Baikie M	P07	Chambers C	G07	Devereaux PJ	P11	Gao Y	SP12	Hess M	A02,D02	Karnauchow T	SP38
Balakumar S	K01	Champagne S	A02,SP28	Didiodato G	B02	Garber G	B02,B04	Hiebert J	D01	Kassam R	L03
Barrett L	P05	Chan KH	P02	Dingle TC	P35	Garceau R	P22	Hill C	P40,P49,SP18	Katz K	A04
Bastien N	P12	Chan KW	P02	Dipchand A	P03	Gauchier-Pitts K	H01	Himsworth C	SP08	Keelan MM	SP35
Baxter M	C03,C04,P38, SP04,SP07	Chan W	C01	Dixit D	SP01	Gaulin C	L05	Hirji Z	B01,B03	Keen P	F05
BCAMM Members	A02	Chang Y	F04,I01	Dlamini S	P48	Gee S	SP26	Hoang L	A02,E05,F04,H04, H05,I01,J03,J04,J05, L02,L04,P13,P22,SP28	Kein D	H06
Beaulac S-N	P06	Chapman W	P29	Doll MK	K04,SP19	Germain M	K03	Hoban DJC	C03,C04,P38,P41, SP04SP07	Kelly J	J04
Beirnes J	D01	Charest H	K04,SP19	Doualla-Bell F	L05,P06,P10	German G	E05	Holmes D	P50	Kenyon C	P48
Bekal S	E05,E06,L05	Chouette K	SP23	Doyle P	SP14	Ghosh A	SP21	Holmes L	A04	Keynan Y	SP11
Belanger P	P55	Charles M	P30,SP32	Dragan T	SP17	Gibbs D	P32	Holovati JL	SP35	Khan S	SP10
Belanger-Trudelle E	E04	Cheng A	F02	Drebot M	P07	Gilani MAS	P59	Hon B	P13	Khateb A	SP24
Béliveau C	SP02	Chernesky M	J01	Dubuc S	K03	Gilbert M	G05	Hope K	SP15	Khine AA	G01
Bell C	SP39	Chirip V	SP33	Dubrovsky S	SP22	Gilchrist J	J01	Horsman GB	E05,G02,J03, J05,L01,P22	Khodai-Booran N	P03
Bennett T	SP26	Chiu I	SP29	Dufault B	SP11	Gilchrist SE	P41	Hosein S	E02	Kibsey P	A02,A04,L04, P54,SP28
Berenger B	P30,SP27,SP32	Chong P	P23	Duplisa K	F01,P42	Gilmour MW	SP11	Hoseinifanar H	SP30	Kidney K	SP12
Bernard K	E02,H07	Chou F	L02	Eftimiadis A	P36	Gnarpe J	P57	Hottes T	F04	Kim S	P24,P26
Bernier F	K03	Christianson S	H06	Egan C	B02,B04	Golden AR	SP04			Kimberly H	E02
Berthiaume L	SP44	Chu K	G05,G06	Eisler D	H03,P16	Golding G	A04,P38			King R	E03
Beyene J	P03	Chui L	E01,E03,E07,L03,SP27	El Bailey S	E05	Gonzales M	K04,SP19			Kiss A	B01,B03
Bharat A	E06	Ciccotelli W	H02			Gorn I	SP33			Kitai I	SP10
		Colantonio D	P50							Kobasa D	G07



Kong L	SP02	Macdonald J	E02	Mulvey MR	A04,E05,E06,I01,	Purych D	G07,I01	Skowronski DM	G07	Valupadas S	I05
Kong T	P29	Mack B	SP28	J03,J05,P22,P23,P26,SP07		Qiu Y	P20	Sligl W	SP17	van Caesele P	P22
Kornherr P	I05	Mackenzie H	P45	Murdoch J	SP20	Quach C	K04,SP09,	Small W	I02	van Domselaar G	J05
Kottlil S	P05	Mahmoud MA	SP35	Musa J	P47		SP19,SP22	Smart G	P08	van Zuilen L	I03
Krajden M	G05,G06,G07,SP37	Mahony J	P11	Nadeau M	E06	Rajapakse N	P51,SP15	Smart N	H06	Vayalunkal J	SP15,SP40
Krollik J	P55	Maier A	P55	Nair P	P36	Ramoutar E	P24,P25	Smieja M	J01	Vearncombe M	P31
Kulasingam V	P50	Main C	SP06,SP16	Nalpathamkalam T	P03	Ratnam S	J01,P22	Smith S	F06,I03,P28,SP17	Vedove LD	P15
Kunimoto D	P45	Majury A	P55	Nelson S	F01,P42	Read R	P51	So M	SP39	Vermeiren C	I04
Lagacé-Wiens P	SP07,SP11	Mak A	G05,G06	Ng C	I01,SP28	Read S	P03	So P	SP14	Volling C	K05
Lalany A	P07	Malejczyk K	E03	Ng V	P03	Rees G	SP15	Soares D	P31	Walker B	L04
Lam F	B02,B04	Malekesmaeili M	P11	Nguyen L	I05	Reid-Smith R	SP08	Sobey A	P39	Walter S	P11
Lamirande R	P10	Man S	D02	Nichol KA	SP04	Remington L	SP29	Somayaji R	SP44	Wan M	SP14
Lamothe F	SP02	Mandés R	E06	Nicole P	P43	Rennie R	C03,C04,H01,	Somily A	P14	Wang A	P32
Lamoury F	SP37	Manji I	P24,P26	Nigh S	P47		P30,P41,SP26,SP32	Soualhine H	E04	Wang B	P49,SP18
Lang A	P17,P21	Marra F	A02	Nilsson B	SP26	Ricci G	I04	Spinato J	E04	Wang C	P05
Langner S	E05	Martin I	J03,J05,P22	O'Brien S	K03	Ritchie G	D03	Stefanovic A	SP28	Ward L	F07
Larios O	B01,B03	Martin L	SP16	O'Neill C	SP21	Robbarts L	E05	Steinberg M	G05	Watt C	I04
Laroche C	F03	Mask A	P07	O'Shea T	SP20	Roberts C	P17	Stevens C	P45	Webster D	P45
Lau SKP	P02	Materniak S	P45	Ogee-Nwankwo A	P10	Robertson J	B02,B04	Stone C	G01	Weger S	E05,K03
Leavitt J	F07	Mauricio W	SP29	Olegario S	F01	Robitaille R	P50	Suh K	A04	Weiss K	B01,B03
Leblanc J	G04,P17,P21	Mazzulli T	G01,G03,K05,	Oleung O	P24,P26	Romney M	P50	Sung M	P58	Wen A	A01
Ledgerwood D	SP15		P17,P34,SP13	Olmstead A	SP37	Rooney B-L	G04	Tadros M	I02	Westmacott G	P23
Lee B	D04	McCaffrey W	SP43	Oosterhoff C	H01	Roscoe D	P41	Talebpour S	G01	Whellams D	SP06
Lee C	A03,P41	McClure J	SP24	Paccagnella A	L02	Rosenthal M	SP04	Tanjaard J	P48	Wiebe D	H07
Lee D	F02	McCombie R	F07	Pacheco AI	H07	Roth V	SP33	Tan K	A02,L04	Willey BM	I04,P24,
Lee M-C	E03,SP27	McConnell M	SP43	Pang XL	D04,G04,P04,P20	Rottengatter K	G03	Tan R	P09		P25,P26,P27
Lee MK	D02	McCracken M	P38	Parmley J	SP08	Routy JP	P06	Tang J	SP01	Williams V	B01,B03
Lee T	H04	McDonald RR	G02,L01	Parsons R	P11	Roy F	J02	Tang P	H03,H04,P16,SP08	Wolfe J	H06
Lefebvre B	E06,J03,J05,P22	McElhaney J	P11	Paton T	P03	Rudnick W	K02	Tayeb S	SP16	Wong A	A04
Lefebvre M-A	SP09	McGeer A	A04,B01,B03,	Patrick D	F05,SP08	Ryan J	SP12	Taylor G	A04,F06,SP01	Wong B	P54
Legault M	P06		K02,K05,SP13	Pearce C	SP15	Sabaiduc S	G07	Tharmaradinam S	P24	Wong E	SP14
Léger D	E05	McNabb A	G06,H03,H04,P16	Peirano G	SP15	Sant N	SP33	Theoret Y	P50	Wong H	SP13
Leloir J	F03	McNeil S	P11,P21	Pelletier R	P50	Sarabia A	P43	Thierjung N	P32	Wong J	P54
Lester R	F04,J04	Mendelson M	P48	Penney C	P03	Sawatzky P	P22	Thiry D	L01	Wong Q	D02
Leto D	C02,P53	Mendoza L	D01	Pereira S	P03	Saxinger L	F05,F06,P39	Thomas E	P09	Wong T	J03,J05,P22
Levett PN	G02,L01,P32	Merrick L	D03	Perrault L	F03	Scalia V	K03	Tilley P	P09	Wong W	SP14
Li V	E03	Mertz D	F02,P58,SP06,	Peterson A	D01	Schechter T	SP34	Tong YT	D04, P04	Woo PCY	P02
Li Y	G07,P12		SP16,SP21	Peterson S	J03	Schiller I	SP02	Toronto Invasive Bacterial	K02	Wood M	SP45
Lindsay R	P07	Meybodi AM	P18,P19P59	Petric M	G07,H05	Schmalenberg K	G02	Diseases Network	P59	Wu K	SP24
Liu G	P22	Michaud S	SP02	Pettipas J	G04	Schulz H	D01	Totouchi M	SP16	Wylie J	E05,J03
Lloyd T	C01	Midodzi W	P33	Pidhorney C	SP15	Schwartz IS	P48,SP11	Tova-Harris M	SP16	Xiong J	P29
Lo P	I04,P24,P25,P26,P27	Millar J	P11	Pillai D	C01,P51	Sekirov I	SP28	Toye B	P41,SP02	Yamamura D	P15,P36,SP43
Lo T	D02	Miller M	A04	Pintar K	L02	Serhir B	P06,P10	Tremblay C	E04,E06,L05,	Yang Y	SP39
Loeb M	P11	Mitchell D	F03	Pitout J	P41,SP15	Severini A	D01,J02,J04		P06,P10	Yau Y	SP34
Loo V	P41,SP02	Mitchell K	SP40	Plevneshi A	K02	Shah B	G01		P26	Yazdi RS	SP30
Louie M	E05,E07	Mithoowani S	F02	Podhorodecki L	D01	Sharma M	H06		P27	Young V	P09
Louie T	F07,SP15	Moazenchi M	P59	Poirier L	SP02	Sherlock C	D03		E01	Yu Y	SP43
Lovgren M	E01,J03,J05,P22	Montoya V	SP37	Pollari F	L02	Sheth P	I02		P24,P26	Yuen KY	P02
Lowe C	D03	Moore D	A04	Pong-Porter S	K02	Shigayeva A	K02		E01	Zabek E	SP08
Lowther N	H03	Moreau D	P54	Poon A	E03,L01	Shokoples S	C03,C04,P50		SP02	Zeidler J	P50
Lungrin D	C02	Morris A	F01,P42,SP39	Pouliot J-F	P41	Shroff A	P52,SP20		C03,C04,	Zelyas N	SP26
Luo I	SP37	Morris C	P28	Poutanen SM	I04,P24,P25,	Shuel M	E01		H01,P30,SP32	Zhanell GG	A04,C03,C04,F03,
Luong C	SP14	Morshed M	D02		P26,P27,P41	Simmonds K	E01,E02		E01		P38,SP04,SP07
Lyle N	SP42	Moussa G	G03	Preiksaitis JK	P04	Simner PJ	SP07		A02	Zhang K	SP24
Lynch T	J05	Mubareka S	P31,SP13	Prematunge C	B02,B04	Simor AE	A04, B01, B03,		P23	Zheng BJ	P02
Maaskant R	G01			Prozesky HW	P48	Singhal N	B04, I04, P31, SP13			Zhou L	H05
Mac B	I01			Prystajecy N	A02,L02,P54		SP06			Zubach V	J02
				Punja N	E02						



Conflict of Interest

Speakers

Speaker	Disclosure
Allen-Vercoe, Emma	No conflict declared
Bernard, Kathy	No conflict declared
Blondel-Hill, Edith	No conflict declared
Bryce, Elizabeth	No conflict declared
Drebot, Michael	No conflict declared
Evans, Gerald	Currently participating or have participated in a clinical trial within the past 2 years with Merck on a CDI study, with Astellas on an isavuconazole, and with Biocryst on a peramivir study
Fisman, David	Received research and educational funding from GSK and Merck
Gagnon, Jean-François	No conflict declared
Galbraith, John	No conflict declared
Gantt, Soren	No conflict declared
Hajek, Jan	No conflict declared
Hammond, Karsten	No conflict declared
Kus, Julianne	Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e., "off-label" use of medication)
Leung, Victor	No conflict declared
Lindsay, Robbin	No conflict declared
Lowe, Christopher	No conflict declared

Speaker	Disclosure
McGeer, Allison	No conflict declared
Morris, Andrew	No conflict declared
Noble, Michael	Received grants or an honorarium from Bio-Rad, Abbott, BD Alere, Pro-Lab, and CSA as sponsors for a conference hosted in the previous year
O'Shea, Tim	No conflict declared
Poutanen, Susan	Member of an Advisory Board or equivalent with Sunovion and Optimer, member of a Speakers bureau with Hoffman-La Roche, Merck, and Pathogenica, received grants or an honorarium from bioMérieux, Bio-Rad, Copan, and Pathogenica
Rau, Neil	Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e., "off-label" use of medication)
Restelli, Veronica	No conflict declared
Robinson, Joan	Currently participating in or have participated in a clinical trial within the past 2 years with Pfizer on an anidulafungin study and with NIH on an influenza observational study
Romney, Marc	Member of an Advisory Board or equivalent with Pfizer as a part of a medical advisory board and currently participating or have participated in a clinical trial within the past 2 years with Cubist for a clinical trial for <i>C. difficile</i> infection.
Sarabia, Alicia	No conflict declared
Skowronski, Danuta	No conflict declared
Weese, Scott	No conflict declared
Wong, Titus	Received a grant or an honorarium from Ondine Biomedical Inc.

Committee Members

Committee Member	Disclosure
Adam, Heather	No conflict declared
Bates, Angela	No conflict declared

Committee Member	Disclosure
Chiu, Isabelle	Member of an Advisory Board or equivalent with Merck, member of a Speakers bureau with Merck, received payment (including gifts or other consideration or 'in kind' compensation) from Merck, received a grant or an honorarium from Merck, Currently participating or have participated in a clinical trial within the past 2 years, indirectly through the University of Alberta, with no direct financial dealings with the sponsoring companies



Committee Member	Disclosure
Dey, Meghan	No conflict declared
Drebot, Michael	No conflict declared
Evans, Gerald	Currently participating or have participated in a clinical trial within the past 2 years with Merck on a CDI study, with Astellas on an isavuconazole, and with Biocryst on a peramivir study
Forgie, Sarah	No conflict declared
Fuller, Jeff	Received a grant or an honorarium from Astellas and Pfizer for invasive fungal infection surveillance and antifungal resistance detection
Gilmour, Matthew	No conflict declared
Gregson, Dan	Member of an Advisory Board or equivalent with the College of Physicians and Surgeons of Alberta in the Member Laboratory Accreditation Committee, received a grant or honorarium from Becton Dickinson Canada Research Funding for multicentre diagnostic Research Studies on BD Max Platform, currently participating in or have participated in a clinical trial within the past 2 years with Merck on fecal colonization with antibiotic resistant Gram-negative bacteria during international travel
Haider, Shariq	Member of an Advisory Board or equivalent with Merck, Pfizer, Sunovion, Optimer, Abbott, Janssen, and Gilead, and currently participating in or have participated in a clinical trial within the last 2 years with Abbott, BMS, Merck, Cubist, ViV, and Optimer
Hatchette, Todd	Co-applicant on an investigator driven grant from GlaxoSmithKline entitled "Sentinel surveillance for influenza requiring hospital admission in Canada adults." It is a collaborative Research Agreement, with Shelley McNeil as the PI, amounting to a total of \$120,000,000, running from Nov. 29, 2011 – Nov. 29, 2014. It is an enhancement of the current PCIRN SOS network
Joffe, A. Mark	Board member of an Advisory Board or equivalent with Cubist on fidaxomicin use for <i>C. difficile</i> , member of a Speakers bureau for Merck on a presentation related to HPV vaccination, and currently participating in or have participated in a clinical trial within the past 2 years with Optimer and Cubist on a <i>C. difficile</i> trial.
Johnston, Lynn	Currently participating or have participated in a clinical trial within the past 2 years with Pfizer on a maraviroc trial and a filibuvir trial
Kogilwaimath, Siddarth	No conflict declared
Krajden, Mel	Member of an Advisory Board or equivalent with Gilead and Roche (monies are deposited to the BCCDC Foundation) and currently participating in research contracts and/or research from Roche, Hologic (Gen-Probe), Merck, Siemens, and Borhinger Ingelheim, but does not receive compensation from any of these grants

Committee Member	Disclosure
Levett, Paul	No conflict declared
Minion, Jessica	No conflict declared
Mirzanejad, Yazdan	Received a grant or honorarium from Merck, Pfizer, and Optimer for speaking engagement, currently participating in or have participated in a clinical trial within the last 2 years on <i>C. diff</i> Toxin vaccine with Sanofi Pasteur
Oughton, Matthew	Member of an Advisory Board or equivalent with Sunovion (Cubicin), received payment from Sunovion (Cubicin) for a presentation to JGH pharmacists, received payment from Cubist (Dificid) for as a paid consultant to prepare reports and present to provincial INESS board
Patel, Samir	No conflict declared
Patrick, David	No conflict declared
Payne, Michael	No conflict declared
Peermohamed, Shaqil	No conflict declared
Poutanen, Susan	Member of an Advisory Board or equivalent with Sunovion and Optimer, member of a Speakers bureau with Hoffman-La Roche, Merck, and Pathogenica, received grants or an honorarium from bioMérieux, Bio-Rad, Copan, and Pathogenica
Sheh, Prameet	No conflict declared
Smyth, Dan	Received an honorarium from AbbVie for HCV consultation work for New Brunswick, have participated in a clinical trial within the last 2 years with Merck and GSK – PCIRN influenza serious outcomes surveillance
Tremblay, Cécile	No conflict declared
Tyrrell, Gregory	Member of a the FAQ Advisory Board for meningococcal B vaccine with Novartis, received a grant or an honorarium from Pfizer for five advisory boards and train the trainer presentations in the last two years, and received a grant or honorarium from Pfizer for an investigator originated proposal for a <i>pneumococcal</i> study
Virmani, Divya	No conflict declared
Webster, Duncan	Received a grant or an honorarium from GlaxoSmithKline, PHAC, and CIHR for operation of a site for the national PCIRN/SOS invasive pneumococcal and influenza surveillance studies. Funding received indirectly through the site
Whellams, Diana	No conflict declared

Integrated Symposia and Workshop Conflict of Interest disclosures will be made available on the Event Mobi app



Speaker Biographies

Emma Allen-Vercoe

Dr. Emma Allen-Vercoe has a B.Sc. (Hons) in Biochemistry and a PhD in Molecular Microbiology and is currently an Associate Professor in the Department of Molecular and Cellular Biology at the University of Guelph. Her research program focuses on the microbial ecology of the human gut, and she has created the 'Robogut' as a platform for this research, a tool to further the understanding of the inner workings of our gut microbial ecosystem and how these affect our health. Known locally as 'The Bacteria Whisperer' and the 'Speaker for the Microbes' she feels passionately that healthcare practices need to change to include effective caretaking of the human microbiota in order to promote health, something that has been hitherto largely neglected by modern medicine.

Edith Blondel-Hill

Dr. Edith Blondel-Hill trained at the University of Alberta, Edmonton, and received specialty training in Internal Medicine, Infectious Diseases and Medical Microbiology. She started her career at the Royal Alexandra Hospital in Edmonton as an Infectious Diseases consultant and Medical Microbiologist and moved to Dynacare Kasper Medical Laboratories in 1997. She moved to British Columbia in 2003 where she worked as a Microbiology/Infectious Diseases consultant at BC Children's Hospital in Vancouver until 2008. She is currently the Microbiology lead and medical director of Infection Prevention and Control for Interior Health and is located at the Larissa Yarr Microbiology Laboratory at the Kelowna General Hospital in Kelowna, British Columbia. She has a long interest in antimicrobial utilization, chairing various antimicrobial advisory committees in Alberta and British Columbia as well as being involved in guideline and policy development for antibiotic use and prescribing. She is co-author of the Bugs and Drugs – Antimicrobial/Infectious Diseases Reference Book (currently in 5th edition) and the medical director of Do Bugs Need Drugs? - an educational program to address antimicrobial resistance funded by both Alberta Health Services and BC Ministry of Health. Her major interests include mechanisms of antimicrobial resistance, susceptibility testing and antimicrobial stewardship.

Elizabeth Bryce

Dr. Elizabeth Bryce is the Regional Medical Director for Infection Control at Vancouver Coastal Health Acute and has been involved in the field of infection prevention and control for the last 20 years. She is dually qualified in Medical Microbiology and Internal Medicine and is a Clinical Professor at the University of British Columbia. She is a past co-chair of the Canadian Nosocomial Infection Surveillance Program and the current co-chair of the Provincial Infection Control Network of British Columbia.

Michael Drebot

Dr. Michael Drebot received his PhD in Microbiology in 1988 from Dalhousie University and was then awarded a postdoctoral fellowship in genetics from the Hospital for Sick Children (Toronto, 1988-1991). In 1991 he joined the National Centre for Enteroviruses in Halifax where he conducted research on the molecular biology of polioviruses and various enteric pathogens. He was cross appointed as a Professor adjunct within the Department of Microbiology and Immunology at Dalhousie University. In 1996, Dr. Drebot joined the Zoonotic Diseases program of Health Canada in Ottawa as a research scientist. In 1999 he became the Chief of Viral Zoonoses within the Zoonotic Diseases and Special Pathogens (ZDSP) section of the National Microbiology Laboratory in Winnipeg. In 2013 he took on the responsibilities of Director of the ZDSP division. Dr. Drebot is an Assistant Professor within the Medical Microbiology department, University of Manitoba.

The focus of his Viral Zoonoses program has been to work with colleagues at ZDSP on the establishment of applied and basic research programs for various zoonotic disease agents including arboviruses (such as West Nile virus) and rodent-borne pathogens such as hantaviruses.



Robbin Lindsay

Dr. Robbin Lindsay received his Bachelor's degree from the University of Winnipeg in 1986, a Master's degree from the University of Manitoba in 1989, and his PhD from the University of Guelph in 1995. He is currently employed with the Public Health Agency of Canada at the National Microbiology Laboratory (NML) in the Zoonotic Disease and Special Pathogens section. The focus of his work is laboratory and field-based surveillance for various zoonotic disease agents including: Lyme borreliosis, hantaviruses and West Nile virus. His program balances reference diagnostic services, surveillance activities and applied research projects and ultimately the information gained from these core activities are used to better define the risk factors, geographic distribution and intervention strategies available to minimize human exposure to zoonotic disease agents.

David Fisman

Dr. Fisman is an infectious disease physician and epidemiologist at the University of Toronto's Dalla Lana School of Public Health, where he is Professor of Epidemiology. He is also a practicing infectious diseases physician at the Toronto Western Hospital. He trained in infectious diseases at Beth Israel Deaconess Medical Centre in Boston and from 1999 to 2001 was an Agency for Healthcare Research and Quality (AHRQ) Fellow in Health Policy at Harvard Centre for Risk Analysis. His interests are in analytical and mathematical epidemiology of infectious diseases, and in health economic evaluation of communicable disease control programs.

Allison McGeer

Dr. McGeer trained in Internal Medicine and Infectious Diseases at the University of Toronto. She then completed a Fellowship in Hospital Epidemiology at Yale New Haven Hospital in 1989 – 1990. She is the director of Infection Control and a Microbiologist and Infectious Diseases consultant at Mount Sinai Hospital in Toronto. She has been a member of Canada's National Advisory Committee on Immunization, is currently a member of the Infection Control Subcommittee of the Ontario Provincial Infectious Diseases Advisory Committee, and has served on national, international and regional Infection Prevention and Pandemic Planning Committees. Her primary areas of research interest are the prevention of healthcare associated infection, the epidemiology of influenza, and adult immunization.

Andrew Morris

Dr. Andrew Morris (MD SM FRCPC) (Toronto, ON) obtained his medical degree at the University of Toronto in 1994, where he subsequently obtained specialty certification in Internal Medicine and subspecialty certification in Infectious Diseases. While undergoing a Canadian Infectious Diseases Society (now AMMI Canada) research fellowship under the supervision of Dr. Allison McGeer, Dr. Morris completed a Masters Degree in Epidemiology from the Harvard School of Public Health in 2000. In 2000, he accepted a position at McMaster University and Hamilton Health Sciences, where he worked as a clinician-teacher for 6 years. He held numerous leadership and administrative roles there, including Chair of the Pharmacy and Therapeutics Committee, Physician Lead for Drug Utilization, and Director of the Infectious Diseases Residency Training Program.

In 2007, he was recruited back to Toronto, where he is Associate Professor in the Department of Medicine, Division of Infectious Diseases, at Mount Sinai Hospital (MSH) and University Health Network (UHN). He currently chairs the Pharmaceuticals & Therapeutics (P&T) Committee at Mount Sinai Hospital. He is the Director of the Antimicrobial Stewardship Program at MSH-UHN, working collaboratively with a variety of healthcare professionals to optimize antimicrobial use in patients; the MSH-UHN ASP is the largest stewardship program in Canada, and one of the largest in the world. He is the project lead for a project funded by the Council of Academic Hospitals of Ontario (CAHO) and the Ontario Ministry of Health and Long-Term Care to introduce antimicrobial stewardship programs in all teaching hospital ICUs throughout Ontario. Working with Critical and Critical Care Services Ontario, he helped develop a system to monitor antimicrobial utilization and *C. difficile* infection for all ICUs in Ontario. Dr. Morris has held the role of Chair, Specialty Committee on Infectious Diseases, Royal College of Physicians and Surgeons of Canada since 2012.

Neil Rau

Dr. Rau completed a Bachelor's of Mathematics degree at the University of Waterloo, followed by medical school training at the University of Toronto from 1987 to 1991. Subsequently, he completed specialty training in Internal Medicine and Infectious Diseases at McGill University, and became a Fellow of the Royal College of Physicians and Surgeons of Canada in Infectious Diseases in 1996.



He was amongst the first community-hospital-based Infectious Diseases specialists in the Toronto area. In 2003, he assumed the position of Medical Director of Infection Prevention and Control for Halton Healthcare Services in Oakville, Ontario. He subsequently completed his Medical Microbiology training during a sabbatical year at the University of Toronto, and he assumed the role of Medical Microbiologist in 2008.

In 2012, Dr. Rau was appointed to the Ontario Committee to Evaluate Drugs (former Drug Quality and Therapeutics Committee) to provide subject expertise regarding anti-infective agents. He is also Section Chair for the Ontario Medical Association ID Section. He was awarded the Queen's Diamond Jubilee Medal in 2012 by the Town of Oakville.

In 2005, following on fears that a pandemic might emerge from H5N1 in Asia, Dr. Rau was hired as a consultant to CTV News. Many bird flu stories later, Dr. Rau continues to be called upon regarding Infectious Diseases / Medical Microbiology matters.

Joan Robinson

Dr. Joan Robinson grew up on a farm near Innisfail, Alberta. She graduated from medical school at the University of Alberta, interned at the Royal Columbian Hospital in New Westminster, and then completed her paediatrics residency at BC Children's Hospital. She returned to Edmonton to train in paediatric Infectious Diseases and has been on staff at the University of Alberta Hospital since 1991. She is currently program director for the Paediatric Infectious Diseases training program, chair of the Paediatric Trainee Research Committee, electives coordinator for Undergraduate Medical Education, Chair of the Canadian Paediatric Society Infectious Diseases & Immunization Committee, Senior Assistant editor for *Paediatrics & Child Health*, Co-editor-in-chief for *Evidence Based Child Health: A Cochrane Review Journal* and Section Associate Editor for the Paediatric Infectious Disease Notes in the *Canadian Journal of Infectious Diseases and Medical Microbiology*.

Danuta Skowronski

Dr. Danuta Skowronski has been Epidemiology Lead for Influenza and Emerging Respiratory Pathogens at the BC Centre for Disease Control for approximately 15 years. In this post, she is responsible for surveillance and rapid response research. As such, Dr. Skowronski led the public health response to SARS in BC in 2003, and was responsible for human health recommendations during outbreaks of avian influenza in BC in

2004 and pandemic influenza in 2009. She has been involved in numerous provincial- and national-level pandemic planning activities and committees since 1998. Dr. Skowronski is an advocate of applied public health research and has more than 100 publications, primarily related to influenza and other emerging or re-emerging respiratory pathogens. She has been recognized for her distinguished career in public health including academic awards such as the University of British Columbia's President's Award for Public Education through Media, and the Faculty of Medicine James M Robinson Award for significant contributions to public health. In addition to these academic accolades, Dr. Skowronski has been recognized by the Vancouver SUN as among the 100 most influential women of BC.

Scott Weese

Dr. Weese is a veterinary Internist and Microbiologist, and a Diplomate of the American College of Veterinary Internal Medicine. He is a Professor at the Ontario Veterinary College, University of Guelph and a Zoonotic Disease/Public health Microbiologist at the University of Guelph's Centre for Public Health and Zoonoses. He is also Chief of Infection Control at the Ontario Veterinary College Teaching Hospital and holds a Canada Research Chair in zoonotic diseases.

Dr. Weese has authored or co-authored over 200 papers in peer reviewed journals, edited two books and speaks extensively on Infectious Disease topics. His research interests include *Clostridium difficile*, microbiome assessment, surgical site infections, antimicrobial resistance, methicillin-resistant staphylococci, infection control, emerging diseases and zoonoses.

Titus Wong

Dr. Titus Wong is a Medical Microbiologist in the Division of Medical Microbiology and Infection Control (Department of Laboratory Medicine) at Vancouver General Hospital. He completed his undergraduate degree in pharmaceutical sciences prior to completing medicine and residency training (Medical Microbiology) at the University of British Columbia (UBC). His current research interests include the prevention of hospital-acquired infections. He is a Clinical Instructor with UBC Medicine and is the assistant program director for the UBC Medical Microbiology residency program.



Exhibitor Overview

EXHIBITOR BOOTH

Abbott Laboratories, Limited	51
AFFINITY Diagnostics Corp.	37
Alere Canada	42
Applied Maths, Inc.	28
Astellas Pharma Canada, Inc.	38
BD Diagnostics	19
Bio Nuclear Diagnostics Inc.	21
bioMérieux Canada, Inc.	55
BioPacific Diagnostic Inc.	2
Bio-Rad Laboratories (Canada) Ltd.	17
Bruker Daltonics	46
Canadian Foundation for Infectious Diseases	62
CEDARLANE	33
CIHR - Institute of Infection and Immunity	24
Copan Diagnostics	41
Cubist Pharmaceuticals, Inc.	15
DiaSorin Canada Inc.	47
EUROIMMUN Medical Diagnostics Canada Inc.	57
Gilead Sciences	6
HOLOGIC	49
i2a Canada	18
IDWeek 2014™	63
Innovatek Medical	53
Inter Medico	4
LabWare Inc.	39
Lumed	1


NUMBER

EXHIBITOR BOOTH

Luminex Corporation	5
Merck Canada	29
Merus Labs	34
National Collaborating Centre for Infectious Diseases	54
Ondine Biomedical Inc.	35
Paladin Labs	64
Pfizer Canada Inc.	44
Phoenix AirMid Biomedical	58
Pro-Lab Diagnostics Inc	22
Promega Corporation	30
Pulsus Group	40
Puritan Diagnostics	52
QIAGEN Inc.	13
Quidel Corporation	60
Roche Diagnostics	61
Seeker Solutions Inc.	25
Sheldon Manufacturing, Inc.	45
Somagen Diagnostics Inc.	23
Starplex Scientific Inc.	31
Sunovion Pharmaceuticals Canada Inc.	3
Thermo Fisher Scientific	12
Thermo Fisher Scientific - Life Technologies Brand - Life Science Solutions Group	32
Thermo Scientific - Oxoid, Remel and TREK Products	61

NUMBER

ENTRANCE



Abbott Laboratories, Limited

BOOTH # 51

We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. We are displaying products from our Molecular and Diagnostic Divisions.

Brian Fellows
National Accounts Manager

7115 Millcreek Drive
Mississauga, Ontario L7M 4J5
Email: brian.fellows@abbott.com

AFFINITY Diagnostics Corp.

BOOTH # 37

AFFINITY Diagnostics provides a wide variety of ELISA-based infectious disease assays and laboratory automation, allowing us to assist Canadian laboratories of all sizes. Visit our website at www.affinitydiagnostics.ca, or call us at 877-370-6300.

Daniel Libertucci
Managing Director

194 Wildcat Road
Toronto, Ontario M3J 2N5
Phone: 877-370-6300
Fax: 416-650-5990
Email: dlibertucci@affinitydiagnostics.ca
Website: www.affinitydiagnostics.ca

Alere Canada

BOOTH # 42

Alere Canada, a foremost leader in laboratory diagnostics with a well-respected brand specializing in cardiovascular infectious disease, women's health, drugs of abuse and oncology.

Kim Orr
Marketing Co-ordinator

1 - 57 Iber Road
Ottawa, Ontario K2S 1E7
Phone: 613-271-1144
Fax: 613-271-1148
Email: kim.orr@alere.com
Website: www.alere.ca

Applied Maths, Inc.

BOOTH # 28

Applied Maths develops innovative software and data management solutions for the biosciences. Today the company continues to be a leader in bioinformatics, with BioNumerics.

Heather Balderach
Sales Manager

280 - 8834 North Capital of Texas Highway
Austin, Texas 78759 USA
Phone: 512-482-9700
Email: heather_balderach@applied-maths.com
Website: www.Applied-Maths.com

Astellas Pharma Canada, Inc.

BOOTH # 38

Astellas Pharma Canada, Inc. is a pharmaceutical company dedicated to improving the health of people around the world through innovative and reliable pharmaceutical products.

John McNeill
Senior Product Manager, Immunology & ID

Suite 500, West Tower, 675 Cochrane Drive
Markham, Ontario L3R 0B8
Phone: 905-946-5626
Fax: 905-470-7799
Email: john.mcneill@astellas.com
Website: www.astellas.ca

BD Diagnostics

BOOTH # 19

BD is a global leader serving the needs of clinicians and healthcare professionals across the healthcare continuum. BD Diagnostic Systems deliver innovative solutions to the laboratory and broader healthcare setting that improve patient outcomes by reducing variability, increasing accuracy and minimizing time to actionable results.

Chris Mitchell
Associate Product Manager

100 - 2100 Derry Road West
Mississauga, Ontario L5N 0B3
Phone: 905-288-6000
Fax: 905-288-6006
Email: chris_mitchell@bd.com
Website: www.bd.com/ds

Bio Nuclear Diagnostics Inc.

BOOTH # 21

BND is a leading supplier of infection control, diagnostic, medical disposable and laboratory products. Focus Diagnostics molecular detection platform and EIAs. Our own medical disposable and laboratory product brand is "Technologist Choice".

Nelson Batista
Technical Sales Representative

1791 Albion Road
Toronto, Ontario M9W 5S7
Phone: 416-674-1545
Toll-free: 800-668-4033
Fax: 416-674-7280
Email: nelson.batista@bndinc.com
Website: www.bndinc.com

bioMérieux Canada, Inc.

BOOTH # 55

bioMérieux is a worldwide group specialized in the field of in vitro diagnostics for medical applications. The group designs, develops, manufactures and markets systems used in the diagnosis of infectious diseases, such as hepatitis, HIV, tuberculosis and respiratory infections, as well as pathologies such as cardiovascular diseases and cancer.

François Turgeon
Clinical Marketing Manager

7815 Henri-Bourassa West
Saint-Laurent, Québec H4S 1P7
Phone: 514-336-7321
Fax: 514-807-0015
Email: francois.turgeon@biomerieux.com
Website: www.biomerieux.ca



BioPacific Diagnostic Inc.**BOOTH # 2**

BioPacific is a Canadian owned and operated company represented coast to coast offering rapid diagnostic test kits, infectious disease kits, tuberculosis and research based kits.

John Skuse

National Sales Manager

114 - 828 Harbourside Drive
North Vancouver, British Columbia V7P 3R9

Phone: 604-985-7000

Fax: 604-985-3366

Email: biopacific@telus.net
jskuse@biopacific.net

Website: www.biopacific.net

Bio-Rad Laboratories (Canada) Ltd. BOOTH # 17

Bio-Rad Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality control, diabetes monitoring, autoimmune diseases and microbiology.

Louis Beaudoin

National Sales Manager

2403 Guénette

Montréal, Québec H4R 2E9

Phone: 514-334-4372

Fax: 514-334-4415

Email: louis_beaudoin@bio-rad.com

Website: www.bio-rad.com

Bruker Daltonics**BOOTH # 46**

Bruker's industry leading MALDI Biotyper identifies a broad range of bacteria and yeast with minimal reagents in minutes! The MALDI Biotyper CA System is for the identification of organisms isolated from clinical specimens.

40 Manning Road

Billerica, Massachusetts 01821 USA

Phone: 978-663-3660

Fax: 978-667-5993

Email: ms-sales@bruker.com

Website: www.bruker.com

Canadian Foundation for Infectious Diseases**BOOTH # 62**

CFID is a charitable organization committed to improving the health of Canadians through the support of research and dissemination of knowledge pertaining to infectious diseases. CFID's vision is to achieve effective research outcomes, strong and extensive stakeholder connections, successful advocacy and a positive impact on public policy.

Dr. Susan Richardson

President, CFID

c/o The Hospital for Sick Children
Microbiology, Room 3654 Atrium

555 University Avenue
Toronto, Ontario M5G 1X8

Phone: 416-813-5992

Email: cfid@researchid.com

Website: www.researchid.com

CEDARLANE**BOOTH # 33**

CEDARLANE® provides ATCC bacterial/viral controls, Millipore's DFA kits, SSI's Strep. Pneumo kit, Altona Diagnostics' PCR kits, Biomed Diagnostics' media system and AdvanDx's rapid pathogen detection platform.

Eddie Johnson

General Manager

4410 Paletta Court
Burlington Ontario L7L 5R2

Phone: 289-288-0001

Toll-free: 800-268-5058

Fax: 289-288-0020

Email: eddie.johnson@cedarlanelabs.com

Website: www.cedarlanelabs.com

CIHR - Institute of Infection and Immunity**BOOTH # 24**

CIHR is the federal agency responsible for funding health research in Canada, and IIR supports research and builds capacity in the areas of infectious diseases and the immune system.

Jennifer Raven

Associate, Strategic Initiatives

2705 boulevard Laurier, TR-62
Québec, Québec G1V 4G2

Phone: 418-577-4688

Fax: 418-577-4689

Email: jennifer.raven@crchul.ulaval.ca

Website: www.cihr-irsc.gc.ca/e/13533.html

Copan Diagnostics**BOOTH # 41**

With a reputation for innovation in preanalytics, COPAN is the leading manufacturer of collection and transport systems. Copan's collaborative approach has resulted in Flocked Swabs, ESwab, Universal Transport Medium and laboratory automation, WASP® and WASPLab.

Jane Lukashevsky

Business Development Manager, Canada

26055 Jefferson Avenue
Murrieta, California 92562 USA

Phone: 800-216-4016

Fax: 800-600-1832

Email: info@copanusa.net

Website: www.copanusa.com

Cubist Pharmaceuticals, Inc.**BOOTH # 15**

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

900 - 4950 Yonge Street
Toronto, Ontario M2N 6K1

DiaSorin Canada Inc.**BOOTH # 47**

DiaSorin, the Diagnostic Specialist, provides specialized reagents and automated diagnostic instrumentation for laboratories. DiaSorin offers immunodiagnostic assays for infectious diseases, autoimmune, bone and endocrine diseases, as well as automated nucleic acid purification from clinical samples.

Jeff Kormos

Commercial Director & Country Manager

Units 3 & 4, 2nd Floor, 205 Export Boulevard
Mississauga, Ontario L5S 1Y4

Phone: 905-677-1600

Toll-free: 855-677-0600

Fax: 905-677-1630

Email: jeff.kormos@diasorin.com

Website: www.diasorin.com



**EUROIMMUN Medical
Diagnostics Canada Inc.**

BOOTH # 57

EUROIMMUN provides more than 6,000 medical laboratories worldwide with high quality reagents and automation for infectious serology, autoantibody determination, allergy testing and molecular diagnostics.

Donglai Ma
Director

36 - 1100 Central Parkway West
Mississauga, Ontario L5C 4E5

Phone: 905-896-1504
Fax: 905-896-1506
Email: info@euroimmun.ca
Website: www.euroimmun.ca

Gilead Sciences

BOOTH #6

Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and commercializes innovative medicines in areas of unmet need; focusing primarily on HIV/AIDS and liver disease.

Geoffrey Christie
OLP Manager – Hepatitis

Gilead Sciences Canada
202 - 6711 Mississauga Road
Mississauga, Ontario, L5N 2W3
Phone: 647-225-2642
Email: Geoffrey.Christie@gilead.com
Website: www.gilead.com

HOLOGIC

BOOTH # 49

HOLOGIC is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, HOLOGIC is committed to improving lives.

Tom Cahill
Canadian Country Manager

250 Campus Drive
Marlborough, Massachusetts 01752 USA
Phone: 416-970-3638
Email: tom.cahill@hologic.com
Website: www.hologic.com

i2a Canada

BOOTH # 18

Company that develops, manufactures and sells microbiology instruments and software systems worldwide. Since 2009, acting as Bruker's MALDI Biotyper distributor in Canada.

Pierre Lacroix
General Manager

1699 chemin 8e Rang
Val-David, Québec J0T 2N0
Phone: 514-910-8051
Fax: 514-331-6441
Email: pierre.lacroix@i2a.info
Website: www.i2a.info

IDWeek 2014™

BOOTH # 63

IDWeek 2014™ - October 8 - 12, Philadelphia, PA - A Joint Meeting of IDSA, SHEA, HIVMA and PIDS with the theme—Advancing Science, Improving Care—IDWeek will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment and epidemiology of infectious diseases, including HIV, across the lifespan.

John Buckley
Director, Meeting Services

300 - 1300 Wilson Boulevard
Arlington, Virginia 22209 USA
Phone: 703-299-0200
Fax: 866-579-0939
Email: jbuckley@idsociety.org
Website: www.idweek.org

Innovatek Medical

BOOTH # 53

A Canadian company selling rapid diagnostic kits in the areas of drugs of abuse, women's health and infectious diseases. Our primary focus is on innovation for clinical laboratory technology.

Marcus Titian Parsad
National Sales Manager

3 - 1600 Derwent Way
Delta, British Columbia V3M 6M5
Phone: 604-522-8303
Fax: 604-522-8318
Email: marcus@innovatekmed.com
Website: www.innovatekmed.com

Inter Medico

BOOTH # 4

Inter Medico provides automated technology solutions for rapid PCR molecular testing such as MRSA, VRE, *C. difficile* and Flu, and general microbiology reagents.

LabWare Inc.

BOOTH # 39

LabWare provides proven software solutions for public health, biobanking clinical research, clinical trials and reference laboratories.

David Trottier
Business Development Manager

102 - 3 Mill Road
Wilmington, Delaware 19806 USA
Phone: 416-769-2446 / 302-658-8444
Fax: 302-658-7894
Email: trottier@labware.com
Website: www.labware.com

Lumed

BOOTH # 1

Our mission is to optimize clinical practice, improve the quality of patient care and reduce costs. We provide cutting edge software solutions like APSS, the first Canadian antimicrobials prescription surveillance system with demonstrated impacts on hospital spending.

Vincent Nault, PhD (c)
CEO
168 rue Boisé
Canton Hatley, Québec J0B 2C0
Phone: 819-574-2471
Fax: 819-829-3286
Email: info@lumed.ca
Website: www.lumed.ca



Luminex Corporation

BOOTH # 5

Luminex pioneers comprehensive molecular diagnostics systems and assays, offering multiplex solutions for infectious diseases, newborn genetics and pharmacogenomics to all clinical diagnostics laboratories.

Maryam Calderone

Diagnosics Business Manager - Canada

900 - 439 University Avenue

Toronto, Ontario M5G 1Y8

Phone: 416-617-3082

Email: mcalderone@luminexcorp.com

Website: www.luminexcorp.com

Merck Canada

BOOTH # 29

Today's Merck is a global healthcare leader working to help the world be well. Through our medicines, vaccines, therapies and products, we work with customers to deliver innovative health solutions. Please visit www.merck.ca.

Angelina Doyle

Exhibits & Conventions Coordinator

16750 Trans-Canada Highway

Kirkland, Québec H9H 4M7

Phone: 514-428-3882

Email: angelina.doyle@merck.com

Website: www.merck.ca

Merus Labs

BOOTH # 34

A leading speciality pharmaceutical company and licensing novel pharmaceutical products. The product being displayed is Vancocin.

Brent Loewen

Regional Therapeutic Specialist

2110 - 100 Wellington Street West

PO Box 151

Toronto, Ontario M5K 1H1

Phone: 416-627-5956

Fax: 416-593-4434

Email: bloewen@meruslabs.com

Website: www.meruslabs.com

National Collaborating Centre for Infectious Diseases

BOOTH # 54

Collaborates to synthesize and disseminate current information on communicable diseases. Projects focus on policy and interventions in the prevention and control of HIV/AIDS, STBBI, AMR, pH1N1 and other emerging infectious diseases.

Sandy Beeman

Communications Coordinator

515 Portage Avenue

Winnipeg, Manitoba R3B 2E9

Phone: 204-947-5092

Fax: 204-946-0927

Email: sbeeman@icid.com

Website: www.nccid.ca

Ondine Biomedical Inc.

BOOTH # 35

MRSAid™ is a non-antibiotic treatment for nasal decolonization of preoperative patients. It is a simple solution to complex infections shown to reduce SSIs by 39%.

Rick Walter

COO

Phone: 604-669-0555, ext. 222

Website: www.mrsaid.com

Paladin Labs

BOOTH # 64

Paladin Labs, headquartered in Montreal, Quebec, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

Anick Toledano

Product Manager

600 - 100 Alexis Nihon Boulevard

St. Laurent, Quebec H4M 2P2

Phone: 514-340-1112, ext. 5309

Email: atoledan@paladinlabs.com

Website: www.paladinlabs.com

Pfizer Canada Inc.

BOOTH # 44

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines and vaccines for humans. At Pfizer, we're working together for a healthier world. For more information, visit www.pfizer.ca.

Nathalie Labonté

CHE Manager

17300 Trans-Canada Highway

Kirkland, Québec H9J 2M5

Phone: 418-580-1073

Fax: 418-877-6174

Email: nathalie.labonte@pfizer.com

Website: www.pfizer.ca

Phoenix AirMid Biomedical

BOOTH # 58

Distributors of flexible molecular diagnostic solutions for multiple platforms to suit the needs of labs across Canada.

Tyler Cann

Account Manager - Western Canada

1166 South Service Road West

Oakville, Ontario L6L 5T7

Phone: 905-469-4253

Fax: 905-825-9795

Email: info@phoenixairmid.com

Website: www.phoenixairmid.com

Pro-Lab Diagnostics Inc

BOOTH # 22

Pro-Lab Diagnostics, Canadian owned and operated, offers high-quality cost-effective immunodiagnostic products, DNA/RNA isothermal amplification technology, biological reagents and laboratory equipment.

Martin Skulnick

Clinical Specialist

4 - 20 Mural Street

Richmond Hill, Ontario L4B 1K3

Phone: 905-731-0300

Toll-free: 800-268-2341

Fax: 905-731-0206

Email: support@pro-lab.com

Website: www.pro-lab.com



Promega Corporation

BOOTH # 30

Promega has over 30 years of expertise delivering reagents to life science and clinical laboratories. We offer GPR- and GPLE-labeled products, including instruments and reagents.

Ron Kolojek
Clinical Account Manager

2800 Woods Hollow Road
Madison, Wisconsin 53711 USA

Phone: 608-274-4330
Fax: 608-277-2516
Email: ron.kolojek@promega.com
Website: www.promega.com

Pulsus Group

BOOTH # 40

Pulsus Group is a Canadian publishing company specializing in high-quality peer-review medical journals including The Canadian Journal of Infectious Diseases & Medical Microbiology.

Ann LeBlanc
Vice President

2902 South Sheridan Way
Oakville, Ontario L6J 7L6

Phone: 905-829-4770
Fax: 905-829-4799
Email: a.leblanc@pulsus.com
Website: www.pulsus.com

Puritan Diagnostics

BOOTH # 52

Puritan Diagnostics is a leading U.S. manufacturer of medical diagnostic products, offering the most comprehensive line of specimen collection devices and transport systems available.

Laurie A. Smith
Executive Admin. Assistant

31 School Street
Guilford, Maine 04443 USA

Phone: 207-876-3311
Fax: 207-876-3130
Email: lasmith@hwppuritan.com
Website: www.puritanmedproducts.com

QIAGEN Inc.

BOOTH # 13

QIAGEN's molecular diagnostic Sample & Assay Technologies cover all application areas in healthcare, including: screening of asymptomatic patients (prevention) and testing of patients who are at risk of carrying a disease (profiling).

Jeff Christiansen
Senior Sales Director

27220 Turnberry Lane
Valencia, California 91355 USA
Phone: 661-702-3000
Email: jeff.christiansen@qiagen.com
Website: www.qiagen.com

Quidel Corporation

BOOTH # 60

Quidel® Corporation is a leading manufacturer of diagnostic healthcare solutions for women's health, as well as respiratory, gastrointestinal and other infectious diseases.

Alanna Prasad, PhD
Associate Sales Director, Canada

10165 McKellar Court
San Diego, California 92121 USA
Phone: 647-527-6074
Fax: 858-431-3558
Email: aprasad@quidel.com
Website: www.quidel.com

Roche Diagnostics

BOOTH # 25

Roche Diagnostics, a division of Hoffmann-La Roche Ltd., is the world leader in in vitro diagnostics and offers a uniquely broad product portfolio and innovative solutions to researchers, physicians, hospitals and laboratories in the fields of diabetes care and anticoagulation therapy, molecular biology, diagnostic in-situ, clinical chemistry, immunology and applied science.

Website: www.rochecanada.com

Seeker Solutions Inc.

BOOTH # 45

Seeker's Affinity3S software streamlines post-discharge communication between patients and healthcare providers by automating the collection and analysis of follow-up data.

Dean Wray

Director of Product Marketing
400 - 1112 Fort Street
Victoria, British Columbia V8V 3K8
Phone: 250-483-4129
Fax: 250-380-9878
Email: dean.wray@seekersolutions.com
Website: www.seekersolutions.com

Sheldon Manufacturing, Inc.

BOOTH # 23

Sheldon Manufacturing, Inc. is an ISO 9001:2008 certified manufacturer of high-quality and innovative constant temperature equipment to the global market. Booth products include: Bactron300 Anaerobic Chamber and Lab Armor Bead Bath.

Jeff Boileau
Sales Manager – Canada

300 North 26th Avenue
Cornelius, Oregon 97113 USA
Phone: 503-640-3000
Email: jeffb@shellab.com
Website: www.shellab.com

Somagen Diagnostics Inc.

BOOTH # 31

As Canada's leading laboratory diagnostics distribution company, we represent an expanding portfolio of innovative products and technologies for microbiology and infectious disease testing.

Jaylene Lavoie
Director of Business Development

9220 - 25 Avenue
Edmonton, Alberta T6N 1E1
Phone: 800-661-9993
Fax: 780-438-6595
Email: info@somagen.com
Website: www.somagen.com

Starplex Scientific Inc.

BOOTH # 3

Starplex Scientific Inc. specializes in premium quality collection and transportation devices including Leakbuster™ containers and Starswab II™ transport swabs.

Susan Finn
QA/RA, Technical Specialist

50A Steinway Boulevard
Etobicoke, Ontario M9W 6Y3
Phone: 416-674-7474
Fax: 416-674-6067
Email: sfinn@starplexscientific.com
Website: www.starplexscientific.com



**Sunovion Pharmaceuticals
Canada Inc.**

Sunovion Pharmaceuticals Canada Inc. is focused on the commercialization of prescription products in Canada. Our strategy is to license pharmaceuticals products that meet the needs of patients and the Canadian health care system. We are focused in the areas of cardiology, central nervous system and infectious disease.

Paul Peters

Business Unit Manager, Cubicin

100 - 6790 Century Avenue
Mississauga, Ontario L5N 2V8

Phone: 905-814-9145

Fax: 905-363-0162

Email: paul.peters@sunovion.com

Website: www.sunovion.ca

Thermo Fisher Scientific

The Thermo Scientific brand leads the way in developing and manufacturing diagnostic reagents, assays, supplies and instruments to determine disease markers of diagnostic interest.

Peggy Rogers

Marketing Communications Manager North America

8365 Valley Pike
Middletown, Virginia 22645 USA

Phone: 800-232-3342

Fax: 540-869-8600

Email:

customerservice.diagnostics.mtn@thermofisher.com

Website: www.thermoscientific.com/aboutsepsis

Facebook: www.facebook.com/AboutSepsis

Twitter: www.twitter.com/AboutSepsis

BOOTH # 12

**Thermo Fisher Scientific -
Life Technologies Brand -
Life Science Solutions Group**

Thermo Fisher Scientific - We enable our customers to make the world healthier, cleaner and safer - Life Science Solutions.

Nav Mangat

Genetic Analysis Systems Solution Sales Consultant-BC

Real Time PCR/Digital PCR/Next Generation

Sequencing/CE Sequencing

Life Science Solutions

5250 Mainway
Burlington, Ontario L7L 5Z1

Phone: 604-360-2368

Email: nav.mangat@thermofisher.com

Website: www.lifetechnologies.com

BOOTH # 61

**Thermo Scientific -
Oxoid, Remel and TREK Products**

The industry-leading Thermo Scientific product portfolio features Oxoid™, Remel™, VersaTREK™ and Sensititre™ manual and automated technologies, renowned for quality, accuracy, reliability and innovation.

100 - 1926 Merivale Road
Nepean, Ontario K2G 1E8

Phone: 800-267-6391

Email: oxoid.ca.webinfo@thermofisher.com


Website: www.thermoscientific.com/microbiology

BOOTH # 36




Floor Plans


Fairmont Empress
Lower Lobby Level




Fairmont Empress
Upper Lobby Level



Victoria Convention Centre Level Two



Victoria Convention Centre Level One



Sponsors

PLATINUM



GOLD



COPPER



PATRON

